<!doctype html><html><head><meta charset=utf-8><title>Review of Vitamin D trials - Grant</title>
<link rel=stylesheet href="/css/main.css?v=1751038173"><link rel=stylesheet href="/css/pagination.css?v=1751038173"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src="/js/search-suggestions.js?v=1751038173"></script><script src="/js/search.js?v=1751038173"></script><script type=module>
        
        window.initPagefind = async function() {
            try {
                console.log('Loading Pagefind module...');
                window.pagefind = await import('/pagefind/pagefind.js');
                if (!window.pagefind) {
                    throw new Error('Failed to load Pagefind module - import returned empty result');
                }
                
                console.log('Initializing Pagefind...');
                const initResult = await window.pagefind.init();
                console.log('Pagefind loaded and initialized');
                
                
                if (window.searchInstance) {
                    console.log('Notifying Search instance of Pagefind initialization');
                    window.searchInstance.initializePagefind(window.pagefind);
                    console.log('Search instance successfully notified');
                } else {
                    console.warn('Search instance not found in global scope yet, but Pagefind is loaded');
                    
                }
            } catch (error) {
                console.error('CRITICAL ERROR: Failed to initialize Pagefind:', error);
                
                const errorDetails = error.stack || error.message || String(error);
                console.error('Error details:', errorDetails);
                
                
                const statusEl = document.querySelector('#search-status');
                const inputEl = document.querySelector('#search-input');
                
                if (statusEl) {
                    statusEl.textContent = 'Search unavailable: ' + error.message;
                    statusEl.style.display = 'block';
                    statusEl.style.color = 'red';
                }
                
                if (inputEl) {
                    inputEl.disabled = true;
                    inputEl.placeholder = 'Search unavailable';
                }
            }
        };
        
        
        window.pagefindInitialized = false;
        
        
        document.addEventListener('DOMContentLoaded', () => {
            console.log('DOM loaded, initializing Pagefind...');
            window.initPagefind();
        });
    </script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>Review of Vitamin D trials - Grant</h1><time>January 10, 2012</time><div data-pagefind-body><h1 id=this-web-page-consists-of-3-sections>This web page consists of 3 sections</h1><ol><li><p>Summary table of Vitamin D Clinical Trials ( in English)</p></li><li><p>References for every entry in the summary table (that is, the references are a superset of the table)</p></li><li><p>Abstracts include all but two of the entries in the summary table, as well as items not in the summary table</p></li></ol><p>There are no hyperlinks between the table entries and the references, abstracts</p><p>If you want to get more information on an item in the table you will need to search for the name of one of the authors and find the correct year.</p><p>First: Highlight author</p><ul><li><p>FireFox: hit cntrl F (control + F key at the same time), then down arrow in lower left of screen</p></li><li><p>Chrome (with efTwo add-on loaded) hit F2 key</p></li></ul><h2 id=a-hrefpostsclick-here-stylecolor-red-text-decoration-underline-titlethis-link-has-an-unknown-page_id-2303click-herea-for--span-stylecolorf00nov-2012-updatespan><a href=/posts/click-here style=color:red;text-decoration:underline title="This link has an unknown page_id: 2303">CLICK HERE</a> for <strong><span style=color:red>Nov 2012 update</span></strong></h2><h1 id=see-also-by-dr-grant>See also by Dr. Grant</h1><ul><li><p><a href=/posts/vitamin-d-overview-by-grant>Vitamin D overview by Grant - Jan 2011</a> - Requirements for Vitamin D Across the Life Span</p></li><li><p><a href=/posts/evidence-for-vitamin-d-grant>Evidence for Vitamin D - Grant Aug 2011</a></p></li><li><p><a href=/posts/dr-grant-on-vitamin-d-and-mortality-in-vitamindwiki>Dr. Grant on vitamin D and mortality in VitaminDWiki</a></p></li></ul><hr><!doctype html><html><head><meta http-equiv=CONTENT-TYPE content="text/html;charset=windows-1252"><title></title>
<meta name=GENERATOR content="OpenOffice.org 3.3  (Win32)"><meta name=AUTHOR content="Bill"><meta name=CREATED content="20111204;10330000"><meta name=CHANGEDBY content="Bill"><meta name=CHANGED content="20120110;17500000"><style type=text/css><!--@page{size:landscape;margin-right:1.25in;margin-top:1in;margin-bottom:.5in}p{margin-bottom:.08in;direction:ltr;color:#000;text-align:left;widows:2;orphans:2}p.western{font-family:times new roman,serif;font-size:12pt;so-language:en-US}p.cjk{font-family:times new roman,serif;font-size:12pt;so-language:zh-CN}p.ctl{font-family:times new roman,serif;font-size:12pt;so-language:ar-SA}h1{margin-top:.19in;margin-bottom:.19in;direction:ltr;color:red;text-align:left;widows:2;orphans:2;page-break-before:auto;page-break-after:auto}h1.western{font-family:times new roman,serif;font-size:16pt;so-language:en-US}h1.cjk{font-family:times new roman,serif;so-language:zh-CN}h1.ctl{font-family:times new roman,serif;so-language:ar-SA}h3{margin-top:.19in;margin-bottom:.19in;direction:ltr;color:#000;text-align:left;widows:2;orphans:2;page-break-after:auto}h3.western{font-size:13pt;so-language:en-US}h3.cjk{font-family:times new roman,serif;font-size:13pt;so-language:zh-CN}h3.ctl{font-family:times new roman,serif;font-size:13pt;so-language:ar-SA}h4{margin-bottom:.04in;direction:ltr;color:#000;text-align:left;widows:2;orphans:2}h4.western{font-size:14pt;so-language:en-US}h4.cjk{font-family:times new roman,serif;font-size:14pt;so-language:zh-CN}h4.ctl{font-family:times new roman,serif;font-size:14pt;so-language:ar-SA}a:link{color:#00f}--></style></head><body lang=en-US text=#000000 link=#0000ff dir=LTR><p class=western style=margin-bottom:0>William B. Grant, Ph.D.</p><p class=western style=margin-bottom:0>Sunlight, Nutrition,<p>and Health Research Center</p></p><p class=western style=margin-bottom:0>P.O. Box 641603</p><p class=western style=margin-bottom:0>San Francisco, CA<p>94164-1603, USA</p></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.sunarc.org/>www.sunarc.org</a></u></font></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=mailto:wbgrant@infionline.net><span lang=nl-NL>wbgrant@infionline.net</span></a></u></font><span lang=nl-NL></span></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0>This is a preliminary<p>summary of what has been demonstrated with vitamin D supplementation</p><p>in randomized controlled trials (RCTs). If I’ve missed any</p><p>important studies other than for falls and fractures, please let me</p><p>know.</p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0>Since many early RCTs<p>did not use more than 400 IU/d vitamin D3, they did not find any</p><p>beneficial effects. The Institute of Medicine did not find any RCTs</p><p>that they wanted to accept for any health outcome other than</p><p>beneficial effects for bones [Chung, 2009, 2011; Ross, 2011].</p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=2 style=font-size:11pt>Table 1. Summary of findings</p><p>from RCTs with vitamin D</font></p></p><table width=816 border=1 bordercolor=#000000 cellpadding=7 cellspacing=0><col width=129><col width=250><col width=256><col width=123><tr valign=TOP><td width=129><p><font size=2 style=font-size:11pt><b>Outcome</b></font></p></td><td width=250><p><font size=2 style=font-size:11pt>Conditions</font></p></td><td width=256><p><font size=2 style=font-size:11pt>Finding</font></p></td><td width=123><p><font size=2 style=font-size:11pt>Reference</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>All cause mortality</b></font></p></td><td width=250><p><font size=2>Mean oral in take 528 IU/d</font></p></td><td width=256><p><font size=2>RR = 0.93 (95% CI, 0.87-0.99)</font></p></td><td width=123><p><font size=2>Autier and Gandini, 2007</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=4><font size=2>daily </font><font size=2>vitamin<p>D</font><font size=2>(3) (800 IU), calcium (1000 mg), both, or</p><p>placebo for 24-62 months, with a follow-up of 3 yr after</p><p>intervention</font></font></p></p></td><td width=256><p><font size=2>(HR) = 0.93; 95% confidence interval (CI) =<p>0.85-1.02]</font></p></p></td><td width=123><p><font size=2>Avenell, epub</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Atopic dermatitis</b></font></p></td><td width=250><p><br></p></td><td width=256><p><br></p></td><td width=123><p><font size=2>Sidbury, 2008</font></p></td></tr><tr valign=TOP><td width=129><p><font size=4><b><font size=2>Bone loss in winter</font></b></font></p></td><td width=250><p><font size=2>oral cholecalciferol (500 IU/day) and calcium (500<p>mg/day) during the winter months</font></p></p></td><td width=256><p><font size=2>In the subjects receiving oral vitamin D3 and<p>calcium, lumbar and femoral BMD increased significantly (lumbar</p><p>spine: +0.8%, p = 0.04 versus year 1; femoral neck: +0.1%, p =</p><p>0.05 versus year 1), whereas controls continued to lose bone</p><p>(intervention group versus control group: lumbar spine, p = 0.03;</p><p>femoral neck, p = 0.05).</font></p></p></td><td width=123><p><font size=2>Meier, 2004</font></p></td></tr><tr valign=TOP><td width=129><p><font size=4><b><font size=2>Cancer, All</font></b></font></p></td><td width=250><p><font size=2>1100 IU/d, 1450 mg/d calcium</font></p></td><td width=256><p><font size=2>When analysis was confined to cancers diagnosed<p>after the first 12 mo, RR for the Ca + D group fell to 0.232 (CI:</p><p>0.09, 0.60; P &lt; 0.005) but did not change significantly for the</p><p>Ca-only group.</font></p></p></td><td width=123><p><font size=2>Lappe, 2007</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=4><font size=2>daily </font><font size=2>vitamin<p>D</font><font size=2>(3) (800 IU), calcium (1000 mg), both, or</p><p>placebo for 24-62 months, with a follow-up of 3 yr after</p><p>intervention</font></font></p></p></td><td width=256><p><font size=2>cancer mortality (HR = 0.85; 95% CI = 0.68-1.06),<p>and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25)</font></p></p></td><td width=123><p><font size=2>Avenell, epub</font></p></td></tr><tr valign=TOP><td width=129><p><font size=4><b><font size=2>Breast, colorectal cancer</font></b></font></p></td><td width=250><p><font size=2>400 IU/d vitamin D3, 1500 mg/d or placebo</font></p></td><td width=256><p><font size=4><font size=2>In 15,646 women (43%) who were not<p>taking personal calcium or </font><font size=2>vitamin D</font><font size=2></p><p>supplements at randomization, CaD significantly decreased the risk</p><p>of total, breast, and invasive breast cancers by 14-20% and</p><p>nonsignificantly reduced the risk of colorectal cancer by 17%. In</p><p>women taking personal calcium or </font><font size=2>vitamin D</font><font size=2></p><p>supplements, CaD did not alter cancer risk (HR: 1.06-1.26).</font></font></p></p></td><td width=123><p><font size=2>Bolland, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Cardiometric</b></font></p></td><td width=250><p><font size=2>In meta-analyses of 10 trials</font></p></td><td width=256><p><font size=2>supplementation nonsignificantly reduced systolic<p>blood pressure (weighted mean difference, -1.9 mm Hg [CI, -4.2 to</p><p>0.4 mm Hg]) and did not affect diastolic blood pressure (weighted</p><p>mean difference, -0.1 mm Hg [CI, -0.7 to 0.5 mm Hg]).</font></p></p></td><td width=123><p><font size=2>Pittas, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Cardiovascular</b></font></p></td><td width=250><p><font size=2>Vitamin D supplementation during weight loss</font></p></td><td width=256><p><font size=2>more pronounced decrease occurred in the vitamin D<p>group than in the placebo group in blood concentrations of</p><p>parathyroid hormone (-26.5% compared with -18.7%; P = 0.014),</p><p>triglycerides (-13.5% compared with +3.0%; P &lt; 0.001), and the</p><p>inflammation marker tumor necrosis factor-alpha (-10.2% compared</p><p>with -3.2%; P = 0.049).</font></p></p></td><td width=123><p><font size=2>Zittermann, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Cardiovascular disease event</b></font></p></td><td width=250><p><font size=2>Pooled study</font></p></td><td width=256><p><font size=4><font size=2>.Results of secondary analyses in 8<p>randomized trials showed a slight but statistically nonsignificant</p><p>reduction in CVD risk (pooled relative risk, 0.90 [95% CI, 0.77 to</p><p>1.05]) with </font><font size=2>vitamin D</font><font size=2></p><p>supplementation at moderate to high doses (approximately 1000</p><p>IU/d) but not with calcium supplementation (pooled relative risk,</p><p>1.14 [CI, 0.92 to 1.41]), or a combination of </font><font size=2>vitamin</p><p>D</font><font size=2> and calcium supplementation (pooled relative</p><p>risk, 1.04 [CI, 0.92 to 1.18]) compared with placebo.</font></font></p></p></td><td width=123><p><font size=2>Wang, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>CVD survival</b></font></p></td><td width=250><p><br></p></td><td width=256><p><font size=4><font size=2>Vitamin D</font><font size=2><p></font><font size=2>supplementation</font><font size=2> conferred</p><p>substantial survival benefit (odds ratio for death 0.39, 95%</p><p>confidence interval 0.277 to 0.534, p &lt;0.0001).</font></font></p></p></td><td width=123><p><font size=2>Vacek, epub</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Chronic kidney disease</b></font></p></td><td width=250><p style=margin-bottom:0><font size=2>Placebo or calcium<p>(1,200 mg) and vitamin D(3) (800 IU) in fixed or separate</p><p>combination.</font></p></p><p style=margin-bottom:0><br></p><p><font size=2>Effect on parathyroid hormone</font></p></td><td width=256><p><font size=2>The proportion with a 30% or greater decrease in<p>iPTH level at 6 months was 50% in all eGFR groups on treatment</p><p>versus 6% to 9% for placebo (P &lt; 0.001 for all). The effects of</p><p>the intervention on iPTH levels did not differ according to</p><p>baseline eGFR (interaction P > 0.1 for all times).</font></p></p></td><td width=123><p><font size=2>Kooienga, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2>1000 IU/d vs. placebo</font></p></td><td width=256><p><font size=2>Mean 25(OH)D levels increased significantly higher<p>in the treatment group (mean increase from baseline: 10.3+/-10.4</p><p>ng/mL vs. 0.8+/-6.8 ng/mL, p&lt;0.0001).</font></p></p></td><td width=123><p><font size=2>Rucker, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Depression</b></font></p></td><td width=250><p><font size=2 style=font-size:9pt>Cross-sectional study and<p>randomized double blind controlled trial of 20,000 or 40,000 IU</p><p>vitamin D per week versus placebo for 1 year.</font></p></p></td><td width=256><p><font size=2>In the two groups given vitamin D, but not in the<p>placebo group, there was a significant improvement in BDI scores</p><p>after 1 year. There was a significant decrease in serum</p><p>parathyroid hormone in the two vitamin D groups without a</p><p>concomitant increase in serum calcium.</font></p></p></td><td width=123><p><font size=2>Jorde, 2008</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Falls, fractures</b></font></p></td><td width=250><p><font size=2>700-1000 IU/d</font></p></td><td width=256><p style=margin-bottom:0><font size=2>Pooled RR = 0.81 (95%<p>CI 0.71 to 0.92)</font></p></p><p><font size=2>No effect for 400 IU/d</font></p></td><td width=123><p><font size=2>Bischoff-Ferrari, 2009b</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Falls</b></font></p></td><td width=250><p><font size=2>Our study population consisted of 242 individuals<p>recruited by advertisements and mailing lists (mean [ +/- SD] age,</p><p>77 +/- 4 years). All serum 25-hydroxyvitamin D (25[OH]D) levels</p><p>were below 78 nmol/l. Individuals received in a double blinded</p><p>fashion either 1000 mg of calcium or 1000 mg of calcium plus 800</p><p>IU of vitamin D per day over a treatment period of 12 months,</p><p>which was followed by a treatment-free but still blinded</p><p>observation period of 8 months.</font></p></p></td><td width=256><p style=margin-bottom:0><font size=2>Compared to calcium<p>mono, supplementation with calcium plus vitamin D resulted in a</p><p>significant decrease in the number of subjects with first falls of</p><p>27% at month 12 (RR = 0.73; CI = 0.54-0.96) and 39% at month 20</p><p>(RR = 0.61; CI = 0.34-0.76).</font></p></p><p><font size=2>Concerning secondary endpoints, we observed<p>significant improvements in quadriceps strength of 8%, a decrease</p><p>in body sway of 28%, and a decrease in time needed to perform the</p><p>TUG test of 11%.</font></p></p></td><td width=123><p><font size=2>Pfeifer, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Non-vertebrate fractures</b></font></p></td><td width=250><p><font size=2>700-1000 IU/d</font></p></td><td width=256><p><font size=2>pooled RR was 0.80 (95% CI, 0.72-0.89;</font></p></td><td width=123><p><font size=2>Bischoff-Ferrari, 2009a</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Gastric bypass</b></font></p></td><td width=250><p><font size=2 style=font-size:9pt>We evaluated three doses of<p>vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective,</p><p>randomized pilot trial of 45 patients undergoing Roux-en-Y gastric</p><p>bypass.</font></p></p></td><td width=256><p><font size=2 style=font-size:9pt>At 12 months, the 800-,<p>2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of</p><p>27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L,</p><p>respectively (p = 0.09) with a maximum increase in each group of</p><p>87.4, 114.8, and 129.8 nmol/L. Forty-four percent, 78%, and 70%</p><p>achieved 25OHD levels >or=75 nmol/L (p = 0.38).</font></p></p></td><td width=123><p><font size=2>Goldner, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=4><b><font size=2>Glucose (fasting plasma) (FPG)</font></b></font></p></td><td width=250><p><font size=4><font size=2>A total of 314 Caucasian adults<p>without diabetes received either 500 mg calcium citrate and 700 IU</p><p></font><font size=2>vitamin D</font><font size=2>(3) or placebos</p><p>daily for 3 years in a double-blind, randomized, controlled trial</p><p>designed for bone-related outcomes.</font></font></p></p></td><td width=256><p><font size=4><font size=2>Among participants with IFG at<p>baseline, those who took combined calcium-</font><font size=2>vitamin</p><p>D</font><font size=2> supplements had a lower rise in FPG at 3</p><p>years compared with those on placebo (0.02 mmol/l [0.4 mg/dl] vs.</p><p>0.34 mmol/l [6.1 mg/dl], respectively, P = 0.042) and a lower</p><p>increase in HOMA-IR (0.05 vs. 0.91, P = 0.031).</font></font></p></p></td><td width=123><p><font size=2>Pitas, 2007</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Haemodialysis</b></font></p></td><td width=250><p><font size=2>HD patients were included in this study if their<p>serum 25(OH)D level was &lt;75 mmol/L. Oral 25(OH)D(3) was</p><p>administered daily at 10-30 microg/day based on the severity of</p><p>the deficiency.</font></p></p></td><td width=256><p><font size=2 style=font-size:9pt>After 6 months of treatment<p>[mean daily 25(OH)D(3): 16 +/- 5 microg/day], the serum 25(OH)D</p><p>level increased (30 +/- 19 to 126 +/- 46 nmol/ L, P &lt; 0.001),</p><p>with 13% of patients in group 1, 57% in group 2 and 30% in group</p><ol start=3><li>The serum intact parathyroid hormone (iPTH) level decreased</li></ol><p>(235 +/- 186 to 189 +/- 137 pg/mL, P = 0.05), except in group 1.</p><p>Bone alkaline phosphatase (BALP) showed a tendency to normalize</p><p>(23 +/- 16 to 18.3 +/- 11 microg/L, P &lt; 0.05), leading to a</p><p>decrease in alfacalcidol administration from 66% to 43% (P &lt;</p><p>0.05), except in group 1. The KDOQI targets achieved increased</p><p>significantly for serum calcium (76% to 85%) and phosphate levels</p><p>(66% to 77%) in all patients. The serum albumin level increased in</p><p>all groups (34.6 +/- 4 to 36.8 +/- 4 g/L, P &lt; 0.05), without</p><p>any significant improvement in normalized protein catabolic rate</p><p>(nPCR) or C-reactive proteins (CRP).</font></p></p></td><td width=123><p><font size=2>Jean, 2008</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Heart failure, congestive</b></font></p></td><td width=250><p><font size=4><font size=2>either 50 mug </font><font size=2>vitamin<p>D</font><font size=2>(3)/d plus 500 mg Ca/d [D(+) group] or</p><p>placebo plus 500 mg Ca/d [D(-) group] for 9 mo</font></font></p></p></td><td width=256><p><font size=2>Compared with baseline, parathyroid hormone was<p>significantly lower and the antiinflammatory cytokine interleukin</p><p>10 was significantly higher in the D(+) group after 9 mo. The</p><p>proinflammatory cytokine tumor necrosis factor alpha increased in</p><p>the D(-) group but remained constant in the D(+) group. The</p><p>survival rate did not differ significantly between the study</p><p>groups during the follow-up period.</font></p></p></td><td width=123><p><font size=2>Schleithoff, 2006</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Infectious diseases</b></font></p></td><td width=250><p><br></p></td><td width=256><p><br></p></td><td width=123><p><font size=2>Yamshchikov, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Infections, symptomatic upper respiratory tract</b></font></p></td><td width=250><p><font size=2>50 microg vitamin D3 (2000 IU) daily or matching<p>placebo for 12 weeks.</font></p></p></td><td width=256><p><font size=2>The mean 25-hydroxyvitamin D level at baseline was<p>similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group;</p><p>63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks,</p><p>25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2</p><p>nmol/l in the vitamin D group, whereas there was no change in</p><p>vitamin D levels in the placebo group. There was no benefit of</p><p>vitamin D3 supplementation in decreasing the incidence or severity</p><p>of symptomatic URIs during winter.</font></p></p></td><td width=123><p><font size=2>Li-Ng, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Influenza</b></font></p></td><td width=250><p><font size=2>800 or 2000 IU/d</font></p></td><td width=256><p><font size=2>40 or 90% reduction</font></p></td><td width=123><p><font size=2>Aloia & Li-Ng, 2007</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Influenza type A</b></font></p></td><td width=250><p><font size=2>1100 IU/d, no other oral intake</font></p></td><td width=256><p style=margin-bottom:0><font size=2>RR: 0.36; 95% CI: 0.17,<p>0.79; P = 0.006</font></p></p><p><font size=2>No effect for type B</font></p></td><td width=123><p><font size=2>Urashima, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Insulin sensitivity</b></font></p></td><td width=250><p><font size=2>120,000 IU/fortnight</font></p></td><td width=256><p><font size=2>Seventy-one of the recruited subjects completed<p>the study (35 in supplemented group, 36 in control group). There</p><p>was an increase in oral glucose insulin sensitivity (OGIS) with</p><p>supplementation by per protocol analysis (P = 0.038;</p><p>intention-to-treat analysis P = 0.055). The age- and baseline</p><p>25-hydroxyvitamin D level-adjusted difference in change in OGIS</p><p>was highly significant (mean difference 41.1 +/- 15.5; P = 0.01).</p><p>No changes in secondary outcome measures (insulin secretion, basal</p><p>indices of insulin sensitivity, blood pressure or lipid profile)</p><p>were found with supplementation.</font></p></p></td><td width=123><p><font size=2>Nagpal, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2>double-blind intervention administering 100 microg<p>(4000 IU) vitamin D(3) (n 42) or placebo (n 39) daily for 6 months</p><p>to South Asian women, aged 23-68 years, living in Auckland, New</p><p>Zealand</font></p></p></td><td width=256><p><font size=2>Significant improvements were seen in insulin<p>sensitivity and IR (P = 0.003 and 0.02, respectively), and fasting</p><p>insulin decreased (P = 0.02) with supplementation compared with</p><p>placebo.</font></p></p></td><td width=123><p><font size=2>Von hurst, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=4><font size=2>participants with low serum 25(OH)D<p>levels were thereafter randomized to receive capsules of 20,000 IU</p><p></font><font size=2>vitamin D</font><font size=2>(3) or</p><p>identical-looking placebo twice weekly for 6 months.</font></font></p></p></td><td width=256><p><font size=4><font size=2 style=font-size:9pt>The 52<p>participants with high serum 25(OH)D levels (85.6 ± 13.5</p><p>nmol/L [mean ± SD]) had significantly higher insulin</p><p>sensitivity index (ISI) and lower HbA(1c) and triglycerides (TGs)</p><p>than the 108 participants with low serum 25(OH)D (40.3 ±</p><p>12.8 nmol/L), but the differences in ISI and TGs were not</p><p>significant after adjustments. After supplementation, serum</p><p>25(OH)D was 142.7 ± 25.7 and 42.9 ± 17.3 nmol/L in</p><p>49 of 51 completing participants randomized to </font><font size=2 style=font-size:9pt>vitamin</p><p>D</font><font size=2 style=font-size:9pt> and 45 of 53</p><p>randomized to placebo, respectively. At the end of the study,</p><p>there were no statistically significant differences in the outcome</p><p>variables between the two groups.</font></font></p></p></td><td width=123><p><font size=2>Grimnes, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2>cholecalciferol (2000 IU once daily) or calcium<p>carbonate (400 mg twice daily) for 16 wk.</font></p></p></td><td width=256><p><font size=4><font size=2 style=font-size:9pt>The<p>disposition index increased in the </font><font size=2 style=font-size:9pt>vitamin</p><p>D</font><font size=2 style=font-size:9pt> group and decreased</p><p>in the no-</font><font size=2 style=font-size:9pt>vitamin D</font><font size=2 style=font-size:9pt></p><p>group (adjusted mean change ± SE: 300 ± 130 compared</p><p>with -126 ± 127, respectively; P = 0.011), which was</p><p>explained by an improvement in insulin secretion (62 ± 39</p><p>compared with -36 ± 37 mU · L(-1) · min,</p><p>respectively; P = 0.046). Hb A(1c) increased less, but</p><p>nonsignificantly, in the </font><font size=2 style=font-size:9pt>vitamin</p><p>D</font><font size=2 style=font-size:9pt> group than in the</p><p>no-</font><font size=2 style=font-size:9pt>vitamin D</font><font size=2 style=font-size:9pt></p><p>group (0.06 ± 0.03% compared with 0.14 ± 0.03%,</p><p>respectively; P = 0.081).</font></font></p></p></td><td width=123><p><font size=2>Mitri, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=4><b><font size=2>Muscle strength</font></b></font></p></td><td width=250><p><font size=2 style=font-size:9pt>6-month supplementation<p>(December to May) of daily calcium plus monthly placebo</p><p>(calcium/placebo group) or daily calcium plus oral cholecalciferol</p><p>(150,000 IU once a month during the first 2 months, followed by</p><p>90,000 IU once a month for the last 4 months; calcium/vitamin D</p><p>group)</font></p></p></td><td width=256><p style=margin-bottom:0><font size=2>SHF was increased in<p>the calcium/vitamin D group by 16.4% (p = 0.0001) and SKE by 24.6%</p><p>(p = 0.0007).</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>[strength of hip flexors (SHF) and knee extensors</p><p>(SKE)]</font></p></p><p><br></p></td><td width=123><p><font size=2>Moreira-Pfrimer, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2>800 or 1600 IU/d plus vibration</font></p></td><td width=256><p><font size=2>Same improvements with both doses</font></p></td><td width=123><p><font size=2>Verschueren, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Musculoskeletal parameters</b></font></p></td><td width=250><p><font size=4><font size=2>One hundred seventy-nine girls, ages<p>10-17 yr, were randomly assigned to receive weekly oral </font><font size=2>vitamin</p><p>D</font><font size=2> doses of 1,400 IU (equivalent to 200 IU/d)</p><p>or 14,000 IU (equivalent to 2,000 IU/d) in a double-blind,</p><p>placebo-controlled, 1-yr protocol.</font></font></p></p></td><td width=256><p><font size=2>In the overall group of girls, lean mass increased<p>significantly in both treatment groups (P &lt; or = 0.05); bone</p><p>area and total hip BMC increased in the high-dose group (P &lt;</p><p>0.02). In premenarcheal girls, lean mass increased significantly</p><p>in both treatment groups, and there were consistent trends for</p><p>increments in BMD and/or BMC at several skeletal sites, reaching</p><p>significance at lumbar spine BMD in the low-dose group and at the</p><p>trochanter BMC in both treatment groups. There was no significant</p><p>change in lean mass, BMD, or BMC in postmenarcheal girls.</font></p></p></td><td width=123><p><font size=2>El-Hajj, 2006</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Multiple sclerosis</b></font></p></td><td width=250><p lang=da-DK><font size=2>6000 IU/d vitamin D2 vs. 1000 IU/d<p>vitamin D2</font></p></p></td><td width=256><p><font size=2>There were 4 relapses with high-dose D2 vs none<p>with low-dose D2 (p = 0.04).</font></p></p></td><td width=123><p><font size=2>Stein, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Neuromuscular</b></font></p></td><td width=250><p><font size=2>8400 IU/week</font></p></td><td width=256><p><font size=2>significantly reduced sway compared with treatment<p>with placebo (P = 0.047) in patients with elevated baseline sway</p><p>but not in patients with normal baseline sway.</font></p></p></td><td width=123><p><font size=2>Lips, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Physical performance</b></font></p></td><td width=250><p><br></p></td><td width=256><p><font size=2>gait speed was higher among subjects supplemented<p>with vitamin (whether trained or not) than in non-supplemented</p><p>subjects (838+/-147 and 768+/-127 m/12 min, respectively, p=0.02).</font></p></p></td><td width=123><p><font size=2>Bunout, 2006</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Pneumonia</b></font></p></td><td width=250><p><font size=2>Children, 100,000 IU once</font></p></td><td width=256><p><font size=2>Children in the </font><font size=2>vitamin D</font><font size=2>(3)<p>group survived longer without experiencing a repeat episode (72</p><p>days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P = 0.02).</font></p></p></td><td width=123><p><font size=2>Manaseki-Holland, 2010</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=4><font size=2>Oral </font><font size=2>vitamin D</font><font size=2><p>(1000 IU for &lt;1 year and 2000 IU for >1 year) (n=100) or</p><p>placebo (lactose) (n=100) once a day for 5 days, from enrolment.</font></font></p></p></td><td width=256><p><font size=4><font size=2>Median duration (SE, 95% CI) of<p>resolution of severe pneumonia was similar in the two groups</p><p>[</font><font size=2>vitamin D</font><font size=2>: 72 (3.7,</p><p>64.7-79.3) hours; placebo: 64 (4.5, 55.2-72.8)hours]. Duration of</p><p>hospitalization and time to resolution of tachypnea, chest</p><p>retractions, and inability to feed were also comparable between</p><p>the two groups.</font></font></p></p></td><td width=123><p><font size=2>Choudhary & Gupta, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Pregnancy</b></font></p></td><td width=250><p><font size=2>4000 IU/d</font></p></td><td width=256><p><font size=2>No adverse effects on serum or urine calcium</font></p></td><td width=123><p><font size=2>Hollis, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Stress fractures</b></font></p></td><td width=250><p><font size=2>Navy females, 800 IU/d, 2000 mg/d calcium</font></p></td><td width=256><p><font size=2>21% lower incidence</font></p></td><td width=123><p><font size=2>Lappe, 2008</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Testosterone</b></font></p></td><td width=250><p><font size=2>Participants received either 83 &mu;g (3,332 IU)<p>vitamin D daily for 1 year (n = 31) or placebo (n =2 3).</font></p></p></td><td width=256><p><font size=2 style=font-size:9pt>Compared to baseline<p>values, a significant increase in total testosterone levels (from</p><p>10.7 ± 3.9 nmol/l to 13.4 ± 4.7 nmol/l; p &lt;</p><p>0.001), bioactive testosterone (from 5.21 ± 1.87 nmol/l to</p><p>6.25 ± 2.01 nmol/l; p = 0.001), and free testosterone</p><p>levels (from 0.222 ± 0.080 nmol/l to 0.267 ± 0.087</p><p>nmol/l; p = 0.001) were observed in the vitamin D supplemented</p><p>group. By contrast, there was no significant change in any</p><p>testosterone measure in the placebo group</font></p></p></td><td width=123><p><font size=2>Pilz, 2011</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Tooth loss</b></font></p></td><td width=250><p><font size=2>Elderly, taking supplements or not</font></p></td><td width=256><p><font size=2>During the randomized trial, 11 of the 82 subjects<p>(13%) taking supplements and 17 of the 63 subjects (27%) taking</p><p>placebo lost one or more teeth (OR = 0.4; 95% CI: 0.2 to 0.9).</font></p></p></td><td width=123><p><font size=2>Krall, 2001</font></p></td></tr><tr valign=TOP><td width=129><p><font size=2><b>Tuberculosis</b></font></p></td><td width=250><p><font size=2>The subjects were randomised to receive vitamin D<p>(0.25 mg/day) or placebo in a double blind method, during the 6th</p><p>initial week of Tb treatment.</font></p></p></td><td width=256><p style=margin-bottom:0><font size=2>One hundred percent of<p>the vitamin D group and only 76.7% of the placebo group had sputum</p><p>conversion. This difference is statistically significant</p><p>(p=0.002).</font></p></p><p><br></p></td><td width=123><p><font size=2>Nursyam, 2006</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2 style=font-size:9pt>The intervention was<p>100,000 IU of cholecalciferol or placebo at inclusion and again 5</p><p>and 8 months after the start of treatment.</font></p></p></td><td width=256><p><font size=4><font size=2 style=font-size:9pt>Overall<p>mortality was 15% (54 of 365) at 1 year of follow-up and similar</p><p>in both arms (30 of 187 for </font><font size=2 style=font-size:9pt>vitamin</p><p>D</font><font size=2 style=font-size:9pt> treated and 24 of 178</p><p>for placebo; relative risk, 1.19 [0.58-1.95]).</font></font></p></p></td><td width=123><p><font size=2>Wejse, 2009</font></p></td></tr><tr valign=TOP><td width=129><p><br></p></td><td width=250><p><font size=2>A single oral dose of 2.5 mg (100,000 IU) vitamin<p>D</font></p></p></td><td width=256><p><font size=2>significantly enhanced the ability of<p>participants&rsquo; whole blood to restrict BCG-lux luminescence in</p><p>vitro without affecting antigen-stimulated IFN-gamma responses.</font></p></p></td><td width=123><p><font size=2>Martineau, 2011</font></p></td></tr></table><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><br></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;page-break-before:always><p><font color=#b80047><font size=4>References</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Ahearn TU, McCullough ML, Flanders WD, Long Q,</p><p>Sidelnikov E, </font><font size=2>Fedirko</font><font size=2> V,</p><p>Daniel CR, Rutherford RE, Shaukat A, </font><font size=2>Bostick</font><font size=2></p><p>RM. A randomized clinical trial of the effects of supplemental</p><p>calcium and vitamin D3 on markers of their metabolism in normal</p><p>mucosa of colorectal adenoma patients. </font><font size=2>Cancer</p><p>Res</font><font size=2>. 2011 Jan 15;71(2):413-23.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Aloia</font><font size=2> JF, </font><font size=2>Li-Ng</font><font size=2></p><p>M. Re: epidemic influenza and vitamin D. </font><font size=2>Epidemiol</p><p>Infect</font><font size=2>. </font><font size=2>2007</font><font size=2></p><p>Oct;135(7):1095-6; author reply 1097-8.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized</p><p>controlled trial of vitamin D3 supplementation in African American</p><p>women. </font><font size=2>Arch Intern Med</font><font size=2>. 2005</p><p>Jul 25;165(14):1618-23.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed/17846391?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=1"><font size=2>Autier</p><p>P, Gandini S. Vitamin D supplementation and total mortality: a</p><p>meta-analysis of randomized controlled trials.</font></a></u></font><font size=2></p><p></font><font size=2>Arch Intern Med</font><font size=2>. 2007 Sep</p><p>10;167(16):1730-7.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Avenell</font><font size=2> A, </font><font size=2>Cook</font><font size=2></p><p>JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent</p><p>infections: a sub-study of a randomised placebo-controlled trial in</p><p>older people (RECORD trial, ISRCTN 51647438). </font><font size=2>Age</p><p>Ageing</font><font size=2>. </font><font size=2>2007</font><font size=2></p><p>Sep;36(5):574-7.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Avenell A, Maclennan GS, Jenkinson DJ, McPherson GC,</p><p>McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C,</p><p>Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA; the</p><p>RECORD Trial Group. Long-Term Follow-Up for Mortality and Cancer in a</p><p>Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium</p><p>(RECORD Trial). </font><font size=2>J Clin Endocrinol Metab</font><font size=2>.</p><p>2011 Nov 23. [Epub ahead of print]</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav</p><p>JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J.</p><p>Fall prevention with supplemental and active forms of vitamin D: a</p><p>meta-analysis of randomised controlled trials. </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bischoff-Ferrari%20HA%2C%20Dawson-Hughes%20B%2C%20Staehelin%20HB%2C%20Orav%20JE%2C%20Stuck%20AE"><font size=2>BMJ.</font></a></u></font><font size=2></p><p>2009b Oct 1;339:b3692. doi: 10.1136/bmj.b3692.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock</p><p>J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D</p><p>supplementation. </font><font size=2>Osteoporos Int</font><font size=2>.</p><p>2010 Jul;21(7):1121-32.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E,</p><p>Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D</p><p>supplementation: a meta-analysis of randomized controlled trials.</p><p></font><font size=2>JAMA</font><font size=2>. 2005 May</p><p>11;293(18):2257-64.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font size=2>Bischoff-Ferrari HA, Willett WC, Wong JB,</p><p>Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J.</p><p></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed/19307517?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=65"><font size=2>Prevention</p><p>of nonvertebral fractures with oral vitamin D and dose dependency: a</p><p>meta-analysis of randomized controlled trials.</font></a></u></font><font size=2></p><p></font><font size=2>Arch Intern Med</font><font size=2>. 2009a Mar</p><p>23;169(6):551-61.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bjelakovic G, Gluud LL, Nikolova D, Whitfield K,</p><p>Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. </font><font size=2>Vitamin</p><p>D</font><font size=2> supplementation for prevention of mortality in</p><p>adults. </font><font size=2>Cochrane Database Syst Rev</font><font size=2>.</p><p>2011 Jul 6;(7):CD007470.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bolland</font><font size=2> MJ, Grey A, Gamble GD, Reid</p><p>IR. Calcium and </font><font size=2>vitamin D</font><font size=2></p><p>supplements and health outcomes: a reanalysis of the Women&rsquo;s Health</p><p>Initiative (WHI) limited-access data set. </font><font size=2>Am J</p><p>Clin Nutr</font><font size=2>. 2011 Oct;94(4):1144-9.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP,</p><p>Avendaño M, Hirsch S. Effects of vitamin D supplementation and</p><p>exercise training on physical performance in Chilean vitamin D</p><p>deficient elderly subjects. </font><font size=2>Exp Gerontol</font><font size=2>.</p><p>2006 Aug;41(8):746-52.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Burgi AA, Gorham ED, Garland CF, Mohr SB, Garland FC,</p><p>Zeng K, Thompson K, Lappe JM. High serum 25-hydroxyvitamin D is</p><p>associated with a low incidence of stress fractures. </font><font size=2>J</p><p>Bone Miner Res</font><font size=2>. 2011 Oct;26(10):2371-7.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Burleigh E, McColl J, Potter J. Does vitamin D stop</p><p>inpatients falling? A randomised controlled trial. </font><font size=2>Age</p><p>Ageing</font><font size=2>. 2007 Sep;36(5):507-13.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Choudhary N, Gupta P. </font><font size=2>Vitamin D</font><font size=2></p><p>Supplementation for Severe Pneumonia A </font><font size=2>Randomized</p><p>Controlled Trial</font><font size=2>. </font><font size=2>Indian</p><p>Pediatr</font><font size=2>. 2011 Aug 15. pii: S097475591100214-1.</p><p>[Epub ahead of print]</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al.</p><p>(2009). Vitamin D and calcium: a systematic review of health</p><p>outcomes. </font><font size=2><i>Evid Rep Technol Assess (Full</p><p>Rep)</i></font><font size=2>(183), 1-420. (Prepared by Tufts</p><p>Evidence-based Practice Center under Contract No. 290-2007-10055-I).</p><p>AHRQ Publication No. 09-E015, Rockville, MD: Agency for Healthcare</p><p>Research and Quality. August 2009.</p><p>(<a href=http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf>http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf</a>)</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA.</p><p>Vitamin D With or Without Calcium Supplementation for Prevention of</p><p>Cancer and Fractures: An Updated Meta-analysis for the U.S.</p><p>Preventive Services Task Force. </font><font size=2>Ann Intern Med</font><font size=2>.</p><p>2011 Dec 20;155(12):827-38.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Dean AJ, Bellgrove MA, Hall T, Phan WM, Eyles DW,</p><p>Kvaskoff D, McGrath JJ. Effects of </font><font size=2>vitamin d</font><font size=2></p><p>supplementation on cognitive and emotional functioning in young</p><p>adults - a </font><font size=2>randomised controlled trial</font><font size=2>.</p><p></font><font size=2>PLoS One</font><font size=2>. 2011;6(11):e25966.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Dhesi</font><font size=2> JK, Jackson SH, Bearne LM,</p><p>Moniz C, Hurley MV, Swift CG, Allain TJ. </font><font size=2>Vitamin</p><p>D</font><font size=2> supplementation improves neuromuscular function</p><p>in older people who fall. </font><font size=2>Age Ageing</font><font size=2>.</p><p></font><font size=2>2004</font><font size=2> Nov;33(6):589-95.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>El-Hajj Fuleihan G, Nabulsi M, Tamim H, Maalouf J,</p><p>Salamoun M, Khalife H, Choucair M, Arabi A, Vieth R. Effect of</p><p>vitamin D replacement on musculoskeletal parameters in school</p><p>children: a randomized controlled trial. </font><font size=2>J Clin</p><p>Endocrinol Metab</font><font size=2>. 2006 Feb;91(2):405-12.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Fedirko</font><font size=2> V, </font><font size=2>Bostick</font><font size=2></p><p>RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen</p><p>V, Dash C. Effects of vitamin D and calcium supplementation on</p><p>markers of apoptosis in normal colon mucosa: a randomized,</p><p>double-blind, placebo-controlled clinical trial. </font><font size=2>Cancer</p><p>Prev Res (Phila)</font><font size=2>. 2009 Mar;2(3):213-23.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Fedirko</font><font size=2> V, </font><font size=2>Bostick</font><font size=2></p><p>RM, Flanders WD, Long Q, Sidelnikov E, Shaukat A, Daniel CR,</p><p>Rutherford RE, Woodard JJ. Effects of vitamin d and calcium on</p><p>proliferation and differentiation in normal colon mucosa: a</p><p>randomized clinical trial. </font><font size=2>Cancer Epidemiol</p><p>Biomarkers Prev</font><font size=2>. 2009 Nov;18(11):2933-41.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Fedirko</font><font size=2> V, </font><font size=2>Bostick</font><font size=2></p><p>RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, Daniel CR,</p><p>Rutherford RE, Shaukat A. Effects of supplemental vitamin D and</p><p>calcium on oxidative DNA damage marker in normal colorectal mucosa: a</p><p>randomized clinical trial. </font><font size=2>Cancer Epidemiol</p><p>Biomarkers Prev</font><font size=2>. 2010 Jan;19(1):280-91.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR,</p><p>Prince RL. Effects of three monthly oral 150,000 IU cholecalciferol</p><p>supplementation on falls, mobility and muscle strength in older</p><p>postmenopausal women: a </font><font size=2>randomised controlled</p><p>trial</font><font size=2>. </font><font size=2>J Bone Miner Res</font><font size=2>.</p><p>2011 Sep 28. doi: 10.1002/jbmr.524. [Epub ahead of print]</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K,</p><p>Larson L, Erickson J, McBride C. Finding the optimal dose of vitamin</p><p>D following Roux-en-Y gastric bypass: a prospective, randomized pilot</p><p>clinical trial. </font><font size=2>Obes Surg</font><font size=2>.</p><p>2009 Feb;19(2):173-9.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Grimnes G, Figenschau Y, Almås B, Jorde R. </font><font size=2>Vitamin</p><p>D</font><font size=2>, insulin secretion, sensitivity, and lipids:</p><p>results from a case-control study and a </font><font size=2>randomized</p><p>controlled trial</font><font size=2> using hyperglycemic clamp</p><p>technique. </font><font size=2>Diabetes</font><font size=2>. 2011</p><p>Nov;60(11):2748-57.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Heaney</font><font size=2> RP, Recker RR, Grote J, Horst</p><p>RL, Armas LA. </font><font size=2>Vitamin</font><font size=2> D(3) is</p><p>more potent than </font><font size=2>vitamin</font><font size=2> D(2)</p><p>in humans. </font><font size=2>J Clin Endocrinol Metab</font><font size=2>.</p><p>2011 Mar;96(3):E447-52.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL.</p><p>Vitamin D supplementation during pregnancy: double-blind, randomized</p><p>clinical trial of safety and effectiveness. </font><font size=2>J</p><p>Bone Miner Res</font><font size=2>. 2011 Oct;26(10):2341-57.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Hopkins MH, Owen J, Ahearn T, </font><font size=2>Fedirko</font><font size=2></p><p>V, Flanders WD, Jones DP, </font><font size=2>Bostick</font><font size=2></p><p>RM. Effects of supplemental vitamin D and calcium on biomarkers of</p><p>inflammation in colorectal adenoma patients: a randomized, controlled</p><p>clinical trial. </font><font size=2>Cancer Prev Res (Phila)</font><font size=2>.</p><p>2011 Oct;4(10):1645-54.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Houghton LA, Vieth R. The case against ergocalciferol</p><p>(vitamin D2) as a vitamin supplement. </font><font size=2>Am J Clin</p><p>Nutr</font><font size=2>. 2006 Oct;84(4):694-7.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor</p><p>B, Chazot C. Daily oral 25-hydroxycholecalciferol supplementation for</p><p>vitamin D deficiency in haemodialysis patients: effects on mineral</p><p>metabolism and bone markers. </font><font size=2>Nephrol Dial</p><p>Transplant</font><font size=2>. 2008 Nov;23(11):3670-6.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K.</p><p>Effects of vitamin D supplementation on symptoms of depression in</p><p>overweight and obese subjects: randomized double blind trial. </font><font size=2>J</p><p>Intern Med</font><font size=2>. 2008 Dec;264(6):599-609.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Kooienga L, Fried L, Scragg R, Kendrick J, Smits G,</p><p>Chonchol M. The effect of combined calcium and vitamin D3</p><p>supplementation on serum intact parathyroid hormone in moderate CKD.</p><p></font><font size=2>Am J Kidney Dis</font><font size=2>. 2009</p><p>Mar;53(3):408-16.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Krall EA, Wehler C, Garcia RI, Harris SS, Dawson-Hughes</p><p>B. Calcium and vitamin D supplements reduce tooth loss in the</p><p>elderly. </font><font size=2>Am J Med</font><font size=2>. 2001 Oct</p><p>15;111(6):452-6.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Kumar GT, Sachdev HS, Chellani H, Rehman AM, Singh V,</p><p>Arora H, Filteau S. Effect of weekly </font><font size=2>vitamin D</font><font size=2></p><p>supplements on mortality, morbidity, and growth of low birthweight</p><p>term infants in India up to age 6 months: </font><font size=2>randomised</p><p>controlled trial</font><font size=2>. </font><font size=2>BMJ</font><font size=2>.</p><p>2011 May 31;342:d2975.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font size=2>Lappe J, Cullen D, Haynatzki G, Recker R,</p><p>Ahlf R, Thompson K. </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed/18433305?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=1"><font size=2>Calcium</p><p>and vitamin d supplementation decreases incidence of stress fractures</p><p>in female navy recruits.</font></a></u></font><font size=2> </font><font size=2>J</p><p>Bone Miner Res</font><font size=2>. 2008 May;23(5):741-9.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Lappe</font><font size=2> JM, Travers-Gustafson D,</p><p>Davies KM, Recker RR, Heaney RP. </font><font size=2>Vitamin D</font><font size=2></p><p>and calcium supplementation reduces cancer risk: results of a</p><p>randomized trial. </font><font size=2>Am J Clin Nutr</font><font size=2>.</p><p>2007 Jun;85(6):1586-91.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font size=2>Li-Ng M, Aloia JF, Pollack S, Cunha BA,</p><p>Mikhail M, Yeh J, Berbari N. </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed/19296870?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=70"><font size=2>A</p><p>randomized controlled trial of vitamin D3 supplementation for the</p><p>prevention of symptomatic upper respiratory tract infections.</font></a></u></font><font size=2></p><p></font><font size=2>Epidemiol Infect</font><font size=2>. 2009</p><p>Oct;137(10):1396-404.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Lips P, Binkley N, Pfeifer M, Recker R, Samanta S, Cohn</p><p>DA, Chandler J, Rosenberg E, Papanicolaou DA. Once-weekly dose of</p><p>8400 IU vitamin D(3) compared with placebo: effects on neuromuscular</p><p>function and tolerability in older adults with vitamin D</p><p>insufficiency. </font><font size=2>Am J Clin Nutr</font><font size=2>.</p><p>2010 Apr;91(4):985-91.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J,</p><p>Zulf Mughal M, Chandramohan D, Walraven G. Effects of </font><font size=2>vitamin</p><p>D</font><font size=2> supplementation to children diagnosed with</p><p>pneumonia in </font><font size=2>Kabul</font><font size=2>: a</p><p>randomised controlled trial. </font><font size=2>Trop Med Int Health</font><font size=2>.</p><p>2010 Oct;15(10):1148-55.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font size=2 style=font-size:11pt>Manaseki-Holland S,</p><p>Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D,</p><p>Walraven G. </font><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20723187><font size=2 style=font-size:11pt>Effects</p><p>of vitamin D supplementation to children diagnosed with pneumonia in</p><p>Kabul: a randomised controlled trial.</font></a></u></font><font size=2 style=font-size:11pt></p><p></font><font size=2 style=font-size:11pt>Trop Med Int Health</font><font size=2 style=font-size:11pt>.</p><p></font><font size=2 style=font-size:11pt>2010 Oct;15(10):1148-55.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Martineau</font><font size=2> AR, Timms PM, Bothamley</p><p>GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC,</p><p>Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward</p><p>NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM,</p><p>Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA,</p><p>Eldridge SM, Griffiths CJ. High-dose </font><font size=2>vitamin D</font><font size=2>(3)</p><p>during intensive-phase antimicrobial treatment of pulmonary</p><p>tuberculosis: a double-blind randomised controlled trial. </font><font size=2>Lancet</font><font size=2>.</p><p>2011 Jan 15;377(9761):242-50.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Martineau</font><font size=2> AR, </font><font size=2>Wilkinson</font><font size=2></p><p>RJ, </font><font size=2>Wilkinson</font><font size=2> KA, Newton SM,</p><p>Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ,</p><p>Rainbow SJ, Berry JL, Griffiths CJ. A single dose of vitamin D</p><p>enhances immunity to mycobacteria. </font><font size=2>Am J Respir</p><p>Crit Care Med</font><font size=2>. 2007 Jul 15;176(2):208-13.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Meier</font><font size=2> C, </font><font size=2>Woitge</font><font size=2></p><p>HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin</p><p>D3 and calcium during winter prevents seasonal bone loss: a</p><p>randomized controlled open-label prospective trial. </font><font size=2>J</p><p>Bone Miner Res</font><font size=2>. 2004 Aug;19(8):1221-30.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of</p><p></font><font size=2>vitamin D</font><font size=2> and calcium</p><p>supplementation on pancreatic β cell function, insulin</p><p>sensitivity, and glycemia in adults at high risk of diabetes: the</p><p>Calcium and </font><font size=2>Vitamin D</font><font size=2> for</p><p>Diabetes Mellitus (CaDDM) </font><font size=2>randomized controlled</p><p>trial</font><font size=2>. </font><font size=2>Am J Clin Nutr</font><font size=2>.</p><p>2011 Aug;94(2):486-94.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Moreira-Pfrimer LD, Pedrosa MA, Teixeira L,</p><p>Lazaretti-Castro M. Treatment of vitamin D deficiency increases lower</p><p>limb muscle strength in institutionalized older people independently</p><p>of regular physical activity: a randomized double-blind controlled</p><p>trial. </font><font size=2>Ann Nutr Metab</font><font size=2>.</p><p>2009;54(4):291-300.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Nagpal J, Pande JN, Bhartia A. A double-blind,</p><p>randomized, placebo-controlled trial of the short-term effect of</p><p>vitamin D3 supplementation on insulin sensitivity in apparently</p><p>healthy, middle-aged, centrally obese men. </font><font size=2>Diabet</p><p>Med</font><font size=2>. 2009 Jan;26(1):19-27.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D</p><p>as supplementary treatment in patients with moderately advanced</p><p>pulmonary tuberculous lesion. </font><font size=2>Acta Med Indones</font><font size=2>.</p><p>2006 Jan-Mar;38(1):3-5.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Papaioannou A, Kennedy CC, Giangregorio L, Ioannidis G,</p><p>Pritchard J, Hanley DA, Farrauto L, DeBeer J, Adachi JD. A </font><font size=2>randomized</p><p>controlled trial</font><font size=2> of </font><font size=2>vitamin D</font><font size=2></p><p>dosing strategies after acute hip fracture: no advantage of loading</p><p>doses over daily supplementation. </font><font size=2>BMC</p><p>Musculoskelet Disord</font><font size=2>. 2011 Jun 20;12:135.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Pfeifer M, Begerow B, Minne HW, Suppan K,</p><p>Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and</p><p>calcium supplementation on falls and parameters of muscle function in</p><p>community-dwelling older individuals. </font><font size=2>Osteoporos</p><p>Int</font><font size=2>. 2009 Feb;20(2):315-22.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J,</p><p>Obermayer-Pietsch B, Wehr E, Zittermann A. Effect of vitamin D</p><p>supplementation on testosterone levels in men. </font><font size=2><span lang=de-DE>Horm</p><p>Metab Res</span></font><font size=2><span lang=de-DE>. 2011</p><p>Mar;43(3):223-5.</span></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2><span lang=de-DE>Pittas AG, Chung M, Trikalinos T,</p><p>Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM.</p><p></span></font><font size=2>Systematic review: Vitamin D and</p><p>cardiometabolic outcomes. </font><font size=2>Ann Intern Med</font><font size=2>.</p><p>2010 Mar 2;152(5):307-14.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Pittas</font><font size=2> AG, Harris SS, Stark PC,</p><p>Dawson-Hughes B. The effects of calcium and </font><font size=2>vitamin</p><p>D</font><font size=2> supplementation on blood glucose and markers of</p><p>inflammation in nondiabetic adults. </font><font size=2>Diabetes</p><p>Care</font><font size=2>. </font><font size=2>2007</font><font size=2></p><p>Apr;30(4):980-6.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM,</p><p>Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs</p><p>CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary</p><p>reference intakes for calcium and vitamin D from the Institute of</p><p>Medicine: what clinicians need to know. </font><font size=2>J Clin</p><p>Endocrinol Metab</font><font size=2>. 2011 Jan;96(1):53-8.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon</p><p>AW. Vitamin D insufficiency and treatment with oral vitamin D3 in</p><p>northern-dwelling patients with chronic kidney disease. </font><font size=2>J</p><p>Nephrol</font><font size=2>. 2009 Jan-Feb;22(1):75-82.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Schleithoff</font><font size=2> SS, Zittermann A,</p><p>Tenderich G, Berthold HK, Stehle P, Koerfer R. </font><font size=2>Vitamin</p><p>D</font><font size=2> supplementation improves cytokine profiles in</p><p>patients with congestive heart failure: a double-blind, randomized,</p><p>placebo-controlled trial. </font><font size=2>Am J Clin Nutr</font><font size=2>.</p><p></font><font size=2>2006</font><font size=2> Apr;83(4):754-9.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Scragg R, Khaw KT, Murphy S. Effect of winter oral</p><p>vitamin D3 supplementation on cardiovascular risk factors in elderly</p><p>adults. </font><font size=2>Eur J Clin Nutr</font><font size=2>. 1995</p><p>Sep;49(9):640-6.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr.</p><p>Randomized controlled trial of vitamin D supplementation for</p><p>winter-related atopic dermatitis in Boston: a pilot study. </font><font size=2>Br</p><p>J Dermatol</font><font size=2>. 2008 Jul;159(1):245-7.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield</p><p>MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ. A</p><p>randomized trial of high-dose vitamin D2 in relapsing-remitting</p><p>multiple sclerosis. </font><font size=2>Neurology</font><font size=2>.</p><p>2011 Oct 25;77(17):1611-8.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E,</p><p>Vitolins MZ, Zeitouni NC, Larson J, Stefanick ML. Calcium plus</p><p></font><font size=2>vitamin D</font><font size=2> supplementation and</p><p>the risk of nonmelanoma and melanoma skin cancer: post hoc analyses</p><p>of the women&rsquo;s health initiative </font><font size=2>randomized</p><p>controlled trial</font><font size=2>. </font><font size=2>J Clin</p><p>Oncol</font><font size=2>. 2011 Aug 1;29(22):3078-84.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Toss G, Magnusson P. Is a daily supplementation with 40</p><p>microgram </font><font size=2>vitamin D</font><font size=2>(3)</p><p>sufficient? A </font><font size=2>randomised controlled trial</font><font size=2>.</p><p></font><font size=2>Eur J Nutr</font><font size=2>. 2011 Nov 16.</p><p>[Epub ahead of print]</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Urashima</font><font size=2> M, Segawa T, Okazaki M,</p><p>Kurihara M, Wada Y, Ida H. Randomized trial of </font><font size=2>vitamin</p><p>D</font><font size=2> supplementation to prevent seasonal influenza A</p><p>in schoolchildren. </font><font size=2>Am J Clin Nutr</font><font size=2>.</p><p>2010 May;91(5):1255-60.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard</p><p>PA. </font><font size=2>Vitamin D</font><font size=2> Deficiency and</p><p></font><font size=2>Supplementation</font><font size=2> and Relation</p><p>to </font><font size=2>Cardiovascular</font><font size=2> Health. </font><font size=2>Am</p><p>J Cardiol</font><font size=2>. 2011 Nov 7. [Epub ahead of print]</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Verschueren SM, Bogaerts A, Delecluse C, Claessens AL,</p><p>Haentjens P, Vanderschueren D, Boonen S. The effects of whole-body</p><p>vibration training and vitamin D supplementation on muscle strength,</p><p>muscle mass, and bone density in institutionalized elderly women: a</p><p>6-month randomized, controlled trial. </font><font size=2>J Bone</p><p>Miner Res</font><font size=2>. 2011 Jan;26(1):42-9.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>von Hurst PR, Stonehouse W, Coad J. Vitamin D</p><p>supplementation reduces insulin resistance in South Asian women</p><p>living in New Zealand who are insulin resistant and vitamin D</p><p>deficient - a randomised, placebo-controlled trial. </font><font size=2><span lang=de-DE>Br</p><p>J Nutr</span></font><font size=2><span lang=de-DE>. 2010</p><p>Feb;103(4):549-55.</span></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2><span lang=de-DE>Wang</span></font><font size=2><span lang=de-DE></p><p>L, </span></font><font size=2><span lang=de-DE>Manson</span></font><font size=2><span lang=de-DE></p><p>JE, Song Y, Sesso HD. </span></font><font size=2>Systematic review:</p><p></font><font size=2>Vitamin D</font><font size=2> and calcium</p><p>supplementation in prevention of cardiovascular events. </font><font size=2>Ann</p><p>Intern Med</font><font size=2>. </font><font size=2>2010</font><font size=2></p><p>Mar 2;152(5):315-23</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Wejse</font><font size=2> C, Gomes VF, Rabna P,</p><p>Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M.</p><p></font><font size=2>Vitamin D</font><font size=2> as supplementary</p><p>treatment for tuberculosis: a double-blind, randomized,</p><p>placebo-controlled trial. </font><font size=2>Am J Respir Crit Care</p><p>Med</font><font size=2>. 2009 May 1;179(9):843-50.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><p><font size=2>Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR,</p><p>Tangpricha V. Vitamin D for treatment and prevention of infectious</p><p>diseases: a systematic review of randomized controlled trials. </font><font size=2>Endocr</p><p>Pract</font><font size=2>. 2009 Jul-Aug;15(5):438-49.</font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font size=2>Zittermann A, Frisch S, Berthold HK,</p><p>Götting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R.</p><p></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed/19321573?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=63"><font size=2>Vitamin</p><p>D supplementation enhances the beneficial effects of weight loss on</p><p>cardiovascular disease risk markers.</font></a></u></font><font size=2></p><p></font><font size=2>Am J Clin Nutr</font><font size=2>. 2009</p><p>May;89(5):1321-7.</font></font></p></p><p style=margin-left:.5in;text-indent:-.5in;margin-bottom:0;background:#fff><p><font size=4><font color=#b80047><font size=4><b>Abstracts</b></font></font></font></p></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19797342><font size=2>BMJ.</font></a></u></font><font size=2><p>2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Fall<p>prevention with supplemental and active forms of vitamin D: a</p><p>meta-analysis of randomised controlled trials.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bischoff-Ferrari<p>HA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Staehelin</p><p>HB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Orav</p><p>JE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stuck</p><p>AE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Theiler</p><p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wong</p><p>JB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Egli</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kiel</p><p>DP</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Henschkowski</p><p>J</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Centre on Aging and<p>Mobility, University of Zurich, Switzerland. <a href=mailto:heike.bischoff@usz.ch>heike.bischoff@usz.ch</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To test the efficacy of<p>supplemental vitamin D and active forms of vitamin D with or without</p><p>calcium in preventing falls among older individuals.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SOURCES:</font></p></h4><p style=margin-bottom:0><font size=2>We searched Medline, the<p>Cochrane central register of controlled trials, BIOSIS, and Embase up</p><p>to August 2008 for relevant articles. Further studies were identified</p><p>by consulting clinical experts, bibliographies, and abstracts. We</p><p>contacted authors for additional data when necessary. Review methods</p><p>Only double blind randomised controlled trials of older individuals</p><p>(mean age 65 years or older) receiving a defined oral dose of</p><p>supplemental vitamin D (vitamin D(3) (cholecalciferol) or vitamin</p><p>D(2) (ergocalciferol)) or an active form of vitamin D</p><p>(1alpha-hydroxyvitamin D(3) (1alpha-hydroxycalciferol) or</p><p>1,25-dihydroxyvitamin D(3) (1,25-dihydroxycholecalciferol)) and with</p><p>sufficiently specified fall assessment were considered for inclusion.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Eight randomised<p>controlled trials (n=2426) of supplemental vitamin D met our</p><p>inclusion criteria. Heterogeneity among trials was observed for dose</p><p>of vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02) and achieved</p><p>25-hydroxyvitamin D(3) concentration (25(OH)D concentration: &lt;60</p><p>nmol/l v >or=60 nmol/l; P=0.005). High dose supplemental vitamin D</p><p>reduced fall risk by 19% (pooled relative risk (RR) 0.81, 95% CI 0.71</p><p>to 0.92; n=1921 from seven trials), whereas achieved serum 25(OH)D</p><p>concentrations of 60 nmol/l or more resulted in a 23% fall reduction</p><p>(pooled RR 0.77, 95% CI 0.65 to 0.90). Falls were not notably reduced</p><p>by low dose supplemental vitamin D (pooled RR 1.10, 95% CI 0.89 to</p><p>1.35; n=505 from two trials) or by achieved serum 25-hydroxyvitamin D</p><p>concentrations of less than 60 nmol/l (pooled RR 1.35, 95% CI 0.98 to</p><p>1.84). Two randomised controlled trials (n=624) of active forms of</p><p>vitamin D met our inclusion criteria. Active forms of vitamin D</p><p>reduced fall risk by 22% (pooled RR 0.78, 95% CI 0.64 to 0.94).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Supplemental vitamin D in<p>a dose of 700-1000 IU a day reduced the risk of falling among older</p><p>individuals by 19% and to a similar degree as active forms of vitamin</p><p>D. Doses of supplemental vitamin D of less than 700 IU or serum</p><p>25-hydroxyvitamin D concentrations of less than 60 nmol/l may not</p><p>reduce the risk of falling among older individuals.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=vitamin%20d%20stress%20fractures%20garland"><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2011</p><p>Oct;26(10):2371-7. doi: 10.1002/jbmr.451.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>High<p>serum 25-hydroxyvitamin D is associated with a low incidence of</p><p></font><font size=2>stress fractures</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Burgi<p>AA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gorham</p><p>ED</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Garland</p><p>CF</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mohr</p><p>SB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Garland</p><p>FC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Zeng</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Thompson</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lappe</p><p>JM</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Behavioral<p>Sciences and Epidemiology, Naval Health Research Center, San Diego,</p><p>CA, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Low serum<p>25-hydroxyvitamin D [25(OH)D] concentrations are associated with hip</p><p></font><font size=2>fractures</font><font size=2>, but the</p><p>dose-response relationship of serum 25(OH)D with risk of </font><font size=2>stress</p><p>fractures</font><font size=2> in young women is unknown. This nested</p><p>case-control study in a cohort of female Navy recruits was designed</p><p>to determine whether those with low prediagnostic serum 25(OH)D</p><p>concentrations had greater risk of </font><font size=2>stress</font><font size=2></p><p>fracture. Sera were drawn in 2002-2009 from 600 women who were</p><p>diagnosed subsequently with </font><font size=2>stress</font><font size=2></p><p>fracture of the tibia or fibula and 600 matched controls who did not</p><p>experience a </font><font size=2>stress</font><font size=2> fracture.</p><p>The 25(OH)D concentration was measured using the DiaSorin</p><p>radioimmunoassay method. Controls were individually matched to cases</p><p>on race (white, black, or other), length of service (±30</p><p>days), and day blood was drawn (±2 days). There was</p><p>approximately half the risk of </font><font size=2>stress</font><font size=2></p><p>fracture in the top compared with the bottom quintile of serum</p><p>25(OH)D concentration (odds ratio [OR]</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>0.51,</p><p>95% CI 0.34-0.76, p</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>≤</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>0.01).</p><p>The range of serum 25(OH)D in the lowest quintile was 1.5 to 19.7</p><p>(mean 13.9) ng/mL, whereas in the highest it was 39.9 to 112 (mean</p><p>49.7) ng/mL. It is concluded that there was a monotonic inverse</p><p>dose-response gradient between serum 25(OH)D and risk of </font><font size=2>stress</font><font size=2></p><p>fracture. There was double the risk of </font><font size=2>stress</p><p>fractures</font><font size=2> of the tibia and fibula in women with</p><p>serum 25(OH)D concentrations of less than 20</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>ng/mL</p><p>compared to those with concentrations of 40</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>ng/mL</p><p>or greater. A target for prevention of </font><font size=2>stress</p><p>fractures</font><font size=2> would be a serum 25(OH)D concentration</p><p>of 40</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>ng/mL</p><p>or greater, achievable with 4000</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>IU/d</p><p>of </font><font size=2>vitamin D</font><font size=2>(3)</p><p>supplementation.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Autier%20P%2C%20Gandini%20S.%20%202007"><font size=2>Arch<p>Intern Med.</font></a></u></font><font size=2> </font><font size=2>2007</font><font size=2></p><p>Sep 10;167(16):1730-7.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D supplementation and total mortality: a meta-analysis of randomized</p><p>controlled trials.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Autier<p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gandini</p><p>S</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>International Agency for<p>Research on Cancer, 150 cours Albert Thomas, F-69372 Lyon, France.</p><p><a href=mailto:autierp@iacr.fr>autierp@iacr.fr</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Ecological and<p>observational studies suggest that low vitamin D status could be</p><p>associated with higher mortality from life-threatening conditions</p><p>including cancer, cardiovascular disease, and diabetes mellitus that</p><p>account for 60% to 70% of total mortality in high-income countries.</p><p>We examined the risk of dying from any cause in subjects who</p><p>participated in randomized trials testing the impact of vitamin D</p><p>supplementation (ergocalciferol [vitamin D(2)] or cholecalciferol</p><p>[vitamin D(3)]) on any health condition.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>The literature up to<p>November 2006 was searched without language restriction using the</p><p>following databases: PubMed, ISI Web of Science (Science Citation</p><p>Index Expanded), EMBASE, and the Cochrane Library.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>We identified 18<p>independent randomized controlled trials, including 57 311</p><p>participants. A total of 4777 deaths from any cause occurred during a</p><p>trial size-adjusted mean of 5.7 years. Daily doses of vitamin D</p><p>supplements varied from 300 to 2000 IU. The trial size-adjusted mean</p><p>daily vitamin D dose was 528 IU. In 9 trials, there was a 1.4- to</p><p>5.2-fold difference in serum 25-hydroxyvitamin D between the</p><p>intervention and control groups. The summary relative risk for</p><p>mortality from any cause was 0.93 (95% confidence interval,</p><p>0.87-0.99). There was neither indication for heterogeneity nor</p><p>indication for publication biases. The summary relative risk did not</p><p>change according to the addition of calcium supplements in the</p><p>intervention.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Intake of ordinary doses<p>of vitamin D supplements seems to be associated with decreases in</p><p>total mortality rates. The relationship between baseline vitamin D</p><p>status, dose of vitamin D supplements, and total mortality rates</p><p>remains to be investigated. Population-based, placebo-controlled</p><p>randomized trials with total mortality as the main end point should</p><p>be organized for confirming these findings.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19321573><font size=2>Am<p>J Clin Nutr.</font></a></u></font><font size=2> 2009</p><p>May;89(5):1321-7. Epub 2009 Mar 25.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D supplementation enhances the beneficial effects of weight loss on</p><p>cardiovascular disease risk markers.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Zittermann<p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Frisch</p><p>S</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Berthold</p><p>HK</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Götting</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kuhn</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kleesiek</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stehle</p><p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Koertke</p><p>H</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Koerfer</p><p>R</font></a></u></font><font size=2>.</font></p></p><h3 lang=de-DE class=western style=margin-top:0;margin-bottom:0><p><font size=2>Source</font></h3></p><p lang=de-DE style=margin-bottom:0><font size=2>Klinik f&uuml;r<p>Thorax- und Kardiovaskularchirurgie and Institut für</p><p>Laboratoriums- und Transfusionsmedizin, Herzzentrum NRW, Ruhr</p><p>Universität Bochum, Bad Oeynhausen, Germany.</p><p><a href=mailto:azittermann@hdz-nrw.de>azittermann@hdz-nrw.de</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>High blood concentrations<p>of parathyroid hormone and low concentrations of the vitamin D</p><p>metabolites 25-hydroxyvitamin D [25(OH)D] and calcitriol are</p><p>considered new cardiovascular disease risk markers. However, there is</p><p>also evidence that calcitriol increases lipogenesis and decreases</p><p>lipolysis.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We investigated the effect<p>of vitamin D on weight loss and traditional and nontraditional</p><p>cardiovascular disease risk markers in overweight subjects.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Healthy overweight<p>subjects (n = 200) with mean 25(OH)D concentrations of 30 nmol/L (12</p><p>ng/mL) received vitamin D (83 microg/d) or placebo in a double-blind</p><p>manner for 12 mo while participating in a weight-reduction program.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Weight loss was not<p>affected significantly by vitamin D supplementation (-5.7 +/- 5.8 kg)</p><p>or placebo (-6.4 +/- 5.6 kg). However, mean 25(OH)D and calcitriol</p><p>concentrations increased by 55.5 nmol/L and 40.0 pmol/L,</p><p>respectively, in the vitamin D group but by only 11.8 nmol/L and 9.3</p><p>pmol/L, respectively, in the placebo group (P &lt; 0.001), whereas a</p><p>more pronounced decrease occurred in the vitamin D group than in the</p><p>placebo group in blood concentrations of parathyroid hormone (-26.5%</p><p>compared with -18.7%; P = 0.014), triglycerides (-13.5% compared with</p><p>+3.0%; P &lt; 0.001), and the inflammation marker tumor necrosis</p><p>factor-alpha (-10.2% compared with -3.2%; P = 0.049). The beneficial</p><p>biochemical effects were independent of the loss in body weight, fat</p><p>mass, and sex. However, compared with placebo, vitamin D</p><p>supplementation also increased LDL-cholesterol concentrations (+5.4%</p><p>compared with -2.5%; P &lt; 0.001).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>The results indicate that<p>a vitamin D supplement of 83 microg/d does not adversely affect</p><p>weight loss and is able to significantly improve several</p><p>cardiovascular disease risk markers in overweight subjects with</p><p>inadequate vitamin D status participating in a weight-reduction</p><p>program. This trial was registered at clinicaltrials.gov as</p><p>NCT00493012.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Lappe%20J%2C%20Cullen%20D%2C%20Haynatzki%20G%2C%20Recker%20R"><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2008</p><p>May;23(5):741-9.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Calcium<p>and vitamin d supplementation decreases incidence of stress fractures</p><p>in female navy recruits.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lappe<p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Cullen</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Haynatzki</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Recker</p><p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ahlf</p><p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Thompson</p><p>K</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Creighton University<p>Osteoporosis Research Center, Omaha, Nebraska, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTRODUCTION:</font></h4><p style=margin-bottom:0><font size=2>Stress fractures (SFx) are<p>one of the most common and debilitating overuse injuries seen in</p><p>military recruits, and they are also problematic for nonmilitary</p><p>athletic populations. The goal of this randomized double-blind,</p><p>placebo-controlled study was to determine whether a calcium and</p><p>vitamin D intervention could reduce the incidence of SFx in female</p><p>recruits during basic training.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MATERIALS<p>AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>We recruited 5201 female<p>Navy recruit volunteers and randomized them to 2000 mg calcium and</p><p>800 IU vitamin D/d or placebo. SFx were ascertained when recruits</p><p>reported to the Great Lakes clinic with symptoms. All SFx were</p><p>confirmed with radiography or technetium scan according to the usual</p><p>Navy protocol.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>A total of 309 subjects<p>were diagnosed with a SFx resulting in an incidence of 5.9% per 8 wk.</p><p>Using intention-to-treat analysis by including all enrolled subjects,</p><p>we found that the calcium and vitamin D group had a 20% lower</p><p>incidence of SFx than the control group (5.3% versus 6.6%,</p><p>respectively, p = 0.0026 for Fisher&rsquo;s exact test). The per protocol</p><p>analysis, including only the 3700 recruits who completed the study,</p><p>found a 21% lower incidence of fractures in the supplemented versus</p><p>the control group (6.8% versus 8.6%, respectively, p = 0.02 for</p><p>Fisher&rsquo;s exact test).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Generalizing the findings<p>to the population of 14,416 women who entered basic training at the</p><p>Great Lakes during the 24 mo of recruitment, calcium and vitamin D</p><p>supplementation for the entire cohort would have prevented</p><p>approximately 187 persons from fracturing. Such a decrease in SFx</p><p>would be associated with a significant decrease in morbidity and</p><p>financial costs.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20219962><font size=2>Am<p>J Clin Nutr.</font></a></u></font><font size=2> 2010</p><p>May;91(5):1255-60. Epub 2010 Mar 10.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Randomized<p>trial of </font><font size=2>vitamin D</font><font size=2></p><p>supplementation to prevent seasonal influenza A in schoolchildren.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Urashima</font></u></font><font color=#0000ff><u><font size=2><p>M</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Segawa</p><p>T</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Okazaki</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kurihara</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wada</p><p>Y</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ida</p><p>H</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Molecular<p>Epidemiology, Jikei University School of Medicine, Nishi-shimbashi</p><p>3-25-8, Minato-ku, Tokyo 105-8461, Japan. </font><font size=2>urashima</font><font size=2>@jikei.ac.jp</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>To our knowledge, no<p>rigorously designed clinical trials have evaluated the relation</p><p>between </font><font size=2>vitamin D</font><font size=2> and</p><p>physician-diagnosed seasonal influenza.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We investigated the effect<p>of </font><font size=2>vitamin D</font><font size=2> supplements on</p><p>the incidence of seasonal influenza A in schoolchildren.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>From December 2008 through<p>March 2009, we conducted a randomized, double-blind,</p><p>placebo-controlled trial comparing </font><font size=2>vitamin D</font><font size=2>(3)</p><p>supplements (1200 IU/d) with placebo in schoolchildren. The primary</p><p>outcome was the incidence of influenza A, diagnosed with influenza</p><p>antigen testing with a nasopharyngeal swab specimen.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Influenza A occurred in 18<p>of 167 (10.8%) children in the </font><font size=2>vitamin D</font><font size=2>(3)</p><p>group compared with 31 of 167 (18.6%) children in the placebo group</p><p>[relative risk (RR), 0.58; 95% CI: 0.34, 0.99; P = 0.04]. The</p><p>reduction in influenza A was more prominent in children who had not</p><p>been taking other </font><font size=2>vitamin D</font><font size=2></p><p>supplements (RR: 0.36; 95% CI: 0.17, 0.79; P = 0.006) and who started</p><p>nursery school after age 3 y (RR: 0.36; 95% CI: 0.17, 0.78; P =</p><p>0.005). In children with a previous diagnosis of asthma, asthma</p><p>attacks as a secondary outcome occurred in 2 children receiving</p><p></font><font size=2>vitamin D</font><font size=2>(3) compared with 12</p><p>children receiving placebo (RR: 0.17; 95% CI: 0.04, 0.73; P = 0.006).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>This study suggests that<p></font><font size=2>vitamin D</font><font size=2>(3) supplementation</p><p>during the winter may reduce the incidence of influenza A, especially</p><p>in specific subgroups of schoolchildren. This trial was registered at</p><p><a href=https://center.umin.ac.jp>https://center.umin.ac.jp</a> as UMIN000001373.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22184690><font size=2>Ann<p>Intern Med.</font></a></u></font><font size=2> 2011 Dec</p><p>20;155(12):827-38.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D With or Without Calcium Supplementation for Prevention of Cancer</p><p>and Fractures: An Updated Meta-analysis for the U.S. Preventive</p><p>Services Task Force.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Chung<p>M</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Lee</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Terasawa</p><p>T</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Lau</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Trikalinos</p><p>TA</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Tufts Evidence-based<p>Practice Center, Institute for Clinical Research and Health Policy</p><p>Studies, Tufts Medical Center, Boston, Massachusetts, and Department</p><p>of Medicine, Fujita Health University School of Medicine, Tsu, Japan.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Background: Studies<p>suggest that vitamin D supplementation may reduce cancer and fracture</p><p>risks. Purpose: To examine the benefits and harms of vitamin D with</p><p>or without calcium supplementation on clinical outcomes of cancer and</p><p>fractures in adults. Data Sources: English-language studies</p><p>identified from MEDLINE and the Cochrane Central Register of</p><p>Controlled Trials through July 2011. Study Selection: Randomized,</p><p>controlled trials (RCTs), prospective cohort studies, and nested</p><p>case-control studies reporting incidence of or death from cancer and</p><p>fracture outcomes. Data Extraction: Multiple reviewers extracted</p><p>details about participant characteristics, including baseline vitamin</p><p>D status and use of supplements; details of statistical analyses,</p><p>including adjustments for confounding; and methodological quality.</p><p>Differences were resolved by consensus. Data Synthesis: 19 RCTs (3</p><p>for cancer and 16 for fracture outcomes) and 28 observational studies</p><p>(for cancer outcomes) were analyzed. Limited data from RCTs suggested</p><p>that high-dose (1000 IU/d) vitamin D supplementation can reduce the</p><p>risk for total cancer, and data from observational studies suggested</p><p>that higher blood 25-hydroxyvitamin D (25-[OH]D) concentrations might</p><p>be associated with increased risk for cancer. Mixed-effects</p><p>dose-response meta-analyses showed that each 10-nmol/L increase in</p><p>blood 25-(OH)D concentration was associated with a 6% (95% CI, 3% to</p><p>9%) reduced risk for colorectal cancer but no statistically</p><p>significant dose-response relationships for prostate and breast</p><p>cancer. Random-effects model meta-analysis showed that combined</p><p>vitamin D and calcium supplementation reduced fracture risk (pooled</p><p>relative risk, 0.88 [CI, 0.78 to 0.99]) in older adults, but the</p><p>effects differed according to study setting: institution (relative</p><p>risk, 0.71 [CI, 0.57 to 0.89]) versus community-dwelling (relative</p><p>risk, 0.89 [CI, 0.76 to 1.04]). One RCT showed adverse outcomes</p><p>associated with supplementation, including increased risk for renal</p><p>and urinary tract stones. Limitations: Most trial participants were</p><p>older (aged ≥65 years) postmenopausal women. Observational studies</p><p>were heterogeneous and were limited by potential confounders.</p><p>Conclusion: Combined vitamin D and calcium supplementation can reduce</p><p>fracture risk, but the effects may be smaller among</p><p>community-dwelling older adults than among institutionalized elderly</p><p>persons. Appropriate dose and dosing regimens, however, require</p><p>further study. Evidence is not sufficiently robust to draw</p><p>conclusions regarding the benefits or harms of vitamin D</p><p>supplementation for the prevention of cancer. Primary Funding Source:</p><p>Agency for Healthcare Research and Quality.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20723187><font size=2>Trop<p>Med Int Health.</font></a></u></font><font size=2> 2010</p><p>Oct;15(10):1148-55. doi: 10.1111/j.1365-3156.2010.02578.x. Epub 2010</p><p>Aug 17.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of </font><font size=2>vitamin D</font><font size=2> supplementation</p><p>to children diagnosed with pneumonia in Kabul: a randomised</p><p>controlled trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Manaseki-Holland</font></u></font><font color=#0000ff><u><font size=2><p>S</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Qader</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Isaq</p><p>Masher M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bruce</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Zulf</p><p>Mughal M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Chandramohan</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Walraven</p><p>G</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Kabul Medical University,<p>Kabul, Afghanistan.</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>Aga</p><p>Khan Health Services, Kabul, Afghanistan</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>To determine whether (i)<p>supplementation of oral 100,000 iu of </font><font size=2>vitamin</p><p>D</font><font size=2>(3) (cholecalciferol) along with antibiotics</p><p>will reduce the duration of illness in children with pneumonia; (ii)</p><p>supplementation will reduce the risk of repeat episodes.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Double-blind individually<p>randomised placebo-controlled trial in an inner-city hospital in</p><p>Kabul, of 453 children aged 1-36 months, diagnosed with non-severe or</p><p>severe pneumonia at the outpatient clinic. Children with rickets,</p><p>other concurrent severe diseases, very severe pneumonia or wheeze,</p><p>were excluded. Children were given </font><font size=2>vitamin D</font><font size=2>(3)</p><p>or placebo drops additional to routine pneumonia treatment.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Two hundred and<p>twenty-four children received </font><font size=2>vitamin D</font><font size=2>(3;)</p><p>and 229 received placebo. There was no significant difference in the</p><p>mean number of days to recovery between the </font><font size=2>vitamin</p><p>D</font><font size=2>(3) (4.74 days; SD 2.22) and placebo arms (4.98</p><p>days; SD 2.89; P = 0.17). The risk of a repeat episode of pneumonia</p><p>within 90 days of supplementation was lower in the intervention</p><p>(92/204; 45%) than the placebo group [122/211; (58%; relative risk</p><p>0.78; 95% CI 0.64, 0.94; P = 0.01]. Children in the </font><font size=2>vitamin</p><p>D</font><font size=2>(3) group survived longer without experiencing a</p><p>repeat episode (72 days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P =</p><p>0.02).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>A single high-dose oral<p></font><font size=2>vitamin D</font><font size=2>(3) supplementation</p><p>to young children along with antibiotic treatment for pneumonia could</p><p>reduce the occurrence of repeat episodes of pneumonia.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pittas%2C%20%20Chung"><font size=2>Ann<p>Intern Med.</font></a></u></font><font size=2> 2010 Mar</p><p>2;152(5):307-14.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Systematic<p>review: Vitamin D and cardiometabolic outcomes.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2><span lang=de-DE>Pittas</span></font></u></font><font color=#0000ff><u><font size=2><span lang=de-DE><p>AG</span></font></u></font></a><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Chung</p><p>M</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Trikalinos</p><p>T</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Mitri</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Brendel</p><p>M</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Patel</p><p>K</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Lichtenstein</p><p>AH</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Lau</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Balk</p><p>EM</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Tufts Medical Center and<p>Friedman School of Nutrition Science and Policy, and Jean Mayer USDA</p><p>Human Nutrition Research Center on Aging, Tufts University, Boston,</p><p>Massachusetts 02111, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D may modify risk<p>for cardiometabolic outcomes (type 2 diabetes, hypertension, or</p><p>cardiovascular disease).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PURPOSE:</font></h4><p style=margin-bottom:0><font size=2>To examine the association<p>between vitamin D status, including the effect of vitamin D</p><p>supplementation, and cardiometabolic outcomes in generally healthy</p><p>adults.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SOURCES:</font></p></h4><p style=margin-bottom:0><font size=2>English-language studies<p>in MEDLINE (inception to 4 November 2009) and the Cochrane Central</p><p>Register of Controlled Trials (fourth quarter of 2009).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>STUDY<p>SELECTION:</font></p></h4><p style=margin-bottom:0><font size=2>11 reviewers screened<p>citations to identify longitudinal cohort studies that reported</p><p>associations between vitamin D status and cardiometabolic outcomes,</p><p>including randomized trials of vitamin D supplementation.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>EXTRACTION:</font></p></h4><p style=margin-bottom:0><font size=2>5 independent reviewers<p>extracted data about study conduct, participant characteristics,</p><p>outcomes, and quality. Differences were resolved by consensus.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SYNTHESIS:</font></p></h4><p style=margin-bottom:0><font size=2>13 observational studies<p>(14 cohorts) and 18 trials were eligible. Three of 6 analyses (from 4</p><p>different cohorts) reported a lower incident diabetes risk in the</p><p>highest versus the lowest vitamin D status groups. Eight trials found</p><p>no effect of vitamin D supplementation on glycemia or incident</p><p>diabetes. In meta-analysis of 3 cohorts, lower 25-hydroxyvitamin D</p><p>concentration was associated with incident hypertension (relative</p><p>risk, 1.8 [95% CI, 1.3 to 2.4]). In meta-analyses of 10 trials,</p><p>supplementation nonsignificantly reduced systolic blood pressure</p><p>(weighted mean difference, -1.9 mm Hg [CI, -4.2 to 0.4 mm Hg]) and</p><p>did not affect diastolic blood pressure (weighted mean difference,</p><p>-0.1 mm Hg [CI, -0.7 to 0.5 mm Hg]). Lower 25-hydroxyvitamin D</p><p>concentration was associated with incident cardiovascular disease in</p><p>5 of 7 analyses (6 cohorts). Four trials found no effect of</p><p>supplementation on cardiovascular outcomes.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>LIMITATIONS:</font></h4><p style=margin-bottom:0><font size=2>Studies included primarily<p>white participants. Observational studies were heterogeneous. Several</p><p>trials reported post hoc analyses.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>The association between<p>vitamin D status and cardiometabolic outcomes is uncertain. Trials</p><p>showed no clinically significant effect of vitamin D supplementation</p><p>at the dosages given.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PRIMARY<p>FUNDING SOURCE:</font></p></h4><p style=margin-bottom:0><font size=2>National Institute of<p>Diabetes and Digestive and Kidney Disease, the National Institutes of</p><p>Health Office of Dietary Supplements, U.S. Food and Drug</p><p>Administration, Agency for Healthcare Research and Quality, and</p><p>Public Health Agency of Canada.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bischoff-Ferrari%20HA%2C%20Willett%20WC%2C%20Wong%20JB%2C%20Stuck%20"><font size=2>Arch<p>Intern Med.</font></a></u></font><font size=2> 2009 Mar</p><p>23;169(6):551-61.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Prevention<p>of nonvertebral fractures with oral vitamin D and dose dependency: a</p><p>meta-analysis of randomized controlled trials.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bischoff-Ferrari<p>HA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Willett</p><p>WC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wong</p><p>JB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stuck</p><p>AE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Staehelin</p><p>HB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Orav</p><p>EJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Thoma</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kiel</p><p>DP</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Henschkowski</p><p>J</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Centre on Aging and<p>Mobility, University of Zurich, University Hospital, Switzerland.</p><p><a href=mailto:heike.bischoff@usz.ch>heike.bischoff@usz.ch</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Antifracture efficacy with<p>supplemental vitamin D has been questioned by recent trials.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>We performed a<p>meta-analysis on the efficacy of oral supplemental vitamin D in</p><p>preventing nonvertebral and hip fractures among older individuals (></p><p>or =65 years). We included 12 double-blind randomized controlled</p><p>trials (RCTs) for nonvertebral fractures (n = 42 279) and 8 RCTs for</p><p>hip fractures (n = 40 886) comparing oral vitamin D, with or without</p><p>calcium, with calcium or placebo. To incorporate adherence to</p><p>treatment, we multiplied the dose by the percentage of adherence to</p><p>estimate the mean received dose (dose x adherence) for each trial.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>The pooled relative risk<p>(RR) was 0.86 (95% confidence interval [CI], 0.77-0.96) for</p><p>prevention of nonvertebral fractures and 0.91 (95% CI, 0.78-1.05) for</p><p>the prevention of hip fractures, but with significant heterogeneity</p><p>for both end points. Including all trials, antifracture efficacy</p><p>increased significantly with a higher dose and higher achieved blood</p><p>25-hydroxyvitamin D levels for both end points. Consistently, pooling</p><p>trials with a higher received dose of more than 400 IU/d resolved</p><p>heterogeneity. For the higher dose, the pooled RR was 0.80 (95% CI,</p><p>0.72-0.89; n = 33 265 subjects from 9 trials) for nonvertebral</p><p>fractures and 0.82 (95% CI, 0.69-0.97; n = 31 872 subjects from 5</p><p>trials) for hip fractures. The higher dose reduced nonvertebral</p><p>fractures in community-dwelling individuals (-29%) and</p><p>institutionalized older individuals (-15%), and its effect was</p><p>independent of additional calcium supplementation.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Nonvertebral fracture<p>prevention with vitamin D is dose dependent, and a higher dose should</p><p>reduce fractures by at least 20% for individuals aged 65 years or</p><p>older</font>.</p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21177785><font size=2><span lang=de-DE>J<p>Clin Endocrinol Metab.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>2011 Mar;96(3):E447-52. </span></font><font size=2>Epub 2010 Dec 22.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin</font><font size=2><p>D(3) is more potent than </font><font size=2>vitamin</font><font size=2></p><p>D(2) in humans.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Heaney</font></u></font><font color=#0000ff><u><font size=2><p>RP</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Recker</p><p>RR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Grote</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Horst</p><p>RL</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Armas</p><p>LA</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Creighton University, 601<p>North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA.</p><p><a href=mailto:rheaney@creighton.edu>rheaney@creighton.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Current unitage for the<p>calciferols suggests that equimolar quantities of vitamins D(2) (</font><font size=2>D2</font><font size=2>)</p><p>and D(3) (D3) are biologically equivalent. Published studies yield</p><p>mixed results.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>The aim of the study was<p>to compare the potencies of </font><font size=2>D2</font><font size=2></p><p>and D3.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>The trial used a<p>single-blind, randomized design in 33 healthy adults. Calciferols</p><p>were dosed at 50,000 IU/wk for 12 wk. Principal outcome variables</p><p>were area under the curve for incremental total 25-hydroxyvitamin D</p><p>[25(OH)D] and change in calciferol content of sc fat.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Incremental mean (sd)<p>25(OH)D area under the curve at 12 wk was 1366 ng · d/ml (516)</p><p>for the </font><font size=2>D2</font><font size=2>-treated group and</p><p>2136 (606) for the D3 (P &lt; 0.001). Mean (sd) steady-state 25(OH)D</p><p>increments showed similar differences: 24 ng/ml for </font><font size=2>D2</font><font size=2></p><p>(10.3) and 45 ng/ml (16.2) for D3 (P &lt;0.001). Subcutaneous fat</p><p>content of </font><font size=2>D2</font><font size=2> rose by 50</p><p>μg/kg in the </font><font size=2>D2</font><font size=2>-treated</p><p>group, and D3 content rose by 104 μg/kg in the D3-treated group.</p><p>Total calciferol in fat rose by only 33 ng/kg in the </font><font size=2>D2</font><font size=2>-treated,</p><p>whereas it rose by 104 μg/kg in the D3-treated group.</p><p>Extrapolating to total body fat D3, storage amounted to just 17% of</p><p>the administered dose.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>D3 is approximately 87%<p>more potent in raising and maintaining serum 25(OH)D concentrations</p><p>and produces 2- to 3-fold greater storage of </font><font size=2>vitamin</font><font size=2></p><p>D than does equimolar </font><font size=2>D2</font><font size=2>. For</p><p>neither was there evidence of sequestration in fat, as had been</p><p>postulated for doses in this range. Given its greater potency and</p><p>lower cost, D3 should be the preferred treatment option when</p><p>correcting </font><font size=2>vitamin</font><font size=2> D</p><p>deficiency.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Houghton%202006%20vitamin%20d2"><font size=2>Am<p>J Clin Nutr.</font></a></u></font><font size=2> </font><font size=2>2006</font><font size=2></p><p>Oct;84(4):694-7.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>The<p>case against ergocalciferol (</font><font size=2>vitamin D2</font><font size=2>)</p><p>as a </font><font size=2>vitamin</font><font size=2> supplement.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Houghton</font></u></font><font color=#0000ff><u><font size=2><p>LA</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Vieth</p><p>R</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>School of Nutrition and<p>Dietetics, Acadia University, Wolfville, Canada.</p><p>lisa.</font><font size=2>houghton</font><font size=2>@acadiau.ca</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Supplemental </font><font size=2>vitamin</font><font size=2><p>D is available in 2 distinct forms: ergocalciferol (</font><font size=2>vitamin</p><p>D2</font><font size=2>) and cholecalciferol (</font><font size=2>vitamin</font><font size=2></p><p>D3). Pharmacopoeias have officially regarded these 2 forms as</p><p>equivalent and interchangeable, yet this presumption of equivalence</p><p>is based on studies of rickets prevention in infants conducted 70 y</p><p>ago. The emergence of 25-hydroxyvitamin D as a measure of </font><font size=2>vitamin</font><font size=2></p><p>D status provides an objective, quantitative measure of the</p><p>biological response to </font><font size=2>vitamin</font><font size=2></p><p>D administration. As a result, </font><font size=2>vitamin</font><font size=2></p><p>D3 has proven to be the more potent form of </font><font size=2>vitamin</font><font size=2></p><p>D in all primate species, including humans. Despite an emerging body</p><p>of evidence suggesting several plausible explanations for the greater</p><p>bioefficacy of </font><font size=2>vitamin</font><font size=2> D3,</p><p>the form of </font><font size=2>vitamin</font><font size=2> D used in</p><p>major preparations of prescriptions in North America is </font><font size=2>vitamin</p><p>D2</font><font size=2>. The case that </font><font size=2>vitamin D2</font><font size=2></p><p>should no longer be considered equivalent to </font><font size=2>vitamin</font><font size=2></p><p>D3 is based on differences in their efficacy at raising serum</p><p>25-hydroxyvitamin D, diminished binding of </font><font size=2>vitamin</p><p>D2</font><font size=2> metabolites to </font><font size=2>vitamin</font><font size=2></p><p>D binding protein in plasma, and a nonphysiologic metabolism and</p><p>shorter shelf life of </font><font size=2>vitamin D2</font><font size=2>.</p><p></font><font size=2>Vitamin D2</font><font size=2>, or</p><p>ergocalciferol, should not be regarded as a nutrient suitable for</p><p>supplementation or fortification.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20130093><font size=2><span lang=de-DE>Am<p>J Clin Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>2010 Apr;91(4):985-91. </span></font><font size=2>Epub 2010 Feb 3.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Once-weekly<p>dose of 8400 IU vitamin D(3) compared with placebo: effects on</p><p>neuromuscular function and tolerability in older adults with vitamin</p><p>D insufficiency.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Lips<p>P</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Binkley</p><p>N</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Pfeifer</p><p>M</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Recker</p><p>R</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Samanta</p><p>S</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Cohn</p><p>DA</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Chandler</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Rosenberg</p><p>E</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Papanicolaou</p><p>DA</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Endocrinology, Vrije Universiteit Medisch Centrum, Amsterdam, The</p><p>Netherlands. <a href=mailto:p.lips@vumc.nl>p.lips@vumc.nl</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D insufficiency,<p>which is prevalent in older individuals, is associated with bone and</p><p>muscle weakness and falls.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We examined the effects of<p>a weekly dose of 8400 IU vitamin D(3) on postural stability, muscle</p><p>strength, and safety.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>In this double-blind<p>trial, subjects aged > or =70 y with serum 25-hydroxyvitamin D</p><p>[25(OH)D] concentrations &lt; or =20 but > or =6 ng/mL were</p><p>randomly assigned to receive a weekly dose of 8400 IU vitamin D(3) (n</p><p>= 114) or a placebo (n = 112). Mediolateral body sway with eyes open</p><p>(assessed with the AccuSway(PLUS) platform; Advanced Medical</p><p>Technology Inc, Watertown, MA) was the primary endpoint. Secondary</p><p>endpoints included the short physical performance battery (SPPB) and</p><p>serum 25(OH)D concentrations. An analysis of covariance model was</p><p>used for treatment comparisons. Safety and tolerability were</p><p>monitored.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Serum 25(OH)D<p>concentrations rose significantly (from 13.9 to 26.2 ng/mL, P &lt;</p><p>0.001) in patients treated with 8400 IU vitamin D(3) but not in</p><p>patients treated with the placebo. After 16 wk, neither mediolateral</p><p>sway nor SPPB differed significantly between treatment groups.</p><p>However, in the post hoc analysis of patients subgrouped by baseline</p><p>sway (> or = 0.46 compared with &lt;0.46 cm), treatment with 8400</p><p>IU vitamin D(3) significantly reduced sway compared with treatment</p><p>with placebo (P = 0.047) in patients with elevated baseline sway but</p><p>not in patients with normal baseline sway. Adverse experiences and</p><p>incidences of hypercalcemia, hypercalciuria, and elevated creatinine</p><p>were similar with both treatments. In patients treated with 8400 IU</p><p>vitamin D(3), but not in placebo-treated patients, parathyroid</p><p>hormone decreased significantly.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Weekly treatment with 8400<p>IU vitamin D(3) raised 25(OH)D concentrations in elderly, vitamin</p><p>D-insufficient individuals. Treatment with 8400 IU vitamin D(3) did</p><p>not reduce mediolateral sway significantly compared with treatment</p><p>with placebo in this population, although in post hoc analysis,</p><p>treatment with 8400 IU vitamin D(3) reduced sway in the subgroup of</p><p>patients who had elevated sway at baseline. Weekly treatment with</p><p>8400 IU vitamin D(3) was well tolerated. This trial was registered at</p><p>clinicaltrials.gov as NCT00242476.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20648661><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2011</p><p>Jan;26(1):42-9.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>The<p>effects of whole-body vibration training and vitamin D</p><p>supplementation on muscle strength, muscle mass, and bone density in</p><p>institutionalized elderly women: a 6-month randomized, controlled</p><p>trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Verschueren<p>SM</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Bogaerts</p><p>A</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Delecluse</p><p>C</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Claessens</p><p>AL</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Haentjens</p><p>P</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Vanderschueren</p><p>D</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Boonen</p><p>S</span></font></a></u></font><font size=2><span lang=da-DK>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of<p>Musculoskeletal Rehabilitation, Department of Rehabilitation Sciences</p><p>and, Faculty of Kinesiology and Rehabilitation Sciences, Katholieke</p><p>Universiteit Leuven, Leuven, Belgium.</p><p><a href=mailto:sabine.verschueren@faber.kuleuven.be>sabine.verschueren@faber.kuleuven.be</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Sarcopenia and<p>osteoporosis represent a growing public health problem. We studied</p><p>the potential benefit of whole-body vibration (WBV) training given a</p><p>conventional or a high dose of daily vitamin D supplementation in</p><p>improving strength, muscle mass, and bone density in postmenopausal</p><p>women. In a 2 × 2 factorial-design trial, 113 institutionalized</p><p>elderly females aged over 70 years (mean age 79.6 years) were</p><p>randomly assigned either to a WBV or a no-training group, receiving</p><p>either a conventional dose (880 IU/day) or a high dose (1600 IU/day)</p><p>of vitamin D(3). The primary aim was to determine the effects of 6</p><p>months of WBV and/or vitamin D supplementation on isometric and</p><p>dynamic strength, leg muscle mass, and hip bone mineral density</p><p>(BMD). Additionally, the increase in 25-hydroxyvitamin D [25(OH)D]</p><p>levels between conventional and high-dose supplementation was</p><p>compared. After 6 months of treatment, dynamic muscle strength, hip</p><p>BMD, and vitamin D serum levels improved significantly in all groups,</p><p>whereas isometric strength and muscle mass did not change. When</p><p>compared with no training, the WBV program did not result in</p><p>additional improvements. When compared with 880 IU, a high dose of</p><p>1600 IU of vitamin D did result in higher serum vitamin D levels but</p><p>did not result in additional improvements. In institutionalized women</p><p>older than 70 years, the WBV training protocol tested is not more</p><p>efficient in enhancing muscle mass, strength, and hip BMD compared</p><p>with vitamin D supplementation. A higher dose of 1600 IU of vitamin D</p><p>does not provide additional musculoskeletal benefit in this</p><p>population compared with conventional doses.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19729890><font size=2>Ann<p>Nutr Metab.</font></a></u></font><font size=2> 2009;54(4):291-300.</p><p>Epub 2009 Aug 31.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Treatment<p>of vitamin D deficiency increases lower limb muscle strength in</p><p>institutionalized older people independently of regular physical</p><p>activity: a randomized double-blind controlled trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Moreira-Pfrimer<p>LD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pedrosa</p><p>MA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Teixeira</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lazaretti-Castro</p><p>M</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Endocrinology,<p>School of Medicine, Federal University of São Paulo/UNIFESP,</p><p>São Paulo, Brazil. <a href=mailto:lindapfrimer@hotmail.com>lindapfrimer@hotmail.com</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>AIMS:</font></h4><p style=margin-bottom:0><font size=2>To investigate the effects<p>of a 6-month supplementation with calcium and cholecalciferol on</p><p>biochemical parameters and muscle strength of institutionalized</p><p>elderly.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>This prospective,<p>double-blind, placebo-controlled, randomized trial included Brazilian</p><p>institutionalized people > or =60 years of age receiving a 6-month</p><p>supplementation (December to May) of daily calcium plus monthly</p><p>placebo (calcium/placebo group) or daily calcium plus oral</p><p>cholecalciferol (150,000 IU once a month during the first 2 months,</p><p>followed by 90,000 IU once a month for the last 4 months;</p><p>calcium/vitamin D group). Fasting blood samples for 25(OH)D, PTH and</p><p>calcium determination were collected (n = 56) and muscle tests were</p><p>performed (n = 46) to measure the strength of hip flexors (SHF) and</p><p>knee extensors (SKE) before (baseline) and after the 6-month</p><p>intervention (6 months).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Due to seasonal<p>variations, serum 25(OH)D significantly enhanced in both groups after</p><p>treatment, but the calcium/vitamin D group had significantly higher</p><p>25 (OH)D levels than the calcium/placebo group (84 vs. 33%,</p><p>respectively; p &lt; 0.0001). No cases of hypercalcemia were</p><p>observed. While the calcium/placebo group showed no improvement in</p><p>SHF and SKE at 6 months (p = 0.93 and p = 0.61, respectively), SHF</p><p>was increased in the calcium/vitamin D group by 16.4% (p = 0.0001)</p><p>and SKE by 24.6% (p = 0.0007).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>The suggested<p>cholecalciferol supplementation was safe and efficient in enhancing</p><p>25(OH)D levels and lower limb muscle strength in the elderly, in the</p><p>absence of any regular physical exercise practice.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/16797903><font size=2>Exp<p>Gerontol.</font></a></u></font><font size=2> 2006 Aug;41(8):746-52.</p><p>Epub 2006 Jun 22.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of </font><font size=2>vitamin D</font><font size=2> supplementation</p><p>and exercise training on physical performance in Chilean </font><font size=2>vitamin</p><p>D</font><font size=2> deficient elderly subjects.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Bunout</font></u></font><font color=#0000ff><u><font size=2><p>D</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Barrera</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Leiva</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gattas</p><p>V</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>de</p><p>la Maza MP</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Avendaño</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hirsch</p><p>S</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>INTA, University of Chile,<p>Santiago, Chile. <a href=mailto:dbunout@inta.cl>dbunout@inta.cl</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>The aim was to assess the<p>effects of resistance training and </font><font size=2>vitamin D</font><font size=2></p><p>supplementation on physical performance of healthy elderly subjects.</p><p>Ninety-six subjects, aged 70 years or more with 25 OH </font><font size=2>vitamin</p><p>D</font><font size=2> levels of 16 ng/ml or less, were randomized to</p><p>a resistance training or control group. Trained and control groups</p><p>were further randomized to receive in a double blind fashion, </font><font size=2>vitamin</p><p>D</font><font size=2> 400 IU plus 800 mg of calcium per day or</p><p>calcium alone. Subjects were followed for nine months. Serum 25 OH</p><p></font><font size=2>vitamin D</font><font size=2> increased from</p><p>12.4+/-2.2 to 25.8+/-6.5 ng/ml among subjects supplemented with</p><p></font><font size=2>vitamin D</font><font size=2>. Trained subjects</p><p>had significant improvements in quadriceps muscle strength, the short</p><p>physical performance test and timed up and go. The latter improved</p><p>more in trained subjects supplemented with </font><font size=2>vitamin</p><p>D</font><font size=2>. At the end of the follow up, gait speed was</p><p>higher among subjects supplemented with vitamin (whether trained or</p><p>not) than in non-supplemented subjects (838+/-147 and 768+/-127 m/12</p><p>min, respectively, p=0.02). Romberg ratio was lower among</p><p>supplemented controls than non-supplemented trained subjects</p><p>(128+/-40% and 144+/-37%, respectively, p=0.05). In conclusion,</p><p></font><font size=2>vitamin D</font><font size=2> supplementation</p><p>improved gait speed and body sway, and training improved muscle</p><p>strength.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19258546><font size=2>Cancer<p>Prev Res (Phila).</font></a></u></font><font size=2> 2009</p><p>Mar;2(3):213-23. Epub 2009 Mar 3.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of vitamin D and calcium supplementation on markers of apoptosis in</p><p>normal colon mucosa: a randomized, double-blind, placebo-controlled</p><p>clinical trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Fedirko</font></u></font><font color=#0000ff><u><font size=2><p>V</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bostick</p><p>RM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Flanders</p><p>WD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Long</p><p>Q</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Shaukat</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rutherford</p><p>RE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Daniel</p><p>CR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Cohen</p><p>V</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dash</p><p>C</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Epidemiology, Rollins School of Public Health, Emory University,</p><p>Atlanta, Georgia 30322, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>To further clarify and/or<p>develop calcium and vitamin D as chemopreventive agents against</p><p>colorectal cancer in humans, understand the mechanisms by which these</p><p>agents reduce risk for the disease, and develop "treatable"</p><p>biomarkers of risk for colorectal cancer, we conducted a pilot,</p><p>randomized, double-blind, placebo-controlled, 2 x 2 factorial</p><p>clinical trial to test the effects of calcium and vitamin D3, alone</p><p>and in combination on markers of apoptosis, in the normal colorectal</p><p>mucosa. Ninety-two men and women with at least one</p><p>pathology-confirmed colorectal adenoma were treated with 2.0 g/d</p><p>calcium or 800 IU/d vitamin D3, alone or in combination, versus</p><p>placebo over 6 months. Overall expression and colorectal crypt</p><p>distributions of Bcl-2 (an apoptosis inhibitor) and Bax (an apoptosis</p><p>promoter) in biopsies of normal-appearing rectal mucosa were detected</p><p>by automated immunohistochemistry and quantified by image analysis.</p><p>After 6 months of treatment, Bax expression along the full lengths of</p><p>crypts increased 56% (P = 0.02) in the vitamin D group and 33% in</p><p>both the calcium (P = 0.31) and calcium plus vitamin D (P = 0.36)</p><p>groups relative to the placebo group. The vitamin D treatment effect</p><p>was more pronounced in the upper 40%, or differentiation zone, of</p><p>crypts (80%; P = 0.01). There were no statistically significant</p><p>treatment effects on Bcl-2 expression. Overall, these preliminary</p><p>results suggest that calcium and vitamin D, individually or together,</p><p>may enhance apoptosis in the normal human colorectal epithelium, and</p><p>the strongest treatment effects may be vitamin D related and in the</p><p>upper sections of the colorectal crypts.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19861511><font size=2>Cancer<p>Epidemiol Biomarkers Prev.</font></a></u></font><font size=2> 2009</p><p>Nov;18(11):2933-41. Epub 2009 Oct 27.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of vitamin d and calcium on proliferation and differentiation in</p><p>normal colon mucosa: a randomized clinical trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Fedirko</font></u></font><font color=#0000ff><u><font size=2><p>V</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bostick</p><p>RM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Flanders</p><p>WD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Long</p><p>Q</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Sidelnikov</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Shaukat</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Daniel</p><p>CR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rutherford</p><p>RE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Woodard</p><p>JJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Epidemiology, Rollins School of Public Health, Winship Cancer</p><p>Institute, Emory University, Atlanta, Georgia, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>To investigate the<p>potential efficacy of calcium and vitamin D in reducing risk for</p><p>colorectal neoplasms and to develop "treatable" phenotypic</p><p>biomarkers of risk for colorectal neoplasms, we conducted a pilot,</p><p>randomized, double-blind, placebo-controlled, 2 x 2 factorial</p><p>clinical trial to test the effects of these agents on cell cycle</p><p>markers in the normal colorectal mucosa. Ninety-two men and women</p><p>with at least one pathology-confirmed colorectal adenoma were treated</p><p>with 2 g/day calcium and/or 800 IU/day vitamin D(3) versus placebo</p><p>over 6 months. Overall expression and distributions of p21(waf1/cip1)</p><p>(marker of differentiation), MIB-1 (marker of short-term</p><p>proliferation), and hTERT (marker of long-term proliferation) in</p><p>colorectal crypts in the normal-appearing rectal mucosa were detected</p><p>by automated immunohistochemistry and quantified by image analysis.</p><p>In the calcium, vitamin D, and calcium plus vitamin D groups relative</p><p>to the placebo, p21 expression increased by 201% (P = 0.03), 242% (P</p><p>= 0.005), and 25% (P = 0.47), respectively, along the full lengths of</p><p>colorectal crypts after 6 months of treatment. There were no</p><p>statistically significant changes in the expression of either MIB-1</p><p>or hTERT in the crypts overall; however, the proportion of hTERT, but</p><p>not MIB-1, expression that extended into the upper 40% of the crypts</p><p>was reduced by 15% (P = 0.02) in the vitamin D plus calcium group</p><p>relative to the placebo. These results indicate that calcium and</p><p>vitamin D promote colorectal epithelial cell differentiation and may</p><p>"normalize" the colorectal crypt proliferative zone in</p><p>sporadic adenoma patients, and support further investigation of</p><p>calcium and vitamin D as chemopreventive agents against colorectal</p><p>neoplasms.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20056649><font size=2>Cancer<p>Epidemiol Biomarkers Prev.</font></a></u></font><font size=2> 2010</p><p>Jan;19(1):280-91.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of supplemental vitamin D and calcium on oxidative DNA damage marker</p><p>in normal colorectal mucosa: a randomized clinical trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Fedirko</font></u></font><font color=#0000ff><u><font size=2><p>V</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bostick</p><p>RM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Long</p><p>Q</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Flanders</p><p>WD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McCullough</p><p>ML</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Sidelnikov</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Daniel</p><p>CR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rutherford</p><p>RE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Shaukat</p><p>A</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Epidemiology, Rollins School of Public Health, Emory University,</p><p>Atlanta, GA 30322, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>The exact antineoplastic<p>effects of calcium and vitamin D(3) in the human colon are unclear.</p><p>Animal and in vitro studies show that these two agents reduce</p><p>oxidative stress; however, these findings have never been</p><p>investigated in humans. To address this, we conducted a pilot,</p><p>randomized, double-blind, placebo-controlled, 2 x 2 factorial</p><p>clinical trial to test the effects of calcium and vitamin D(3) on a</p><p>marker of oxidative DNA damage, 8-hydroxy-2&rsquo;-deoxyguanosine</p><p>(8-OH-dG), in the normal colorectal mucosa. Patients (N = 92) with at</p><p>least one pathology-confirmed colorectal adenoma were treated with 2</p><p>g/d calcium and/or 800 IU/d vitamin D(3) versus placebo over 6</p><p>months. Overall labeling and colorectal crypt distribution of 8-OH-dG</p><p>in biopsies of normal-appearing rectal mucosa were detected by</p><p>standardized automated immunohistochemistry and quantified by image</p><p>analysis. After 6 months of treatment, 8-OH-dG labeling along the</p><p>full lengths of colorectal crypts decreased by 22% (P = 0.15) and 25%</p><p>(P = 0.10) in the calcium and vitamin D(3) groups, respectively, but</p><p>not in the calcium plus vitamin D(3) group. The estimated treatment</p><p>effects were strongest among participants with higher baseline colon</p><p>crypt vitamin D receptor expression (P = 0.05). Overall, these</p><p>preliminary results indicate that calcium and vitamin D(3) may</p><p>decrease oxidative DNA damage in the normal human colorectal mucosa,</p><p>support the hypothesis that 8-OH-dG labeling in colorectal crypts is</p><p>a treatable oxidative DNA damage biomarker of risk for colorectal</p><p>neoplasms, and provide support for further investigation of calcium</p><p>and vitamin D(3) as chemopreventive agents against colorectal</p><p>neoplasms.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21084270><font size=2>Cancer<p>Res.</font></a></u></font><font size=2> 2011 Jan 15;71(2):413-23.</p><p>Epub 2010 Nov 17.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>randomized clinical trial of the effects of supplemental calcium and</p><p>vitamin D3 on markers of their metabolism in normal mucosa of</p><p>colorectal adenoma patients.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ahearn<p>TU</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McCullough</p><p>ML</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Flanders</p><p>WD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Long</p><p>Q</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Sidelnikov</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Fedirko</p><p>V</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Daniel</p><p>CR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rutherford</p><p>RE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Shaukat</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bostick</p><p>RM</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Nutrition and Health<p>Sciences Program, Graduate Division of Biological and Biomedical</p><p>Sciences, Winship Cancer Institute, Emory University, Department of</p><p>Epidemiology, Rollins School of Public Health, Atlanta, Georgia</p><p>30322, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>In cancer cell lines and<p>rodent models, calcium and vitamin D favorably modulate cell</p><p>proliferation, differentiation, and apoptosis in colonic epithelia.</p><p>These effects may be modulated by local expression of the calcium</p><p>receptor (CaR), the vitamin D receptor (VDR), and the P450</p><p>cytochromes, CYP27B1 and CYP24A1; however, they have yet to be</p><p>investigated in humans. To address this gap, we conducted a</p><p>randomized, double-blinded, placebo-controlled 2×2 factorial</p><p>clinical trial. Patients with at least one pathology-confirmed</p><p>colorectal adenoma were treated with 2 g/d elemental calcium and/or</p><p>800 IU/d vitamin D3 versus placebo over 6 months (n=92; 23 per</p><p>group). CaR, VDR, CYP27B1, and CYP24A1 expression and distribution in</p><p>biopsies of normal appearing rectal mucosa were detected by</p><p>standardized, automated immunohistochemistry and quantified by image</p><p>analysis. In the calcium-supplemented group, CaR expression increased</p><p>27% (P=0.03) and CYP24A1 expression decreased 21% (P=0.79). In the</p><p>vitamin D3-supplemented group, CaR expression increased 39% (P=0.01)</p><p>and CYP27B1 expression increased 159% (P=0.06). In patients</p><p>supplemented with both calcium and vitamin D3, VDR expression</p><p>increased 19% (P=0.13) and CaR expression increased 24% (P=0.05).</p><p>These results provide mechanistic support for further investigation</p><p>of calcium and vitamin D3 as chemopreventive agents against</p><p>colorectal neoplasms, and CaR, VDR, CYP27B1, and CYP24A1 as</p><p>modifiable, preneoplastic risk biomarkers for colorectal neoplasms.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22025459><font size=2>Neurology.</font></a></u></font><font size=2><p>2011 Oct 25;77(17):1611-8.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>randomized trial of high-dose vitamin D2 in relapsing-remitting</p><p></font><font size=2>multiple sclerosis</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stein<p>MS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Liu</p><p>Y</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gray</p><p>OM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Baker</p><p>JE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kolbe</p><p>SC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ditchfield</p><p>MR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Egan</p><p>GF</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mitchell</p><p>PJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Harrison</p><p>LC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Butzkueven</p><p>H</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kilpatrick</p><p>TJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Endocrinology, Royal Melbourne Hospital, Parkville, Victoria,</p><p>Australia. <a href=mailto:Mark.Stein@mh.org.au>Mark.Stein@mh.org.au</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>Higher latitude, lower<p>ultraviolet exposure, and lower serum 25-hydroxyvitamin D (25OHD)</p><p>correlate with higher </font><font size=2>multiple sclerosis</font><font size=2></p><p>(MS) prevalence, relapse rate, and mortality. We therefore evaluated</p><p>the effects of high-dose vitamin D2 (D2) in MS.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Adults with clinically<p>active relapsing-remitting MS (RRMS) were randomized to 6 months'</p><p>double-blind placebo-controlled high-dose vitamin D2, 6,000 IU</p><p>capsules, dose adjusted empirically aiming for a serum 25OHD 130-175</p><p>nM. All received daily low-dose (1,000 IU) D2 to prevent deficiency.</p><p>Brain MRIs were performed at baseline, 4, 5, and 6 months. Primary</p><p>endpoints were the cumulative number of new gadolinium-enhancing</p><p>lesions and change in the total volume of T2 lesions. Secondary</p><p>endpoints were Expanded Disability Status Scale (EDSS) score and</p><p>relapses.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Twenty-three people were<p>randomized, of whom 19 were on established interferon or glatiramer</p><p>acetate (Copaxone) treatment. Median 25OHD rose from 54 to 69 nM</p><p>(low-dose D2) vs 59 to 120 nM (high-dose D2) (p = 0.002). No</p><p>significant treatment differences were detected in the primary MRI</p><p>endpoints. Exit EDSS, after adjustment for entry EDSS, was higher</p><p>following high-dose D2 than following low-dose D2 (p = 0.05). There</p><p>were 4 relapses with high-dose D2 vs none with low-dose D2 (p =</p><p>0.04).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>We did not find a<p>therapeutic advantage in RRMS for high-dose D2 over low-dose D2</p><p></font><font size=2>supplementation</font><font size=2>.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CLASSIFICATION<p>OF EVIDENCE:</font></p></h4><p style=margin-bottom:0><font size=2>This study provides Class<p>I evidence that high-dose vitamin D2 (targeting 25OHD 130-175 nM),</p><p>compared to low-dose </font><font size=2>supplementation</font><font size=2></p><p>(1,000 IU/d), was not effective in reducing MRI lesions in patients</p><p>with RRMS.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21724580><font size=2>Cancer<p>Prev Res (Phila).</font></a></u></font><font size=2> 2011</p><p>Oct;4(10):1645-54. Epub 2011 Jun 30.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of supplemental vitamin D and calcium on biomarkers of inflammation</p><p>in colorectal adenoma patients: a randomized, controlled clinical</p><p>trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hopkins<p>MH</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Owen</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ahearn</p><p>T</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Fedirko</p><p>V</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Flanders</p><p>WD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Jones</p><p>DP</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bostick</p><p>RM</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Epidemiology, Rollins School of Public Health, Emory University,</p><p>Atlanta, GA 30322, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Vitamin D and calcium<p>affect several pathways involved in inflammation, tumor growth, and</p><p>immune surveillance relevant to carcinogenesis. Also, epidemiologic</p><p>evidence indicates that calcium and vitamin D may reduce risk for</p><p>developing colorectal adenomas and cancer. To investigate the effects</p><p>of calcium and vitamin D on biomarkers of inflammation in colorectal</p><p>adenoma patients, we conducted a pilot, randomized, double-blind,</p><p>placebo-controlled, 2 × 2 factorial clinical trial (n = 92) of</p><p>2 g/d calcium and/or 800 IU/d vitamin D(3) supplementation versus</p><p>placebo over 6 months. Plasma concentrations of proinflammatory</p><p>markers [C-reactive protein (CRP), TNF-α, interleukin (IL)-6,</p><p>IL-1β, and IL-8] and an anti-inflammatory marker (IL-10) were</p><p>measured using ELISAs. After 6 months of treatment, in the vitamin</p><p>D(3) supplementation group, CRP decreased 32% overall (P = 0.11), 37%</p><p>in men (P = 0.05), and 41% among non-nonsteroidal anti-inflammatory</p><p>drug (NSAID) users (P = 0.05) relative to placebo. In the vitamin</p><p>D(3) supplementation group, TNF-α decreased 13%, IL-6 32%,</p><p>IL-1β 50%, and IL-8 15%; in the calcium supplementation group,</p><p>IL-6 decreased 37%, IL-8 11%, and IL-1β 27%. Although these</p><p>changes were not statistically significant, a combined inflammatory</p><p>markers z-score decreased 77% (P = 0.003) in the vitamin D(3)</p><p>treatment group overall, 83% (P = 0.01) among men, and 48% among</p><p>non-NSAID users (P = 0.01). There was no evidence of synergy between</p><p>vitamin D(3) and calcium or effects on IL-10. These preliminary</p><p>results are consistent with a pattern of reduction in tumor-promoting</p><p>inflammation biomarkers with vitamin D(3) or calcium supplementation</p><p>alone and support further investigation of vitamin D(3) as a</p><p>chemopreventive agent against inflammation and colorectal neoplasms.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Nagpal%2C%20%20Pande%20vitamin%20d"><font size=2>Diabet<p>Med.</font></a></u></font><font size=2> 2009 Jan;26(1):19-27.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>double-blind, randomized, placebo-controlled trial of the short-term</p><p>effect of vitamin D3 supplementation on insulin sensitivity in</p><p>apparently healthy, middle-aged, centrally obese men.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Nagpal</font></u></font><font color=#0000ff><u><font size=2><p>J</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pande</p><p>JN</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bhartia</p><p>A</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Sitaram Bhartia Institute<p>of Science and Research, New Delhi, India.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>AIM:</font></h4><p style=margin-bottom:0><font size=2>To determine the<p>short-term effect of </font><font size=2>vitamin D</font><font size=2>(3)</p><p>supplementation on insulin sensitivity in apparently healthy,</p><p>middle-aged, centrally obese men.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SUBJECTS<p>AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>A double-blind randomized<p>controlled trial was conducted at a tertiary care facility in which</p><p>100 male volunteers aged > or = 35 years received three doses of</p><p></font><font size=2>vitamin D</font><font size=2>(3) (120,000 IU</p><p>each; supplemented group) fortnightly or placebo (control group).</p><p>Hepatic fasting insulin sensitivity [homeostasis model assessment</p><p>(HOMA), quantitative insulin-sensitivity check index, HOMA-2],</p><p>postprandial insulin sensitivity [oral glucose insulin sensitivity</p><p>(OGIS)], insulin secretion (HOMA%B, HOMA2-%B), lipid profile and</p><p>blood pressure were measured at baseline and at 6 weeks&rsquo; follow-up.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Seventy-one of the<p>recruited subjects completed the study (35 in supplemented group, 36</p><p>in control group). There was an increase in OGIS with supplementation</p><p>by per protocol analysis (P = 0.038; intention-to-treat analysis P =</p><p>0.055). The age- and baseline 25-hydroxyvitamin D level-adjusted</p><p>difference in change in OGIS was highly significant (mean difference</p><p>41.1 +/- 15.5; P = 0.01). No changes in secondary outcome measures</p><p>(insulin secretion, basal indices of insulin sensitivity, blood</p><p>pressure or lipid profile) were found with supplementation.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>The trial indicates that<p></font><font size=2>vitamin D</font><font size=2>(3) supplementation</p><p>improves postprandial insulin sensitivity (OGIS) in apparently</p><p>healthy men likely to have insulin resistance (centrally obese but</p><p>non-diabetic).</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19491064><font size=2>Endocr<p>Pract.</font></a></u></font><font size=2> 2009 Jul-Aug;15(5):438-49.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D for treatment and prevention of infectious diseases: a systematic</p><p>review of randomized controlled trials.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Yamshchikov</font></u></font><font color=#0000ff><u><font size=2><p>AV</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Desai</p><p>NS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Blumberg</p><p>HM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ziegler</p><p>TR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Tangpricha</p><p>V</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Infectious<p>Diseases, Department of Medicine, Emory University School of</p><p>Medicine, Atlanta, Georgia 30030, USA. <a href=mailto:AYAMSHC@emory.edu>AYAMSHC@emory.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To review the existing<p>human controlled intervention studies of vitamin D as adjunctive</p><p>therapy in settings of infection and provide recommendations for</p><p>design and implementation of future studies in this field on the</p><p>basis of the evidence reviewed.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>We conducted a systematic<p>review of randomized controlled clinical trials that studied vitamin</p><p>D for treatment or prevention of infectious diseases in humans.</p><p>Studies from 1948 through 2009 were identified through search terms</p><p>in PubMed and Ovid MEDLINE.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Thirteen published<p>controlled trials were identified by our search criteria. Ten trials</p><p>were placebo controlled, and 9 of the 10 were conducted in a rigorous</p><p>double-blind design. The selected clinical trials demonstrated</p><p>substantial heterogeneity in baseline patient demographics, sample</p><p>size, and vitamin D intervention strategies. Serious adverse events</p><p>attributable to vitamin D supplementation were rare across all</p><p>studies. On the basis of studies reviewed to date, the strongest</p><p>evidence supports further research into adjunctive vitamin D therapy</p><p>for tuberculosis, influenza, and viral upper respiratory tract</p><p>illnesses. In the selected studies, certain aspects of study design</p><p>are highlighted to help guide future clinical research in the field.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>More rigorously designed<p>clinical trials are needed for further evaluation of the relationship</p><p>between vitamin D status and the immune response to infection as well</p><p>as for delineation of necessary changes in clinical practice and</p><p>medical care of patients with vitamin D deficiency in infectious</p><p>disease settings.</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/17463418><font size=2>Am<p>J Respir Crit Care Med.</font></a></u></font><font size=2> 2007 Jul</p><p>15;176(2):208-13. Epub 2007 Apr 26.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>single dose of vitamin D enhances immunity to mycobacteria.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Martineau</font></u></font><font color=#0000ff><u><font size=2><p>AR</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wilkinson</p><p>RJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wilkinson</p><p>KA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Newton</p><p>SM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kampmann</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hall</p><p>BM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Packe</p><p>GE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Davidson</p><p>RN</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Eldridge</p><p>SM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Maunsell</p><p>ZJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rainbow</p><p>SJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Berry</p><p>JL</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Griffiths</p><p>CJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Centre for Health<p>Sciences, Queen Mary&rsquo;s School of Medicine and Dentistry, Barts and</p><p>The London, and Department of Clinical Biochemistry, North West</p><p>London Hospitals NHS Trust, Northwick Park Hospital, Harrow, E1 2AT,</p><p>UK. a.</font><font size=2>martineau</font><font size=2>@qmul.ac.uk</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RATIONALE:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D was used to<p>treat tuberculosis (TB) in the preantibiotic era. Prospective studies</p><p>to evaluate the effect of vitamin D supplementation on</p><p>antimycobacterial immunity have not previously been performed.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>To determine the effect of<p>vitamin D supplementation on antimycobacterial immunity and vitamin D</p><p>status.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>A double-blind randomized<p>controlled trial was conducted in 192 healthy adult TB contacts in</p><p>London, United Kingdom. Participants were randomized to receive a</p><p>single oral dose of 2.5 mg vitamin D or placebo and followed up at 6</p><p>weeks.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MEASUREMENTS<p>AND MAIN RESULTS:</font></p></h4><p style=margin-bottom:0><font size=2>The primary outcome<p>measure was assessed with a functional whole blood assay (BCG-lux</p><p>assay), which measures the ability of whole blood to restrict</p><p>luminescence, and thus growth, of recombinant reporter mycobacteria</p><p>in vitro; the readout is expressed as a luminescence ratio</p><p>(luminescence postinfection/baseline luminescence). IFN-gamma</p><p>responses to the Mycobacterium tuberculosis antigens early secretory</p><p>antigenic target-6 and culture filtrate protein 10 were determined</p><p>with a second whole blood assay. Vitamin D supplementation</p><p>significantly enhanced the ability of participants&rsquo; whole blood to</p><p>restrict BCG-lux luminescence in vitro compared with placebo (mean</p><p>luminescence ratio at follow-up, 0.57, vs. 0.71, respectively; 95%</p><p>confidence interval for difference, 0.01-0.25; p=0.03) but did not</p><p>affect antigen-stimulated IFN-gamma secretion.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>A single oral dose of 2.5<p>mg vitamin D significantly enhanced the ability of participants'</p><p>whole blood to restrict BCG-lux luminescence in vitro without</p><p>affecting antigen-stimulated IFN-gamma responses. Clinical trials</p><p>should be performed to determine whether vitamin D supplementation</p><p>prevents reactivation of latent TB infection. Clinical trial</p><p>registered with <a href=https://www.clinicaltrials.gov>www.clinicaltrials.gov</a> (NCT 00157066).</font></p></p><p class=western style=margin-left:.5in;text-indent:-.5in;margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19185400><font size=2>Am<p>J Kidney Dis.</font></a></u></font><font size=2> 2009</p><p>Mar;53(3):408-16. Epub 2009 Jan 29.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>The<p>effect of combined calcium and vitamin D3 supplementation on serum</p><p>intact parathyroid hormone in moderate CKD.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kooienga<p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Fried</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Scragg</p><p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kendrick</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Smits</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Chonchol</p><p>M</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Renal Diseases<p>and Hypertension, University of Colorado Health Sciences Center,</p><p>Denver, CO 80262, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Studies addressing the<p>effects of vitamin D(3) supplementation on secondary</p><p>hyperparathyroidism in patients with moderate chronic kidney disease</p><p>are scarce.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>STUDY<p>DESIGN:</font></p></h4><p style=margin-bottom:0><font size=2>Post hoc analysis of the<p>randomized clinical trial Vitamin D, Calcium, Lyon Study II (DECALYOS</p><p>II) to assess effects according to baseline estimated glomerular</p><p>filtration rate (eGFR).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SETTING<p>&amp;#38; PARTICIPANTS:</font></p></h4><p style=margin-bottom:0><font size=2>Multicenter, randomized,<p>double-blinded, placebo-controlled study of 639 elderly women</p><p>randomly assigned to calcium-vitamin D(3) fixed combination; calcium</p><p>plus vitamin D(3) separate combination, or placebo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTERVENTIONS:</font></h4><p style=margin-bottom:0><font size=2>Placebo or calcium (1,200<p>mg) and vitamin D(3) (800 IU) in fixed or separate combination.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OUTCOMES<p>&amp;#38; MEASUREMENTS:</font></p></h4><p style=margin-bottom:0><font size=2>Proportion of participants<p>with a mean decrease in intact parathyroid hormone (iPTH) level of</p><p>30% or greater. eGFR was calculated using the 4-variable Modification</p><p>of Diet in Renal Disease (MDRD) Study equation and categorized as 60</p><p>or greater, 45 to 59, and less than 45 mL/min/1.73 m(2).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>610 participants had an<p>eGFR at baseline: 288 (47.2%), 222 (36.4%), and 100 (16.4%) were in</p><p>each decreasing eGFR category. Across decreasing eGFR groups, 88%,</p><p>86%, and 89% had 25-hydroxyvitamin D (25[OH]D) levels less than 15</p><p>ng/mL at baseline. On treatment, similar improvements in the</p><p>proportion of participants achieving 25(OH)D levels greater than 30</p><p>ng/mL at 6 months were seen in all kidney function groups (43%, 49%,</p><p>and 41%, respectively). Active regimens versus placebo increased mean</p><p>25(OH)D levels from baseline in all eGFR groups at all times (P &lt;</p><p>0.001 for all). The proportion with a 30% or greater decrease in iPTH</p><p>level at 6 months was 50% in all eGFR groups on treatment versus 6%</p><p>to 9% for placebo (P &lt; 0.001 for all). The effects of the</p><p>intervention on iPTH levels did not differ according to baseline eGFR</p><p>(interaction P > 0.1 for all times).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>LIMITATIONS:</font></h4><p style=margin-bottom:0><font size=2>This study included only<p>elderly white women.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D(3) was effective<p>in increasing 25(OH)D and decreasing iPTH levels in patients with</p><p>moderate chronic kidney disease.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19229821><font size=2>J<p>Nephrol.</font></a></u></font><font size=2> 2009 Jan-Feb;22(1):75-82.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D insufficiency and treatment with oral vitamin D3 in</p><p>northern-dwelling patients with chronic kidney disease.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rucker<p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Tonelli</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Coles</p><p>MG</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Yoo</p><p>S</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Young</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McMahon</p><p>AW</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Medicine,<p>Division of General Internal Medicine, University of Alberta,</p><p>University of Alberta Hospital, Edmonton, Alberta, Canada.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D insufficiency is<p>common in people living at northern latitudes and those with chronic</p><p>kidney disease (CKD). We studied persons with both of these risk</p><p>factors to determine the prevalence of vitamin D insufficiency and</p><p>whether serum 25-hydroxyvitamin D (25(OH)D) levels were affected by</p><p>oral vitamin D3 supplementation.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>This was a prospective<p>controlled trial of 128 patients with stage 3-5 non-dialysis</p><p>dependent CKD. Patients were assigned to the intervention (oral</p><p>vitamin D3 1,000 IU/day) in a 1:1 ratio at the discretion of the</p><p>attending dietitian. Serum biochemical markers were measured at</p><p>baseline (May-July) and after 3 months of follow-up. There were 63</p><p>control and 65 intervention subjects.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Mean 25(OH)D levels<p>increased significantly higher in the treatment group (mean increase</p><p>from baseline: 10.3+/-10.4 ng/mL vs. 0.8+/-6.8 ng/mL, p&lt;0.0001).</p><p>This difference remained significant after adjustment for differing</p><p>baseline characteristics between groups (p&lt;0.0001). Treatment with</p><p>oral vitamin D3 reduced vitamin D insufficiency by 37%, as compared</p><p>with a 2% increase in prevalence among the control group (p&lt;0.0001).</p><p>Considering the entire study population, 93% of patients had levels</p><p>less than &lt;30 ng/mL at least once during the study.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D insufficiency is<p>highly prevalent in northern-dwelling patients with stage 3-5 CKD,</p><p>and is moderated by oral supplementation with 1,000 IU of vitamin D3</p><p>daily.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/7498100><font size=2><span lang=de-DE>Eur<p>J Clin Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>1995 Sep;49(9):640-6.</span></font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effect<p>of winter oral vitamin D3 supplementation on cardiovascular risk</p><p>factors in elderly adults.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Scragg<p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Khaw</p><p>KT</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Murphy</p><p>S</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Clinical Gerontology Unit,<p>University of Cambridge School of Clinical Medicine, Addenbrooke&rsquo;s</p><p>Hospital, UK.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>A possible role for<p>vitamin D deficiency in contributing to the winter increase in</p><p>cardiovascular disease mortality was investigated by testing the</p><p>effect of vitamin D supplementation on blood pressure and other</p><p>cardiovascular risk factors during winter.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Randomised double-blind<p>trial of vitamin D supplementation in winter.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SUBJECTS:</font></h4><p style=margin-bottom:0><font size=2>Men and women, mean age 70<p>years (range 63-76) recruited from general practitioner age-sex</p><p>registers in Cambridge (UK).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTERVENTION:</font></h4><p style=margin-bottom:0><font size=2>95 people received a<p>single oral dose of 2.5 mg cholecalciferol and 94 received the</p><p>placebo at baseline interviews during December 1991. Follow-up</p><p>assessment was 5 weeks later during January 1992.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Comparing follow-up with<p>baseline assessment, serum 25-hydroxyvitamin D increased in the</p><p>treated group and decreased slightly in the placebo group [mean</p><p>(s.d.) change: 7.2 (+/- 3.8) vs -1.4 (+/- 1.1) ng/ml, P = 0.0001];</p><p>while parathyroid hormone decreased in the treated, and increased in</p><p>the placebo, group [-0.27 (+/- 0.78) vs 0.13 (+/- 0.75) pmol/l, P =</p><p>0.0004]. However, the mean change in blood pressure was similar in</p><p>both groups: systolic -5 (+/- 13) vs -5 (+/- 16) mmHg, P = 0.81;</p><p>diastolic -1 (+/- 9) vs -1 (+/- 9), P = 0.92; as was the mean change</p><p>in serum cholesterol [-0.07 (+/- 0.52) vs -0.05 (+/- 0.60) mmol/l, P</p><p>= 0.81]. In contrast, the mean change in radial pulse was</p><p>significantly decreased in the treated group compared with placebo</p><p>[-2 (+/- 9) vs 1 (+/- 7) beats per min, P = 0.030].</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>The failure of vitamin D<p>supplementation to change blood pressure or serum cholesterol</p><p>suggests that the winter increase in these factors is not caused by</p><p>decreased vitamin D levels.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/16479024><font size=2>Acta<p>Med Indones.</font></a></u></font><font size=2> 2006</p><p>Jan-Mar;38(1):3-5.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>The<p>effect of vitamin D as supplementary treatment in patients with</p><p>moderately advanced pulmonary tuberculous lesion.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Nursyam<p>EW</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Amin</p><p>Z</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Rumende</p><p>CM</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Departement of Internal<p>Medicine, Faculty of Medicine, University of Indonesia-dr.Cipto</p><p>Mangunkusumo Hospital, Jakarta.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>AIM:</font></h4><p style=margin-bottom:0><font size=2>to compare the vitamin D<p>group of pulmonary tuberculosis patients with a placebo group in</p><p>terms of clinical improvement, nutritional status, sputum conversion,</p><p>and radiological improvement.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>sixty seven tuberculosis<p>patient visiting the Pulmonary Clinic, of Cipto Mangunkusumo</p><p>Hospital, Jakarta, from January 1st to August 31st, 2001 were</p><p>included in this study. The subjects were randomised to receive</p><p>vitamin D (0.25 mg/day) or placebo in a double blind method, during</p><p>the 6th initial week of Tb treatment. The rate of sputum conversion,</p><p>complete blood counts, blood chemistry as well as radiologic</p><p>examination were evaluated.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>there were more male<p>patients than females (39:28), 78.7% were in the productive age</p><p>group, 71.6% had low nutritional status, 62.4% with low education</p><p>level, and 67.2% with low income. One hundred percent of the vitamin</p><p>D group and only 76.7% of the placebo group had sputum conversion.</p><p>This difference is statistically significant (p=0.002).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>the sputum conversion had<p>no correlation with the hemoglobin level, blood clotting time,</p><p>calcium level, lymphocyte count, age, sex, and nutritional status.</p><p>There were more subjects with radiological improvement in the vitamin</p><p>D group.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19296870><font size=2>Epidemiol<p>Infect.</font></a></u></font><font size=2> </font><font size=2>2009</font><font size=2></p><p>Oct;137(10):1396-404. Epub </font><font size=2>2009</font><font size=2></p><p>Mar 19.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>randomized controlled trial of vitamin D3 supplementation for the</p><p>prevention of symptomatic upper respiratory tract infections.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Li-Ng</font></u></font><font color=#0000ff><u><font size=2><p>M</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Aloia</p><p>JF</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pollack</p><p>S</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Cunha</p><p>BA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mikhail</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Yeh</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Berbari</p><p>N</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Bone Mineral Research<p>Center, Winthrop University Hospital, Mineola, NY, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Vitamin D has been shown<p>to be an important immune system regulator. Vitamin D insufficiency</p><p>during winter may cause increased susceptibility to upper respiratory</p><p>tract infections (URIs). To determine whether vitamin D</p><p>supplementation during the winter season prevents or decreases URI</p><p>symptoms, 162 adults were randomized to receive 50 microg vitamin D3</p><p>(2000 IU) daily or matching placebo for 12 weeks. A bi-weekly</p><p>questionnaire was used to record the incidence and severity of URI</p><p>symptoms. There was no difference in the incidence of URIs between</p><p>the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively,</p><p>P=0.57). There was no difference in the duration or severity of URI</p><p>symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs.</p><p>5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in</p><p>duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at</p><p>baseline was similar in both groups (64.3+/-25.4 nmol/l in the</p><p>vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.).</p><p>After 12 weeks, 25-hydroxyvitamin D levels increased significantly to</p><p>88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no</p><p>change in vitamin D levels in the placebo group. There was no benefit</p><p>of vitamin D3 supplementation in decreasing the incidence or severity</p><p>of symptomatic URIs during winter. Further studies are needed to</p><p>determine the role of vitamin D in infection.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21215445><font size=2>Lancet.</font></a></u></font><font size=2><p>2011 Jan 15;377(9761):242-50. Epub 2011 Jan 5.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>High-dose<p></font><font size=2>vitamin D</font><font size=2>(3) during</p><p>intensive-phase antimicrobial treatment of pulmonary tuberculosis: a</p><p>double-blind randomised controlled trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Martineau</font></u></font><font color=#0000ff><u><font size=2><p>AR</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Timms</p><p>PM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bothamley</p><p>GH</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hanifa</p><p>Y</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Islam</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Claxton</p><p>AP</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Packe</p><p>GE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Moore-Gillon</p><p>JC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Darmalingam</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Davidson</p><p>RN</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Milburn</p><p>HJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Baker</p><p>LV</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Barker</p><p>RD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Woodward</p><p>NJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Venton</p><p>TR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Barnes</p><p>KE</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mullett</p><p>CJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Coussens</p><p>AK</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rutterford</p><p>CM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mein</p><p>CA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Davies</p><p>GR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wilkinson</p><p>RJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Nikolayevskyy</p><p>V</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Drobniewski</p><p>FA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Eldridge</p><p>SM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Griffiths</p><p>CJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Queen Mary University of<p>London, Barts and The London School of Medicine and Dentistry,</p><p>London, UK. a.</font><font size=2>martineau</font><font size=2>@qmul.ac.uk</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>was used to treat tuberculosis in the pre-antibiotic era, and its</p><p>metabolites induce antimycobacterial immunity in vitro. Clinical</p><p>trials investigating the effect of adjunctive </font><font size=2>vitamin</p><p>D</font><font size=2> on sputum culture conversion are absent.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>We undertook a multicentre<p>randomised controlled trial of adjunctive </font><font size=2>vitamin</p><p>D</font><font size=2> in adults with sputum smear-positive pulmonary</p><p>tuberculosis in London, UK. 146 patients were allocated to receive</p><p>2·5 mg </font><font size=2>vitamin D</font><font size=2>(3) or</p><p>placebo at baseline and 14, 28, and 42 days after starting standard</p><p>tuberculosis treatment. The primary endpoint was time from initiation</p><p>of antimicrobial treatment to sputum culture conversion. Patients</p><p>were genotyped for TaqI and FokI polymorphisms of the </font><font size=2>vitamin</p><p>D</font><font size=2> receptor, and interaction analyses were done to</p><p>assess the influence of the </font><font size=2>vitamin D</font><font size=2></p><p>receptor genotype on response to </font><font size=2>vitamin D</font><font size=2>(3).</p><p>This trial is registered with ClinicalTrials.gov number NCT00419068.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>FINDINGS:</font></h4><p style=margin-bottom:0><font size=2>126 patients were included<p>in the primary efficacy analysis (62 assigned to intervention, 64</p><p>assigned to placebo). Median time to sputum culture conversion was</p><p>36·0 days in the intervention group and 43·5 days in</p><p>the placebo group (adjusted hazard ratio 1·39, 95% CI</p><p>0·90-2·16; p=0.14). TaqI genotype modified the effect</p><p>of </font><font size=2>vitamin D</font><font size=2> supplementation</p><p>on time to sputum culture conversion (p(interaction)=0·03),</p><p>with enhanced response seen only in patients with the tt genotype</p><p>(8·09, 95% CI 1·36-48·01; p=0·02). FokI</p><p>genotype did not modify the effect of </font><font size=2>vitamin D</font><font size=2></p><p>supplementation (p(interaction)=0·85). Mean serum</p><p>25-hydroxyvitamin D concentration at 56 days was 101·4 nmol/L</p><p>in the intervention group and 22·8 nmol/L in the placebo group</p><p>(95% CI for difference 68·6-88·2; p&lt;0·0001).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTERPRETATION:</font></h4><p style=margin-bottom:0><font size=2>Administration of four<p>doses of 2·5 mg </font><font size=2>vitamin D</font><font size=2>(3)</p><p>increased serum 25-hydroxyvitamin D concentrations in patients</p><p>receiving intensive-phase treatment for pulmonary tuberculosis.</p><p></font><font size=2>Vitamin D</font><font size=2> did not</p><p>significantly affect time to sputum culture conversion in the whole</p><p>study population, but it did significantly hasten sputum culture</p><p>conversion in participants with the tt genotype of the TaqI </font><font size=2>vitamin</p><p>D</font><font size=2> receptor polymorphism.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Krall%2C%20%20Wehler%202001"><font size=2>Am<p>J Med.</font></a></u></font><font size=2> </font><font size=2>2001</font><font size=2></p><p>Oct 15;111(6):452-6.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Calcium<p>and vitamin D supplements reduce tooth loss in the elderly.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Krall</font></u></font><font color=#0000ff><u><font size=2><p>EA</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wehler</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Garcia</p><p>RI</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Harris</p><p>SS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Health<p>Policy and Health Services Research, Boston University Goldman School</p><p>of Dental Medicine, 715 Albany Street, Boston, MA O2118, USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PURPOSE:</font></h4><p style=margin-bottom:0><font size=2>Oral bone and tooth loss<p>are correlated with bone loss at nonoral sites. Calcium and vitamin D</p><p>supplementation slow the rate of bone loss from various skeletal</p><p>sites, but it is not known if intake of these nutrients affects oral</p><p>bone and, in turn, tooth retention.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SUBJECTS<p>AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>Tooth loss was examined in<p>145 healthy subjects aged 65 years and older who completed a 3-year,</p><p>randomized, placebo-controlled trial of the effect of calcium and</p><p>vitamin D supplementation on bone loss from the hip, as well as a</p><p>2-year follow-up study after discontinuation of study supplements.</p><p>Teeth were counted at 18 months and 5 years. A comprehensive oral</p><p>examination at 5 years included assessment of caries, oral hygiene,</p><p>and periodontal disease. The odds ratio (OR) and 95% confidence</p><p>interval (CI) of tooth loss were estimated by stepwise multivariate</p><p>logistic regression. Initial age (mean +/- SD) of subjects was 71 +/-</p><p>5 years, and the number of teeth remaining was 22 +/- 7.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>During the randomized<p>trial, 11 of the 82 subjects (13%) taking supplements and 17 of the</p><p>63 subjects (27%) taking placebo lost one or more teeth (OR = 0.4;</p><p>95% CI: 0.2 to 0.9). During the 2-year follow-up period, 31 of the 77</p><p>subjects (40%) with total calcium intake of at least 1000 mg per day</p><p>lost one or more teeth compared with 40 of the 68 subjects (59%) who</p><p>consumed less (OR = 0.5; 95% CI: 0.2 to 0.9).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>These findings suggest<p>that intake levels of calcium and vitamin D aimed at preventing</p><p>osteoporosis have a beneficial effect on tooth retention.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/18579534><font size=2>Nephrol<p>Dial Transplant.</font></a></u></font><font size=2> 2008</p><p>Nov;23(11):3670-6. Epub 2008 Jun 24.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Daily<p>oral 25-hydroxycholecalciferol supplementation for vitamin D</p><p>deficiency in haemodialysis patients: effects on mineral metabolism</p><p>and bone markers.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Jean<p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Terrat</p><p>JC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Vanel</p><p>T</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hurot</p><p>JM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lorriaux</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mayor</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Chazot</p><p>C</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Centre de Rein Artificiel,<p>42 avenue du 8 mai 1945, 69160, Tassin la Demi-lune, France.</p><p><a href=mailto:guillaume-jean-crat@wanadoo.fr>guillaume-jean-crat@wanadoo.fr</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D deficiency is<p>frequently observed in end-stage renal disease (ESRD) patients;</p><p>however, the effects of vitamin D supplementation have rarely been</p><p>reported. We aimed to assess the effects of daily 25(OH)D(3)</p><p>supplementation on mineral metabolism, bone markers and Kidney</p><p>Disease Outcomes Quality Initiative (KDOQI) targets in haemodialysis</p><p>(HD) patients for a period of 6 months.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>HD patients were included<p>in this study if their serum 25(OH)D level was &lt;75 mmol/L. Oral</p><p>25(OH)D(3) was administered daily at 10-30 microg/day based on the</p><p>severity of the deficiency. Characteristics of the patients were</p><p>compared from the baseline to 6 months on the basis of their response</p><p>to 25(OH)D(3) administration and the patients were divided into three</p><p>groups. Patients who showed partial response [serum 25(OH)D &lt;75</p><p>nmol/L] were placed in group 1, those who showed normal response</p><p>[serum 25(OH)D ranging from 75 to 150 nmol/L] were placed in group 2</p><p>and those who showed excessive response [serum 25(OH)D >150</p><p>nmol/L] were placed in group 3.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Of the 253 HD patients,<p>225 (89%) showed vitamin D insufficiency or deficiency, 172 were</p><p>included in the study and 149 patients completed the study. After 6</p><p>months of treatment [mean daily 25(OH)D(3): 16 +/- 5 microg/day], the</p><p>serum 25(OH)D level increased (30 +/- 19 to 126 +/- 46 nmol/ L, P &lt;</p><p>0.001), with 13% of patients in group 1, 57% in group 2 and 30% in</p><p>group 3. The serum intact parathyroid hormone (iPTH) level decreased</p><p>(235 +/- 186 to 189 +/- 137 pg/mL, P = 0.05), except in group 1. Bone</p><p>alkaline phosphatase (BALP) showed a tendency to normalize (23 +/- 16</p><p>to 18.3 +/- 11 microg/L, P &lt; 0.05), leading to a decrease in</p><p>alfacalcidol administration from 66% to 43% (P &lt; 0.05), except in</p><p>group 1. The KDOQI targets achieved increased significantly for serum</p><p>calcium (76% to 85%) and phosphate levels (66% to 77%) in all</p><p>patients. The serum albumin level increased in all groups (34.6 +/- 4</p><p>to 36.8 +/- 4 g/L, P &lt; 0.05), without any significant improvement</p><p>in normalized protein catabolic rate (nPCR) or C-reactive proteins</p><p>(CRP).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>With a daily dose ranging<p>from 10 to 30 microg, daily oral 25(OH)D(3) supplementation corrects</p><p>most vitamin D deficiencies or insufficiencies in HD patients,</p><p>without any evident toxicity. The main effects observed included</p><p>correction of excessive bone turnover, despite less alfacalcidol</p><p>administration, increase in serum albumin level and increase in the</p><p>percentage of patients with serum calcium and phosphorus levels</p><p>within the recommendation of the KDOQI guidelines.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/18793245><font size=2>J<p>Intern Med.</font></a></u></font><font size=2> 2008</p><p>Dec;264(6):599-609. Epub 2008 Sep 10.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of vitamin D supplementation on symptoms of depression in overweight</p><p>and obese subjects: randomized double blind trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Jorde<p>R</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Sneve</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Figenschau</p><p>Y</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Svartberg</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Waterloo</p><p>K</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Institute of Clinical<p>Medicine, University of Tromsø, Tromsø, Norway.</p><p><a href=mailto:rolf.jorde@unn.no>rolf.jorde@unn.no</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>The objective of the<p>present study was to examine the cross-sectional relation between</p><p>serum 25-hydroxyvitamin D [25-(OH) D] levels and depression in</p><p>overweight and obese subjects and to assess the effect of vitamin D</p><p>supplementation on depressive symptoms.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Cross-sectional study and<p>randomized double blind controlled trial of 20,000 or 40,000 IU</p><p>vitamin D per week versus placebo for 1 year.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SETTING:</font></h4><p style=margin-bottom:0><font size=2>A total of 441 subjects<p>(body mass index 28-47 kg m(-2), 159 men and 282 women, aged 21-70</p><p>years) recruited by advertisements or from the out-patient clinic at</p><p>the University Hospital of North Norway.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MAIN<p>OUTCOME MEASURES:</font></p></h4><p style=margin-bottom:0><font size=2>Beck Depression Inventory<p>(BDI) score with subscales 1-13 and 14-21.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Subjects with serum<p>25(OH)D levels &lt; 40 nmol L(-1) scored significantly higher (more</p><p>depressive traits) than those with serum 25(OH)D levels > or = 40</p><p>nmol L(-1) on the BDI total [6.0 (0-23) versus 4.5 (0-28) (median and</p><p>range)] and the BDI subscale 1-13 [2.0 (0-15) versus 1.0 (0-29.5)] (P</p><p>&lt; 0.05). In the two groups given vitamin D, but not in the placebo</p><p>group, there was a significant improvement in BDI scores after 1</p><p>year. There was a significant decrease in serum parathyroid hormone</p><p>in the two vitamin D groups without a concomitant increase in serum</p><p>calcium.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>It appears to be a<p>relation between serum levels of 25(OH)D and symptoms of depression.</p><p>Supplementation with high doses of vitamin D seems to ameliorate</p><p>these symptoms indicating a possible causal relationship.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/18795378><font size=2>Obes<p>Surg.</font></a></u></font><font size=2> 2009 Feb;19(2):173-9. Epub</p><p>2008 Sep 16.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Finding<p>the optimal dose of vitamin D following Roux-en-Y gastric bypass: a</p><p>prospective, randomized pilot clinical trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Goldner<p>WS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stoner</p><p>JA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lyden</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Thompson</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Taylor</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Larson</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Erickson</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McBride</p><p>C</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Section of Diabetes,<p>Endocrinology, and Metabolism, Department of Internal Medicine,</p><p>University of Nebraska Medical Center, Omaha, NE 68198-3020, USA.</p><p><a href=mailto:wgoldner@unmc.edu>wgoldner@unmc.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D deficiency is<p>common following bariatric surgery and is due to a combination of</p><p>baseline deficiency and postoperative malabsorption. There are few</p><p>prospective studies evaluating the appropriate dose of vitamin D to</p><p>prevent and treat vitamin D deficiency following bariatric surgery.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>We evaluated three doses<p>of vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective,</p><p>randomized pilot trial of 45 patients undergoing Roux-en-Y gastric</p><p>bypass. Serum 25 hydroxy Vitamin D (25OHD), intact PTH (iPTH),</p><p>calcium, and urine calcium/creatinine ratios were measured at 6, 12,</p><p>and 24 months postoperatively. Due to a high dropout rate at 24</p><p>months, we focus on the 12-month data.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>At 12 months, the 800-,<p>2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of</p><p>27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L, respectively</p><p>(p = 0.09) with a maximum increase in each group of 87.4, 114.8, and</p><p>129.8 nmol/L. Forty-four percent, 78%, and 70% achieved 25OHD levels</p><p>>or=75 nmol/L (p = 0.38). Results for the 6- and 24-month time</p><p>points were similar to the 12-month results. Mean weight loss at 24</p><p>months of the study was not different among groups (p = 0.52). Serum</p><p>calcium did not change significantly, and there were no cases of</p><p>hypercalcemia or sustained hypercalciuria.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Higher doses of vitamin D<p>supplementation trend towards higher levels of 25OHD. Vitamin D</p><p>replacement as high as 5,000 IU /day is safe and necessary in many</p><p>patients to treat vitamin D deficiency following Roux-en-Y gastric</p><p>bypass yet is still suboptimal in others.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/18629569><font size=2>Osteoporos<p>Int.</font></a></u></font><font size=2> 2009 Feb;20(2):315-22. Epub</p><p>2008 Jul 16.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of a long-term vitamin D and calcium supplementation on falls and</p><p>parameters of muscle function in community-dwelling older</p><p>individuals.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pfeifer<p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Begerow</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Minne</p><p>HW</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Suppan</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Fahrleitner-Pammer</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dobnig</p><p>H</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Institute of Clinical<p>Osteology Gustav Pommer and Clinic Der Fürstenhof, Bad Pyrmont,</p><p>Germany. <a href=mailto:iko_pyrmont@t-online.de>iko_pyrmont@t-online.de</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>In 242 community-dwelling<p>seniors, supplementation with either 1000 mg of calcium or 1000 mg of</p><p>calcium plus vitamin D resulted in a decrease in the number of</p><p>subjects with first falls of 27% at month 12 and 39% at month 20.</p><p>Additionally, parameters of muscle function improved significantly.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTRODUCTION:</font></h4><p style=margin-bottom:0><font size=2>The efficacy of vitamin D<p>and calcium supplementation on risk of falling in the elderly is</p><p>discussed controversially. Randomized controlled trials using falls</p><p>as primary outcome are needed. We investigated long-term effects of</p><p>calcium and vitamin D on falls and parameters of muscle function in</p><p>community-dwelling elderly women and men.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Our study population<p>consisted of 242 individuals recruited by advertisements and mailing</p><p>lists (mean [ +/- SD] age, 77 +/- 4 years). All serum</p><p>25-hydroxyvitamin D (25[OH]D) levels were below 78 nmol/l.</p><p>Individuals received in a double blinded fashion either 1000 mg of</p><p>calcium or 1000 mg of calcium plus 800 IU of vitamin D per day over a</p><p>treatment period of 12 months, which was followed by a treatment-free</p><p>but still blinded observation period of 8 months. Falls were</p><p>documented using diaries. The study took place in Bad Pyrmont,</p><p>Germany (latitude 52 degrees ) and Graz, Austria (latitude 46 degrees</p><p>).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Compared to calcium mono,<p>supplementation with calcium plus vitamin D resulted in a significant</p><p>decrease in the number of subjects with first falls of 27% at month</p><p>12 (RR = 0.73; CI = 0.54-0.96) and 39% at month 20 (RR = 0.61; CI =</p><p>0.34-0.76). Concerning secondary endpoints, we observed significant</p><p>improvements in quadriceps strength of 8%, a decrease in body sway of</p><p>28%, and a decrease in time needed to perform the TUG test of 11%.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DISCUSSION:</font></h4><p style=margin-bottom:0><font size=2>Combined calcium and<p>vitamin D supplementation proved superior to calcium alone in</p><p>reducing the number of falls and improving muscle function in</p><p>community-dwelling older individuals.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/17656420><font size=2>Age<p>Ageing.</font></a></u></font><font size=2> 2007 Sep;36(5):507-13.</p><p>Epub 2007 Jul 26.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Does<p>vitamin D stop inpatients falling? A randomised controlled trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Burleigh<p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McColl</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Potter</p><p>J</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Medicine for<p>the Elderly, Mansionhouse Unit, Victoria Infirmary, 21 Mansionhouse</p><p>Road, Glasgow, G41 3DX, UK. <a href=mailto:Liz.Burleigh@sgh.scot.nhs.uk>Liz.Burleigh@sgh.scot.nhs.uk</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D deficiency is<p>common in older people and may increase risk of falls and fracture.</p><p>Hospital inpatients are at particular risk of falling. Previous</p><p>studies suggest that vitamin D improves neuromuscular function and</p><p>reduces falls.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To determine whether<p>routine supplementation with vitamin D plus calcium reduces numbers</p><p>of fallers and falls in a cohort of hospital admissions while they</p><p>are inpatients.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Randomised, double-blind,<p>controlled study. Participants: two hundred and five acute admissions</p><p>>65 years to a geriatric medical unit.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Patients were randomised<p>to intervention of daily vitamin D 800 iu plus calcium 1,200 mg or</p><p>control group of daily calcium 1,200 mg, until discharge or death.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Baseline characteristics<p>were similar in both groups with a median age 84 years and a median</p><p>length of stay = 30 days (IQR 14.75-71.00). In a pre-selected</p><p>sub-group (54/205 participants), median admission vitamin D level =</p><p>22.00 nmol/l (IQR 15.00-30.50). This did not significantly increase</p><p>in the treatment versus control group. Median study drug adherence =</p><p>88%, with no significant difference between study groups</p><p>(Mann-Whitney: P = 0.711). Although there were fewer fallers in the</p><p>vitamin D cohort, this did not reach statistical significance</p><p>(vitamin D: calcium = 36:45 fallers; RR 0.82 (CI 0.59-1.16). Neither</p><p>the mean number of falls (vitamin D: calcium = 1.040:1.155;</p><p>Mann-Whitney P = 0.435) or time to first fall (Log-rank test P =</p><p>0.377) differed between groups.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>In a population of<p>geriatric hospital inpatients, vitamin D did not reduce the number of</p><p>fallers. Routine supplementation cannot be recommended to reduce</p><p>falls in this</font> group.</p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/15501836><font size=2>Age<p>Ageing.</font></a></u></font><font size=2> </font><font size=2>2004</font><font size=2></p><p>Nov;33(6):589-95.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> supplementation improves neuromuscular function</p><p>in older people who fall.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Dhesi</font></u></font><font color=#0000ff><u><font size=2><p>JK</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Jackson</p><p>SH</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bearne</p><p>LM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Moniz</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hurley</p><p>MV</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Swift</p><p>CG</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Allain</p><p>TJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Elderly Day Hospital,<p>Thomas Guy House, Guys Hospital, St Thomas Street, London, UK.</p><p>jugdeep.</font><font size=2>dhesi</font><font size=2>@gsst.nhs.uk</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>vitamin D</font><font size=2><p>supplementation reduces the incidence of fractures in older adults.</p><p>This may be partly mediated by effects of </font><font size=2>vitamin</p><p>D</font><font size=2> on neuromuscular function.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>to determine the effects<p>of </font><font size=2>vitamin D</font><font size=2> supplementation</p><p>on aspects of neuromuscular function known to be risk factors for</p><p>falls and fractures.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>randomised, double-blind,<p>placebo-controlled study.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SETTING:</font></h4><p style=margin-bottom:0><font size=2>falls clinic taking<p>referrals from general practitioners and accident and emergency</p><p>department.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SUBJECTS:</font></h4><p style=margin-bottom:0><font size=2>139 ambulatory subjects<p>(>/=65 years) with a history of falls and 25-hydroxyvitamin D</p><p>(25OHD) &lt;/=12 microg/l. Intervention: patients were randomised to</p><p>receive a single intramuscular injection of 600,000 i.u.</p><p>ergocalciferol or placebo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OUTCOME<p>MEASURES:</font></p></h4><p style=margin-bottom:0><font size=2>assessments including<p>biochemistry, postural sway, choice reaction time (CRT), aggregate</p><p>functional performance time (AFPT), and quadriceps strength were</p><p>carried out at baseline and 6 months post-intervention.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>baseline characteristics<p>were comparable between both groups. 25OHD in the treatment group</p><p>increased significantly at 6 months. AFPT deteriorated in the control</p><p>group and improved in the intervention group, representing a</p><p>significant difference between groups (+6.6 s versus -2.0 s, t =</p><p>2.80, P &lt; 0.05). Similar changes were observed for CRT (-0.06 s</p><p>versus +0.41 s, t = -2.52, P &lt; 0.01) and postural sway (+0.0025</p><p>versus -0.0138, t = 2.35, P &lt; 0.02). There was no significant</p><p>difference in muscle strength change between groups (-10 N versus -2</p><p>N, t = -1.26, ns). A significant correlation between change in AFPT</p><p>and change in 25OHD levels was observed (r = 0.19, P = 0.03). There</p><p>was no significant difference in the number of falls (0.39 versus</p><p>0.24, t = 1.08, P = 0.28) or fallers (14 versus 11, P = 0.52) between</p><p>two groups.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>vitamin D</font><font size=2><p>supplementation, in fallers with </font><font size=2>vitamin D</font><font size=2></p><p>insufficiency, has a significant beneficial effect on functional</p><p>performance, reaction time and balance, but not muscle strength. This</p><p>suggests that </font><font size=2>vitamin D</font><font size=2></p><p>supplementation improves neuromuscular or neuroprotective function,</p><p>which may in part explain the mechanism whereby </font><font size=2>vitamin</p><p>D</font><font size=2> reduces falls and fractures.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19179490><font size=2>Am<p>J Respir Crit Care Med.</font></a></u></font><font size=2> 2009 May</p><p>1;179(9):843-50. Epub 2009 Jan 29.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> as supplementary treatment for tuberculosis: a</p><p>double-blind, randomized, placebo-controlled trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Wejse</font></u></font><font color=#0000ff><u><font size=2><p>C</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gomes</p><p>VF</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Rabna</p><p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gustafson</p><p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Aaby</p><p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lisse</p><p>IM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Andersen</p><p>PL</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Glerup</p><p>H</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Sodemann</p><p>M</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Infectious Disease<p>Research Unit, Aarhus University Hospital, Skejby,</p><p>Brendstrupgaardsvej, 8200 Aarhus N, Denmark. </font><font size=2>wejse</font><font size=2>@dadlnet.dk</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RATIONALE:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>has been shown to be involved in the host immune response toward</p><p>Mycobacterium tuberculosis.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>To test whether </font><font size=2>vitamin<p>D</font><font size=2> supplementation of patients with tuberculosis</p><p>(TB) improved clinical outcome and reduced mortality.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>We conducted a randomized,<p>double-blind, placebo-controlled trial in TB clinics at a demographic</p><p>surveillance site in Guinea-Bissau. We included 365 adult patients</p><p>with TB starting antituberculosis treatment; 281 completed the</p><p>12-month follow-up. The intervention was 100,000 IU of</p><p>cholecalciferol or placebo at inclusion and again 5 and 8 months</p><p>after the start of treatment.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MEASUREMENTS<p>AND MAIN RESULTS:</font></p></h4><p style=margin-bottom:0><font size=2>The primary outcome was<p>reduction in a clinical severity score (TBscore) for all patients</p><p>with pulmonary TB. The secondary outcome was 12-month mortality. No</p><p>serious adverse effects were reported; mild hypercalcemia was rare</p><p>and present in both arms. Reduction in TBscore and sputum smear</p><p>conversion rates did not differ among patients treated with </font><font size=2>vitamin</p><p>D</font><font size=2> or placebo. Overall mortality was 15% (54 of</p><ol start=365><li>at 1 year of follow-up and similar in both arms (30 of 187 for</li></ol><p></font><font size=2>vitamin D</font><font size=2> treated and 24 of</p><p>178 for placebo; relative risk, 1.19 [0.58-1.95]). HIV infection was</p><p>seen in 36% (131 of 359): 21% (76 of 359) HIV-1, 10% (36 of 359)</p><p>HIV-2, and 5% (19 of 357) HIV-1+2.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>does not improve clinical outcome among patients with TB and the</p><p>trial showed no overall effect on mortality in patients with TB; it</p><p>is possible that the dose used was insufficient. Clinical trial</p><p>registered with <a href=https://www.controlled-trials.com/isrctn>www.controlled-trials.com/isrctn</a> (ISRCTN35212132).</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/17277040><font size=2>Diabetes<p>Care.</font></a></u></font><font size=2> </font><font size=2>2007</font><font size=2></p><p>Apr;30(4):980-6. Epub </font><font size=2>2007</font><font size=2></p><p>Feb 2.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>The<p>effects of calcium and </font><font size=2>vitamin D</font><font size=2></p><p>supplementation on blood glucose and markers of inflammation in</p><p>nondiabetic adults.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Pittas</font></u></font><font color=#0000ff><u><font size=2><p>AG</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Harris</p><p>SS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stark</p><p>PC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Endocrinology, Diabetes, and Metabolism, Tufts-New England Medical</p><p>Center, Boston, MA 02111, USA. <a href=mailto:apittas@tufts-nemc.org>apittas@tufts-nemc.org</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We sought to compare the<p>effects of combined calcium and </font><font size=2>vitamin D</font><font size=2></p><p>supplementation versus placebo on blood glucose and markers of</p><p>inflammation in nondiabetic adults aged > or =65 years.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESEARCH<p>DESIGN AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>A total of 314 Caucasian<p>adults without diabetes received either 500 mg calcium citrate and</p><p>700 IU </font><font size=2>vitamin D</font><font size=2>(3) or</p><p>placebos daily for 3 years in a double-blind, randomized, controlled</p><p>trial designed for bone-related outcomes. In a post hoc analysis,</p><p>fasting plasma glucose (FPG), insulin sensitivity (estimated by</p><p>homeostasis model assessment of insulin resistance [HOMA-IR]), plasma</p><p>C-reactive protein, and interleukin-6, were measured at baseline and</p><p>3 years.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>The effects of combined<p>calcium-</font><font size=2>vitamin D</font><font size=2></p><p>supplementation on 3-year change in FPG depended on baseline FPG (P =</p><p>0.02 for interaction). Therefore, we conducted analyses separately in</p><p>participants with normal fasting glucose (NFG) (FPG &lt;5.6 mmol/l, n</p><p>= 222) and impaired fasting glucose (IFG) (FPG 5.6-6.9 mmol/l, n =</p><ol start=92><li>at baseline. Among participants with IFG at baseline, those who</li></ol><p>took combined calcium-</font><font size=2>vitamin D</font><font size=2></p><p>supplements had a lower rise in FPG at 3 years compared with those on</p><p>placebo (0.02 mmol/l [0.4 mg/dl] vs. 0.34 mmol/l [6.1 mg/dl],</p><p>respectively, P = 0.042) and a lower increase in HOMA-IR (0.05 vs.</p><p>0.91, P = 0.031). In the NFG subgroup, there was no difference in the</p><p>change in FPG or HOMA-IR between the two treatment arms. There were</p><p>no differences in C-reactive protein or interleukin-6 between the two</p><p>treatment arms in either subgroup.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>In healthy, older adults<p>with IFG, supplementation with calcium and </font><font size=2>vitamin</p><p>D</font><font size=2> may attenuate increases in glycemia and insulin</p><p>resistance that occur over time. However, our findings should be</p><p>considered hypothesis generating and need to be confirmed in</p><p>randomized trials specifically designed for the outcomes of interest.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20194238><font size=2>Ann<p>Intern Med.</font></a></u></font><font size=2> </font><font size=2>2010</font><font size=2></p><p>Mar 2;152(5):315-23.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Systematic<p>review: </font><font size=2>Vitamin D</font><font size=2> and calcium</p><p>supplementation in prevention of cardiovascular events.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2><span lang=de-DE>Wang</span></font></u></font><font color=#0000ff><u><font size=2><span lang=de-DE><p>L</span></font></u></font></a><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Manson</p><p>JE</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Song</p><p>Y</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Sesso</p><p>HD</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Brigham and Women's<p>Hospital and Harvard School of Public Health, Boston, Massachusetts</p><p>02215, USA. <a href=mailto:luwang@rics.bwh.harvard.edu>luwang@rics.bwh.harvard.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>and calcium may affect the cardiovascular system independently and</p><p>interactively.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PURPOSE:</font></h4><p style=margin-bottom:0><font size=2>To assess whether </font><font size=2>vitamin<p>D</font><font size=2> and calcium supplements reduce the risk for</p><p>cardiovascular events in adults.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SOURCES:</font></p></h4><p style=margin-bottom:0><font size=2>Studies published in<p>English from 1966 to July 2009 in MEDLINE, EMBASE, and the Cochrane</p><p>Central Register of Controlled Trials.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>STUDY<p>SELECTION:</font></p></h4><p style=margin-bottom:0><font size=2>Two investigators<p>independently selected 17 prospective studies and randomized trials</p><p>that examined </font><font size=2>vitamin D</font><font size=2></p><p>supplementation, calcium supplementation, or both and subsequent</p><p>cardiovascular events.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>EXTRACTION:</font></p></h4><p style=margin-bottom:0><font size=2>Three investigators<p>extracted and checked data about study designs, participants,</p><p>exposures or interventions, outcomes, and data quality.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SYNTHESIS:</font></p></h4><p style=margin-bottom:0><font size=2>Five prospective studies<p>of patients receiving dialysis and 1 study involving a general</p><p>population showed consistent reductions in cardiovascular disease</p><p>(CVD) mortality among adults who received </font><font size=2>vitamin</p><p>D</font><font size=2> supplements. Four prospective studies of</p><p>initially healthy persons found no differences in incidence of CVD</p><p>between calcium supplement recipients and nonrecipients. Results of</p><p>secondary analyses in 8 randomized trials showed a slight but</p><p>statistically nonsignificant reduction in CVD risk (pooled relative</p><p>risk, 0.90 [95% CI, 0.77 to 1.05]) with </font><font size=2>vitamin D</font><font size=2></p><p>supplementation at moderate to high doses (approximately 1000 IU/d)</p><p>but not with calcium supplementation (pooled relative risk, 1.14 [CI,</p><p>0.92 to 1.41]), or a combination of </font><font size=2>vitamin D</font><font size=2></p><p>and calcium supplementation (pooled relative risk, 1.04 [CI, 0.92 to</p><p>1.18]) compared with placebo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>LIMITATIONS:</font></h4><p style=margin-bottom:0><font size=2>Only articles published in<p>English that reported cardiovascular event outcomes were included.</p><p>The small number of studies, the lack of trials designed specifically</p><p>to assess primary effects on cardiovascular outcomes, and important</p><p>between-study heterogeneity preclude definitive conclusions.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Evidence from limited data<p>suggests that </font><font size=2>vitamin D</font><font size=2></p><p>supplements at moderate to high doses may reduce CVD risk, whereas</p><p>calcium supplements seem to have minimal cardiovascular effects.</p><p>Further research is needed to elucidate the role of these supplements</p><p>in CVD prevention.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/16043680><font size=2>Arch<p>Intern Med.</font></a></u></font><font size=2> 2005 Jul</p><p>25;165(14):1618-23.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p>randomized controlled trial of vitamin D3 supplementation in African</p><p>American women.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Aloia<p>JF</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Talwar</p><p>SA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pollack</p><p>S</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Yeh</p><p>J</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Medicine,<p>Bone Mineral Research Center, Winthrop University Hospital, Mineola,</p><p>NY 11501, USA. <a href=mailto:jaloia@winthrop.org>jaloia@winthrop.org</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>We conducted a randomized,<p>placebo-controlled, double-blind trial to test the hypothesis that</p><p>vitamin D(3) supplementation would prevent bone loss in</p><p>calcium-replete, African American postmenopausal women.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Two hundred eight healthy<p>black postmenopausal women, 50 to 75 years of age, were assigned to</p><p>receive either placebo or 20 microg/d (800 IU) of vitamin D(3).</p><p>Calcium supplements were provided to ensure a total calcium intake of</p><p>1200 to 1500 mg/d. After 2 years, the vitamin D(3) dose was increased</p><p>to 50 microg/d (2000 IU) in the active group, and the study continued</p><p>for an additional year. Bone mineral density (BMD) was measured every</p><p>6 months. Markers of bone turnover, vitamin D metabolites, and</p><p>parathyroid hormone (PTH) levels were measured in serum.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>There were no significant<p>differences in BMD between the active and control groups throughout</p><p>the study. There was also no relationship between serum</p><p>25-hydroxyvitamin D levels attained and rates of bone loss. There was</p><p>an increase in BMD of the total body, hip, and radius at 1 year in</p><p>both groups. Over the 3 years, BMD declined at these sites by 0.26%</p><p>to 0.55% per year. The BMD of the lumbar spine increased slightly in</p><p>the placebo and active groups. There were no persistent changes in</p><p>serum PTH levels or the markers of bone turnover, although there was</p><p>a transient decline in PTH in both groups at 3 months. No significant</p><p>adverse events were attributed to vitamin D supplementation.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>There was no observed<p>effect of vitamin D(3) supplementation on bone loss or bone turnover</p><p>markers in calcium-replete, postmenopausal African American women.</p><p>Further studies are needed to determine if these findings are</p><p>applicable to women of other ethnic groups.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/15231008><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2004</p><p>Aug;19(8):1221-30. Epub 2004 May 24.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Supplementation<p>with oral vitamin D3 and calcium during winter prevents seasonal bone</p><p>loss: a randomized controlled open-label prospective trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Meier</font></u></font><font color=#0000ff><u><font size=2><p>C</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Woitge</p><p>HW</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Witte</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lemmer</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Seibel</p><p>MJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Bone Research Program,<p>ANZAC Research Institute, University Sydney, Concord, New South</p><p>Wales, Australia.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Bone metabolism follows a<p>seasonal pattern with high bone turnover and bone loss during the</p><p>winter. In a randomized, open-label 2-year sequential follow-up study</p><p>of 55 healthy adults, we found that supplementation with oral vitamin</p><p>D3 and calcium during winter abolished seasonal changes in</p><p>calciotropic hormones and markers of bone turnover and led to an</p><p>increase in BMD. Supplementation with oral vitamin D3 and calcium</p><p>during the winter months seems to counteract the effects of seasonal</p><p>changes in </font><font size=2>vitamin D</font><font size=2> and thus</p><p>may be beneficial as a primary prevention strategy for age-related</p><p>bone loss.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTRODUCTION:</font></h4><p style=margin-bottom:0><font size=2>Bone metabolism follows a<p>seasonal pattern characterized by high bone turnover and bone loss</p><p>during winter. We investigated whether wintertime supplementation</p><p>with oral vitamin D3 and calcium had beneficial effects on the</p><p>circannual changes in bone turnover and bone mass.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MATERIALS<p>AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>This prospective study<p>comprised an initial observation period of 12 months ("year 1"),</p><p>followed by an intervention during parts of year 2. Fifty-five</p><p>healthy subjects living in southwestern Germany (latitude, 49.5</p><p>degrees N) were randomized into two groups: 30 subjects were assigned</p><p>to the treatment group and received oral cholecalciferol (500 IU/day)</p><p>and calcium (500 mg/day) during the winter months of year 2</p><p>(October-April), while 25 subjects assigned to the control group</p><p>obtained no supplements. Primary endpoints were changes in</p><p>calciotropic hormones [serum 25(OH)D, 1,25(OH)2D, and parathyroid</p><p>hormone], markers of bone formation (serum bone-specific alkaline</p><p>phosphatase) and of bone resorption (urinary pyridinoline and</p><p>deoxypyridinoline), and changes in lumbar spine and femoral neck BMD.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Forty-three subjects<p>completed the study. During year 1, calciotropic hormones, markers of</p><p>bone turnover, and BMD varied by season in both groups. During the</p><p>winter months of year 1, bone turnover was significantly accelerated,</p><p>and lumbar spine and femoral BMD declined by 0.3-0.9%. In year 2,</p><p>seasonal changes in calciotropic hormones and markers of bone</p><p>turnover were either reversed or abolished in the intervention group</p><p>while unchanged in the control cohort. In the subjects receiving oral</p><p>vitamin D3 and calcium, lumbar and femoral BMD increased</p><p>significantly (lumbar spine: +0.8%, p = 0.04 versus year 1; femoral</p><p>neck: +0.1%, p = 0.05 versus year 1), whereas controls continued to</p><p>lose bone (intervention group versus control group: lumbar spine, p =</p><p>0.03; femoral neck, p = 0.05).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Supplementation with oral<p>vitamin D3 and calcium during winter prevents seasonal changes in</p><p>bone turnover and bone loss in healthy adults. It seems conceivable</p><p>that annually recurring cycles of low </font><font size=2>vitamin D</font><font size=2></p><p>and mild secondary hyperparathyroidism during the winter months</p><p>contributes, at least in part and over many years, to age-related</p><p>bone loss. Supplementation with low-dose oral vitamin D3 and calcium</p><p>during winter may be an efficient and inexpensive strategy for the</p><p>primary prevention of bone loss in northern latitudes.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/16600924><font size=2><span lang=de-DE>Am<p>J Clin Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p></span></font><font size=2><span lang=de-DE>2006</span></font><font size=2><span lang=de-DE></p><p>Apr;83(4):754-9.</span></font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> supplementation improves cytokine profiles in</p><p>patients with congestive heart failure: a double-blind, randomized,</p><p>placebo-controlled trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2><span lang=de-DE>Schleithoff</span></font></u></font><font color=#0000ff><u><font size=2><span lang=de-DE><p>SS</span></font></u></font></a><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Zittermann</p><p>A</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Tenderich</p><p>G</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Berthold</p><p>HK</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Stehle</p><p>P</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Koerfer</p><p>R</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Institute of Nutrition and<p>Food Science, University of Bonn, Bonn, Germany.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Elevated circulating<p>concentrations of proinflammatory cytokines may contribute to the</p><p>pathogenesis of congestive heart failure (CHF). In vitro studies</p><p>suggest that </font><font size=2>vitamin D</font><font size=2></p><p>suppresses proinflammatory cytokines and increases antiinflammatory</p><p>cytokines.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We evaluated the effect of<p></font><font size=2>vitamin D</font><font size=2> supplementation on</p><p>the survival rate and different biochemical variables in patients</p><p>with CHF.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>One hundred twenty-three<p>patients randomly received either 50 mug </font><font size=2>vitamin</p><p>D</font><font size=2>(3)/d plus 500 mg Ca/d [D(+) group] or placebo</p><p>plus 500 mg Ca/d [D(-) group] for 9 mo. Biochemical variables were</p><p>assessed at baseline and after 9 mo. The survival rate was calculated</p><p>for a follow-up period of 15 mo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Ninety-three patients<p>completed the study. Significant treatment effects were observed on</p><p>logarithmic-transformed serum concentrations of 25-hydroxyvitamin D</p><p>(P = 0.001), parathyroid hormone (P = 0.007), tumor necrosis factor</p><p>alpha (P = 0.006), and interleukin 10 (P = 0.042). 25-Hydroxyvitamin</p><p>D increased by 26.8 ng/mL in the D(+) group but increased only by 3.6</p><p>ng/mL in the D(-) group. Compared with baseline, parathyroid hormone</p><p>was significantly lower and the antiinflammatory cytokine interleukin</p><p>10 was significantly higher in the D(+) group after 9 mo. The</p><p>proinflammatory cytokine tumor necrosis factor alpha increased in the</p><p>D(-) group but remained constant in the D(+) group. The survival rate</p><p>did not differ significantly between the study groups during the</p><p>follow-up period.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2>(3)<p>reduces the inflammatory milieu in CHF patients and might serve as a</p><p>new antiinflammatory agent for the future treatment of the disease.</p><p>Our data provide evidence for the involvement of an impaired </font><font size=2>vitamin</p><p>D</font><font size=2>-parathyroid hormone axis in the progression of</p><p>CHF.</font></p></p><p style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/16278262><font size=2>J<p>Clin Endocrinol Metab.</font></a></u></font><font size=2> 2006</p><p>Feb;91(2):405-12. Epub 2005 Nov 8.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effect<p>of </font><font size=2>vitamin D</font><font size=2> replacement on</p><p>musculoskeletal parameters in school children: a randomized</p><p>controlled trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>El-Hajj<p>Fuleihan G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Nabulsi</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Tamim</p><p>H</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Maalouf</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Salamoun</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Khalife</p><p>H</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Choucair</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Arabi</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Vieth</p><p>R</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Calcium Metabolism and<p>Osteoporosis Program, American University of Beirut-Medical Center,</p><p>Bliss Street, 113-6044 Beirut, Lebanon. <a href=mailto:gf01@aub.edu.lb>gf01@aub.edu.lb</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Despite the high<p>prevalence of hypovitaminosis D in children and adolescents</p><p>worldwide, the impact of </font><font size=2>vitamin D</font><font size=2></p><p>deficiency on skeletal health is unclear.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>One hundred seventy-nine<p>girls, ages 10-17 yr, were randomly assigned to receive weekly oral</p><p></font><font size=2>vitamin D</font><font size=2> doses of 1,400 IU</p><p>(equivalent to 200 IU/d) or 14,000 IU (equivalent to 2,000 IU/d) in a</p><p>double-blind, placebo-controlled, 1-yr protocol. Areal bone mineral</p><p>density (BMD) and bone mineral content (BMC) at the lumbar spine,</p><p>hip, forearm, total body, and body composition were measured at</p><p>baseline and 1 yr. Serum calcium, phosphorus, alkaline phosphatase,</p><p>and </font><font size=2>vitamin D</font><font size=2> metabolites</p><p>were measured during the study.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>In the overall group of<p>girls, lean mass increased significantly in both treatment groups (P</p><p>&lt; or = 0.05); bone area and total hip BMC increased in the</p><p>high-dose group (P &lt; 0.02). In premenarcheal girls, lean mass</p><p>increased significantly in both treatment groups, and there were</p><p>consistent trends for increments in BMD and/or BMC at several</p><p>skeletal sites, reaching significance at lumbar spine BMD in the</p><p>low-dose group and at the trochanter BMC in both treatment groups.</p><p>There was no significant change in lean mass, BMD, or BMC in</p><p>postmenarcheal girls.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>replacement had a positive impact on musculoskeletal parameters in</p><p>girls, especially during the premenarcheal period.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21628364><font size=2>BMJ.</font></a></u></font><font size=2><p>2011 May 31;342:d2975. doi: 10.1136/bmj.d2975.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effect<p>of weekly </font><font size=2>vitamin D</font><font size=2></p><p>supplements on mortality, morbidity, and growth of low birthweight</p><p>term infants in India up to age 6 months: </font><font size=2>randomised</p><p>controlled trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Kumar<p>GT</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Sachdev</p><p>HS</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Chellani</p><p>H</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Rehman</p><p>AM</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Singh</p><p>V</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Arora</p><p>H</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Filteau</p><p>S</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Institute of Home<p>Economics, Delhi University, F-4 Haus Khas Enclave, New Delhi 110016,</p><p>India. <a href=mailto:geetatrilokkumar@gmail.com>geetatrilokkumar@gmail.com</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To investigate whether<p></font><font size=2>vitamin D</font><font size=2> supplementation can</p><p>decrease the mortality and morbidity of low birthweight infants in</p><p>low income countries.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Randomised controlled<p>trial</font><font size=2>.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SETTING:</font></h4><p style=margin-bottom:0><font size=2>Large government hospital<p>in New Delhi, India.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PARTICIPANTS:</font></h4><p style=margin-bottom:0><font size=2>2079 low birthweight<p>infants born at term (>37 weeks&rsquo; gestation).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MAIN<p>OUTCOME MEASURES:</font></p></h4><p style=margin-bottom:0><font size=2>Primary outcome was<p>admission to hospital or death during the first six months of life.</p><p>Main secondary outcome was growth.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTERVENTIONS:</font></h4><p style=margin-bottom:0><font size=2>Weekly </font><font size=2>vitamin<p>D</font><font size=2> supplements for six months at a dose of one</p><p>recommended nutrient intake per day (35 µg/week). Infants were</p><p>visited weekly at home for observed supplementation and were brought</p><p>to the clinic monthly for clinical examination and anthropometric</p><p>measurements.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Between group differences<p>were not significant for death or hospital admissions (92 among 1039</p><p>infants in the </font><font size=2>vitamin D</font><font size=2></p><p>group v 99 among 1040 infants in the placebo group; adjusted rate</p><p>ratio 0.93, 95% confidence interval 0.68 to 1.29; P = 0.68), or</p><p>referral to the outpatient clinic for moderate morbidity. </font><font size=2>Vitamin</p><p>D</font><font size=2> supplementation resulted in better </font><font size=2>vitamin</p><p>D</font><font size=2> status as assessed by plasma calcidiol levels</p><p>at six months. In adjusted analyses, </font><font size=2>vitamin D</font><font size=2></p><p>treatment significantly increased standard deviation (z) scores at</p><p>six months for weight, length, and arm circumference and decreased</p><p>the proportion of children with stunted growth (length for age z</p><p>score ≤ 2) or with arm circumference z scores of 2 or less.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>A weekly dose of </font><font size=2>vitamin<p>D</font><font size=2> resulted in better </font><font size=2>vitamin</p><p>D</font><font size=2> status and benefited the classic </font><font size=2>vitamin</p><p>D</font><font size=2> function of bone growth but did not decrease</p><p>the incidence of severe morbidity or death among young low</p><p>birthweight infants. Trial registration ClinicalTrials.gov</p><p>NCT00415402.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21689448><font size=2>BMC<p>Musculoskelet Disord.</font></a></u></font><font size=2> 2011 Jun</p><p>20;12:135.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>A<p></font><font size=2>randomized controlled trial</font><font size=2></p><p>of </font><font size=2>vitamin D</font><font size=2> dosing</p><p>strategies after acute hip fracture: no advantage of loading doses</p><p>over daily supplementation.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Papaioannou<p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kennedy</p><p>CC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Giangregorio</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ioannidis</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pritchard</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hanley</p><p>DA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Farrauto</p><p>L</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>DeBeer</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Adachi</p><p>JD</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>McMaster University, HHSC,<p>St. Peter&rsquo;s Hospital Juravinski Research Centre, 88 Maplewood Avenue</p><p>Hamilton, ON L8M 1W9, Canada. <a href=mailto:papaioannou@hhsc.ca>papaioannou@hhsc.ca</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>There remains uncertainty<p>regarding the appropriate therapeutic management of hip fracture</p><p>patients. The primary aim of our study was to examine whether large</p><p>loading doses in addition to daily </font><font size=2>vitamin D</font><font size=2></p><p>offered any advantage over a simple daily low-dose </font><font size=2>vitamin</p><p>D</font><font size=2> regimen for increasing </font><font size=2>vitamin</p><p>D</font><font size=2> levels.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>In this randomized<p>controlled study, patients over age 50 with an acute fragility hip</p><p>fracture were enrolled from two hospital sites in Ontario, Canada.</p><p>Participants were randomized to one of three loading dose groups:</p><p>placebo; 50,000 IU vitamin D2; or 100,000 IU D2. Following a</p><p>placebo/loading dose, all patients received a daily tablet of 1,000</p><p>IU vitamin D3 for 90 days. Serum 25-hydroxy </font><font size=2>vitamin</p><p>D</font><font size=2> (25-OHD) was measured at baseline, discharge</p><p>from acute care (approximately 4-weeks), and 3-months.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Sixty-five patients were<p>enrolled in the study (44% male). An immediate rise in 25-OHD</p><p>occurred in the 100,000 group, however there were no significant</p><p>differences in 25-OHD between the placebo, 50,000 and 100,000 loading</p><p>dose groups after 4-weeks (69.3, 84.5, 75.6 nmol/L, p = 0.15) and</p><p>3-months (86.7, 84.2, 73.3 nmol/L, p = 0.09), respectively. At the</p><p>end of the study, approximately 75% of the placebo and 50,000 groups</p><p>had reached the target therapeutic range (75 nmol/L), and 44% of the</p><p>100,000 group.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>In correcting </font><font size=2>vitamin<p>D</font><font size=2> insufficiency/deficiency in elderly patients</p><p>with hip fracture, our findings suggest that starting with a lower</p><p>daily dose of Vitamin D3 achieved similar results as providing an</p><p>additional large loading dose of Vitamin D2. At the end of the study,</p><p>all three groups were equally effective in attaining improvement in</p><p>25-OHD levels. Given that a daily dose of 1,000 IU vitamin D3 (with</p><p>or without a loading dose) resulted in at least 25% of patients</p><p>having suboptimal </font><font size=2>vitamin D</font><font size=2></p><p>status, patients with acute hip fracture may benefit from a higher</p><p>daily dose of </font><font size=2>vitamin D</font><font size=2>.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21715514><font size=2><span lang=de-DE>Am<p>J Clin Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>2011 Aug;94(2):486-94. </span></font><font size=2>Epub 2011 Jun 29.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of </font><font size=2>vitamin D</font><font size=2> and calcium</p><p>supplementation on pancreatic β cell function, insulin</p><p>sensitivity, and glycemia in adults at high risk of diabetes: the</p><p>Calcium and </font><font size=2>Vitamin D</font><font size=2> for</p><p>Diabetes Mellitus (CaDDM) </font><font size=2>randomized controlled</p><p>trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Mitri<p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hu</p><p>FB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pittas</p><p>AG</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Endocrinology,<p>Diabetes, and Metabolism, Tufts Medical Center, Boston, MA 02111,</p><p>USA.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>A suboptimal </font><font size=2>vitamin<p>D</font><font size=2> and calcium status has been associated with</p><p>higher risk of type 2 diabetes in observational studies, but evidence</p><p>from trials is lacking.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We determined whether<p></font><font size=2>vitamin D</font><font size=2> supplementation,</p><p>with or without calcium, improved glucose homeostasis in adults at</p><p>high risk of diabetes.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Ninety-two adults were<p>randomly assigned in a 2-by-2 factorial-design, double-masked,</p><p>placebo-controlled trial to receive either cholecalciferol (2000 IU</p><p>once daily) or calcium carbonate (400 mg twice daily) for 16 wk. The</p><p>primary outcome was the change in pancreatic β cell function as</p><p>measured by the disposition index after an</p><p>intravenous-glucose-tolerance test. Other outcomes were acute insulin</p><p>response, insulin sensitivity, and measures of glycemia.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Participants had a mean<p>age of 57 y, a body mass index (BMI; in kg/m(2)) of 32, and glycated</p><p>hemoglobin (Hb A(1c)) of 5.9%. There was no significant </font><font size=2>vitamin</p><p>D</font><font size=2> × calcium interaction on any outcomes.</p><p>The disposition index increased in the </font><font size=2>vitamin D</font><font size=2></p><p>group and decreased in the no-</font><font size=2>vitamin D</font><font size=2></p><p>group (adjusted mean change ± SE: 300 ± 130 compared</p><p>with -126 ± 127, respectively; P = 0.011), which was explained</p><p>by an improvement in insulin secretion (62 ± 39 compared with</p><p>-36 ± 37 mU · L(-1) · min, respectively; P =</p><p>0.046). Hb A(1c) increased less, but nonsignificantly, in the </font><font size=2>vitamin</p><p>D</font><font size=2> group than in the no-</font><font size=2>vitamin</p><p>D</font><font size=2> group (0.06 ± 0.03% compared with 0.14 ±</p><p>0.03%, respectively; P = 0.081). There was no significant difference</p><p>in any outcomes with calcium compared with no calcium.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>In adults at risk of type<p>2 diabetes, short-term supplementation with cholecalciferol improved</p><p>β cell function and had a marginal effect on attenuating the</p><p>rise in Hb A(1c). This trial was registered at clinicaltrials.gov as</p><p>NCT00436475.</font></p></p><p style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21709199><font size=2>J<p>Clin Oncol.</font></a></u></font><font size=2> 2011 Aug</p><p>1;29(22):3078-84. Epub 2011 Jun 27.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Calcium<p>plus </font><font size=2>vitamin D</font><font size=2></p><p>supplementation and the risk of nonmelanoma and melanoma skin cancer:</p><p>post hoc analyses of the women&rsquo;s health initiative </font><font size=2>randomized</p><p>controlled trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Tang<p>JY</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Fu</p><p>T</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Leblanc</p><p>E</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Manson</p><p>JE</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Feldman</p><p>D</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Linos</p><p>E</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Vitolins</p><p>MZ</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Zeitouni</p><p>NC</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Larson</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Stefanick</p><p>ML</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Dermatology,<p>Stanford University School of Medicine, 450 Broadway, Pavilion C, MC</p><p>5334, Redwood City, CA, USA. <a href=mailto:tangy@stanford.edu>tangy@stanford.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PURPOSE:</font></h4><p style=margin-bottom:0><font size=2>In light of inverse<p>relationships reported in observational studies of </font><font size=2>vitamin</p><p>D</font><font size=2> intake and serum 25-hydroxyvitamin D levels</p><p>with risk of nonmelanoma skin cancer (NMSC) and melanoma, we</p><p>evaluated the effects of </font><font size=2>vitamin D</font><font size=2></p><p>combined with calcium supplementation on skin cancer in a randomized</p><p>placebo-controlled trial.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Postmenopausal women age<p>50 to 79 years (N = 36,282) enrolled onto the Women&rsquo;s Health</p><p>Initiative (WHI) calcium/</font><font size=2>vitamin D</font><font size=2></p><p>clinical trial were randomly assigned to receive 1,000 mg of</p><p>elemental calcium plus 400 IU of vitamin D3 (CaD) daily or placebo</p><p>for a mean follow-up period of 7.0 years. NMSC and melanoma skin</p><p>cancers were ascertained by annual self-report; melanoma skin cancers</p><p>underwent physician adjudication.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Neither incident NMSC nor<p>melanoma rates differed between treatment (hazard ratio [HR], 1.02;</p><p>95% CI, 0.95 to 1.07) and placebo groups (HR, 0.86; 95% CI, 0.64 to</p><p>1.16). In subgroup analyses, women with history of NMSC assigned to</p><p>CaD had a reduced risk of melanoma versus those receiving placebo</p><p>(HR, 0.43; 95% CI, 0.21 to 0.90; P(interaction) = .038), which was</p><p>not observed in women without history of NMSC.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>supplementation at a relatively low dose plus calcium did not reduce</p><p>the overall incidence of NMSC or melanoma. However, in women with</p><p>history of NMSC, CaD supplementation reduced melanoma risk,</p><p>suggesting a potential role for calcium and </font><font size=2>vitamin</p><p>D</font><font size=2> supplements in this high-risk group. Results</p><p>from this post hoc subgroup analysis should be interpreted with</p><p>caution but warrant additional investigation.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21735411><font size=2><span lang=nb-NO>Cochrane<p>Database Syst Rev.</span></font></a></u></font><font size=2><span lang=nb-NO></p><p>2011 Jul 6;(7):CD007470.</span></font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> supplementation for prevention of mortality in</p><p>adults.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bjelakovic<p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gluud</p><p>LL</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Nikolova</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Whitfield</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wetterslev</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Simonetti</p><p>RG</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bjelakovic</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gluud</p><p>C</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Internal<p>Medicine - Gastroenterology and Hepatology, Medical Faculty,</p><p>University of Nis, Zorana Djindjica 81, Nis, Serbia, 18000.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>The available evidence on<p></font><font size=2>vitamin D</font><font size=2> and mortality is</p><p>inconclusive.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>To assess the beneficial<p>and harmful effects of </font><font size=2>vitamin D</font><font size=2></p><p>for prevention of mortality in adults.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SEARCH<p>STRATEGY:</font></p></h4><p style=margin-bottom:0><font size=2>We searched The Cochrane<p>Library, MEDLINE, EMBASE, LILACS, the Science Citation Index</p><p>Expanded, and Conference Proceedings Citation Index-Science (to</p><p>January 2011). We scanned bibliographies of relevant publications and</p><p>asked experts and pharmaceutical companies for additional trials.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SELECTION<p>CRITERIA:</font></p></h4><p style=margin-bottom:0><font size=2>We included randomised<p>trials that compared </font><font size=2>vitamin D</font><font size=2></p><p>at any dose, duration, and route of administration versus placebo or</p><p>no intervention. </font><font size=2>Vitamin D</font><font size=2></p><p>could have been administered as supplemental </font><font size=2>vitamin</p><p>D</font><font size=2> (</font><font size=2>vitamin D</font><font size=2>(3)</p><p>(cholecalciferol) or </font><font size=2>vitamin D</font><font size=2>(2)</p><p>(ergocalciferol)) or an active form of </font><font size=2>vitamin D</font><font size=2></p><p>(1α-hydroxyvitamin D (alfacalcidol) or 1,25-dihydroxyvitamin D</p><p>(calcitriol)).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>COLLECTION AND ANALYSIS:</font></p></h4><p style=margin-bottom:0><font size=2>Six authors extracted data<p>independently. Random-effects and fixed-effect model meta-analyses</p><p>were conducted. For dichotomous outcomes, we calculated the risk</p><p>ratios (RR). To account for trials with zero events, meta-analyses of</p><p>dichotomous data were repeated using risk differences (RD) and</p><p>empirical continuity corrections. Risk of bias was considered in</p><p>order to minimise risk of systematic errors. Trial sequential</p><p>analyses were conducted to minimise the risk of random errors.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>MAIN<p>RESULTS:</font></p></h4><p style=margin-bottom:0><font size=2>Fifty randomised trials<p>with 94,148 participants provided data for the mortality analyses.</p><p>Most trials included elderly women (older than 70 years). </font><font size=2>Vitamin</p><p>D</font><font size=2> was administered for a median of two years.</p><p>More than one half of the trials had a low risk of bias. Overall,</p><p></font><font size=2>vitamin D</font><font size=2> decreased mortality</p><p>(RR 0.97, 95% confidence interval (CI) 0.94 to 1.00, I(2) = 0%). When</p><p>the different forms of </font><font size=2>vitamin D</font><font size=2></p><p>were assessed separately, only </font><font size=2>vitamin D</font><font size=2>(3)</p><p>decreased mortality significantly (RR 0.94, 95% CI 0.91 to 0.98, I(2)</p><p>= 0%; 74,789 participants, 32 trials) whereas </font><font size=2>vitamin</p><p>D</font><font size=2>(2), alfacalcidol, or calcitriol did not. Trial</p><p>sequential analysis supported our finding regarding </font><font size=2>vitamin</p><p>D</font><font size=2>(3), corresponding to 161 individuals treated to</p><p>prevent one additional death. </font><font size=2>Vitamin D</font><font size=2>(3)</p><p>combined with calcium increased the risk of nephrolithiasis (RR 1.17,</p><p>95% CI 1.02 to 1.34, I(2) = 0%). Alfacalcidol and calcitriol</p><p>increased the risk of hypercalcaemia (RR 3.18, 95% CI 1.17 to 8.68,</p><p>I(2) = 17%). Data on health-related quality of life and health</p><p>economics were inconclusive.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>AUTHORS'<p>CONCLUSIONS:</font></p></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>in the form of </font><font size=2>vitamin D</font><font size=2>(3)</p><p>seems to decrease mortality in predominantly elderly women who are</p><p>mainly in institutions and dependent care. </font><font size=2>Vitamin</p><p>D</font><font size=2>(2), alfacalcidol, and calcitriol had no</p><p>statistically significant effect on mortality. </font><font size=2>Vitamin</p><p>D</font><font size=2>(3) combined with calcium significantly</p><p>increased nephrolithiasis. Both alfacalcidol and calcitriol</p><p>significantly increased hypercalcaemia.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21911741><font size=2>Diabetes.</font></a></u></font><font size=2><p>2011 Nov;60(11):2748-57. Epub 2011 Sep 12.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2>, insulin secretion, sensitivity, and lipids:</p><p>results from a case-control study and a </font><font size=2>randomized</p><p>controlled trial</font><font size=2> using hyperglycemic clamp</p><p>technique.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Grimnes<p>G</span></font></a></u></font><font size=2><span lang=da-DK>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Figenschau</p><p>Y</span></font></a></u></font><font size=2><span lang=da-DK>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Almås</p><p>B</span></font></a></u></font><font size=2><span lang=da-DK>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=da-DK>Jorde</p><p>R</span></font></a></u></font><font size=2><span lang=da-DK>.</span></font></p></p><h3 lang=da-DK class=western style=margin-top:0;margin-bottom:0><p><font size=2>Source</font></h3></p><p style=margin-bottom:0><font size=2>Troms&#248; Endocrine<p>Research Group, Department of Clinical Medicine, University of</p><p>Tromsø, Tromsø, Norway. <a href=mailto:guri.grimnes@unn.no>guri.grimnes@unn.no</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>deficiency is associated with an unfavorable metabolic profile in</p><p>observational studies. The intention was to compare insulin</p><p>sensitivity (the primary end point) and secretion and lipids in</p><p>subjects with low and high serum 25(OH)D (25-hydroxyvitamin D) levels</p><p>and to assess the effect of </font><font size=2>vitamin D</font><font size=2></p><p>supplementation on the same outcomes among the participants with low</p><p>serum 25(OH)D levels.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESEARCH<p>DESIGN AND METHODS:</font></p></h4><p style=margin-bottom:0><font size=2>Participants were<p>recruited from a population-based study (the Tromsø Study)</p><p>based on their serum 25(OH)D measurements. A 3-h hyperglycemic clamp</p><p>was performed, and the participants with low serum 25(OH)D levels</p><p>were thereafter randomized to receive capsules of 20,000 IU </font><font size=2>vitamin</p><p>D</font><font size=2>(3) or identical-looking placebo twice weekly</p><p>for 6 months. A final hyperglycemic clamp was then performed.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>The 52 participants with<p>high serum 25(OH)D levels (85.6 ± 13.5 nmol/L [mean ±</p><p>SD]) had significantly higher insulin sensitivity index (ISI) and</p><p>lower HbA(1c) and triglycerides (TGs) than the 108 participants with</p><p>low serum 25(OH)D (40.3 ± 12.8 nmol/L), but the differences in</p><p>ISI and TGs were not significant after adjustments. After</p><p>supplementation, serum 25(OH)D was 142.7 ± 25.7 and 42.9 ±</p><p>17.3 nmol/L in 49 of 51 completing participants randomized to </font><font size=2>vitamin</p><p>D</font><font size=2> and 45 of 53 randomized to placebo,</p><p>respectively. At the end of the study, there were no statistically</p><p>significant differences in the outcome variables between the two</p><p>groups.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Vitamin D</font><font size=2><p>supplementation to apparently healthy subjects with insufficient</p><p>serum 25(OH)D levels does not improve insulin sensitivity or</p><p>secretion or serum lipid profile.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21956713><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2011 Sep 28. doi:</p><p>10.1002/jbmr.524. [Epub ahead of print]</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of three monthly oral 150,000 IU cholecalciferol supplementation on</p><p>falls, mobility and muscle strength in older postmenopausal women: a</p><p></font><font size=2>randomised controlled trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Glendenning<p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Zhu</p><p>K</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Inderjeeth</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Howat</p><p>P</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lewis</p><p>JR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Prince</p><p>RL</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>School of Medicine and<p>Pharmacology, University of Western Australia, Perth, Australia;</p><p>School of Pathology and Laboratory Medicine, University of Western</p><p>Australia, Perth, Australia; Department of Core Clinical Pathology</p><p>and Biochemistry, Royal Perth Hospital, Perth, Australia.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Daily </font><font size=2>vitamin<p>D</font><font size=2> in addition to calcium supplementation reduces</p><p>falls and fractures in older women. However, poor adherence to</p><p>therapy is a common clinical problem. To examine the effects of</p><p>supervised oral 3 monthly </font><font size=2>vitamin D</font><font size=2></p><p>therapy on falls, muscle strength and mobility, we conducted a</p><p>nine-month randomised, double-blind, placebo-controlled trial in 686</p><p>community-dwelling ambulant women aged over 70 years. Participants</p><p>received either oral cholecalciferol 150,000 IU every 3 months</p><p>(n</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>353)</p><p>or an identical placebo (n</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>333).</p><p>All participants were advised to increase dietary calcium intake.</p><p>Falls data were collected three monthly. At baseline, 3, 6 and 9</p><p>months, muscle strength was measured by a handheld dynamometer and</p><p>mobility by the Timed Up and Go (TUG) test. Serum 25 hydroxyvitamin D</p><p>(25OHD) was measured in a subgroup of 40 subjects. Mean age at</p><p>baseline was 76.7</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>±</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>4.1</p><p>years. The average serum 25OHD value at baseline was 65.8</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>±</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>22.7</p><p>nmol/L. By three, six and nine months after supplementation, 25OHD</p><p>levels of the </font><font size=2>vitamin D</font><font size=2> group</p><p>were approximately 15 nmol/L higher than the placebo group. Calcium</p><p>intake did not change significantly between baseline</p><p>(864</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>±</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>412</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>mg/day)</p><p>and 9 months (855</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>±</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>357</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>mg/day).</p><p>Faller rates in the two groups did not differ: </font><font size=2>vitamin</p><p>D</font><font size=2> group 102/353(29%); placebo group 89/333(27%).</p><p>At 9 months, compared to placebo or baseline, muscle strength and TUG</p><p>were not altered by </font><font size=2>vitamin D</font><font size=2>.</p><p>In conclusion, oral cholecalciferol 150,000 IU therapy administered</p><p>three monthly had neither beneficial nor adverse effects on falls or</p><p>physical function. These data together with previous findings confirm</p><p>that intermittent large doses of </font><font size=2>vitamin D</font><font size=2></p><p>are ineffective or have a deleterious effect on falls. Thus despite</p><p>adherence issues with daily </font><font size=2>vitamin D</font><font size=2></p><p>replacement, an intermittent, high dose </font><font size=2>vitamin D</font><font size=2></p><p>regimen cannot be supported as a strategy to reduce falls and</p><p>fractures. © 2011 American Society for Bone and Mineral</p><p>Research.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22073146><font size=2>PLoS<p>One.</font></a></u></font><font size=2> 2011;6(11):e25966. Epub 2011</p><p>Nov 4.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of </font><font size=2>vitamin d</font><font size=2> supplementation</p><p>on cognitive and emotional functioning in young adults - a </font><font size=2>randomised</p><p>controlled trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dean<p>AJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bellgrove</p><p>MA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hall</p><p>T</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Phan</p><p>WM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Eyles</p><p>DW</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Kvaskoff</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McGrath</p><p>JJ</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Queensland Brain<p>Institute, The University of Queensland, St Lucia, Australia.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Epidemiological research<p>links </font><font size=2>vitamin D</font><font size=2> status to</p><p>various brain-related outcomes. However, few trials examine whether</p><p>supplementation can improve such outcomes and none have examined</p><p>effects on cognition. This study examined whether </font><font size=2>Vitamin</p><p>D</font><font size=2> supplementation led to improvements in diverse</p><p>measures of cognitive and emotional functioning, and hypothesised</p><p>that supplementation would lead to improvements in these outcomes</p><p>compared to placebo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS/PRINCIPAL<p>FINDINGS:</font></p></h4><p style=margin-bottom:0><font size=2>Healthy young adults were<p>recruited to a parallel-arm, double-blind trial conducted at The</p><p>University of Queensland. Participants were randomly allocated to</p><p>receive </font><font size=2>Vitamin D</font><font size=2> (one</p><p>capsule daily, containing 5000 IU cholecalciferol) or identical</p><p>placebo capsule for six weeks. All participants and outcome assessors</p><p>were blinded to group assignment. Primary outcome measures assessed</p><p>at baseline and 6 weeks were working memory, response inhibition and</p><p>cognitive flexibility. Secondary outcomes were:</p><p>hallucination-proneness, psychotic-like experiences, and ratings of</p><p>depression, anxiety and anger. 128 participants were recruited,</p><p>randomised and included in primary analyses (</font><font size=2>vitamin</p><p>D</font><font size=2> n</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>63;</p><p>placebo n</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>65).</p><p>Despite significant increases in </font><font size=2>vitamin D</font><font size=2></p><p>status in the active group, no significant changes were observed in</p><p>working memory (F</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>1.09;</p><p>p</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>0.30),</p><p>response inhibition (F</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>0.82;</p><p>p</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>0.37),</p><p>cognitive flexibility (F</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>1.37;</p><p>p</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2></p><p></font></font><font size=2>0.24)</p><p>or secondary outcomes. No serious adverse effects were reported.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Our findings indicate that<p></font><font size=2>vitamin D</font><font size=2> supplementation</p><p>does not influence cognitive or emotional functioning in healthy</p><p>young adults. Future controlled trials in targeted populations of</p><p>interest are required to determine whether supplementation can</p><p>improve functioning in these domains. Australian and New Zealand</p><p>Clinical Trials Registry; ACTRN12610000318088.</font></p></p><p style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21992858><font size=2>Indian<p>Pediatr.</font></a></u></font><font size=2> 2011 Aug 15. pii:</p><p>S097475591100214-1. [Epub ahead of print]</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> Supplementation for Severe Pneumonia A</p><p></font><font size=2>Randomized Controlled Trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Choudhary<p>N</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gupta</p><p>P</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Pediatrics,<p>University College of Medical Sciences and Guru Teg Bahadur Hospital,</p><p>Dilshad Garden, Delhi, India. Correspondence to: Dr Nidhi Choudhary,</p><p>Block ED, 72A, Pitampura, Delhi 110 034, India,</p><p><a href=mailto:nidhi_mamc2001@yahoo.co.in>nidhi_mamc2001@yahoo.co.in</a>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To determine the role of<p>oral </font><font size=2>vitamin D</font><font size=2></p><p>supplementation for resolution of severe pneumonia in under-five</p><p>children.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>Randomized double blind<p>placebo-controlled trial.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>SETTING:</font></h4><p style=margin-bottom:0><font size=2>Inpatients from a tertiary<p>care hospital.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PARTICIPANTS:</font></h4><p style=margin-bottom:0><font size=2>Two hundred children [mean<p>(SD) age: 13.9 (11.7) months; boys: 120] between 2 months to 5 years</p><p>with severe pneumonia. Pneumonia was diagnosed in the presence of</p><p>fever, cough, tachypnea (as per WHO cutoffs) and crepitations.</p><p>Children with pneumonia and chest indrawing or at least one of the</p><p>danger sign (inability to feed, lethargy, cyanosis) were diagnosed as</p><p>having severe pneumonia. The two groups were comparable for baseline</p><p>characteristics including age, anthropometry, socio-demographic</p><p>profile and clinical and laboratory parameters.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTERVENTION:</font></h4><p style=margin-bottom:0><font size=2>Oral </font><font size=2>vitamin<p>D</font><font size=2> (1000 IU for &lt;1 year and 2000 IU for >1</p><p>year) (n=100) or placebo (lactose) (n=100) once a day for 5 days,</p><p>from enrolment. Both the groups received antibiotics as per the</p><p>Indian Academy of Pediatrics guidelines, and supportive care (oxygen,</p><p>intravenous fluids and monitoring).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OUTCOME<p>VARIABLES:</font></p></h4><p style=margin-bottom:0><font size=2>Primary: time to<p>resolution of severe pneumonia. SECONDARY: duration of</p><p>hospitalization and time to resolution of tachypnea, chest</p><p>retractions and inability to feed.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Median duration (SE, 95%<p>CI) of resolution of severe pneumonia was similar in the two groups</p><p>[</font><font size=2>vitamin D</font><font size=2>: 72 (3.7,</p><p>64.7-79.3) hours; placebo: 64 (4.5, 55.2-72.8)hours]. Duration of</p><p>hospitalization and time to resolution of tachypnea, chest</p><p>retractions, and inability to feed were also comparable between the</p><p>two groups.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Short-term supplementation<p>with oral </font><font size=2>vitamin D</font><font size=2></p><p>(1000-2000 IU per day for 5 days) has no beneficial effect on</p><p>resolution of severe pneumonia in under-five children. Further</p><p>studies needs to be conducted with higher dose of </font><font size=2>Vitamin</p><p>D</font><font size=2> or longer duration of supplementation to</p><p>corroborate these findings.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22086300><font size=2>Eur<p>J Nutr.</font></a></u></font><font size=2> 2011 Nov 16. [Epub ahead</p><p>of print]</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Is<p>a daily supplementation with 40 microgram </font><font size=2>vitamin</p><p>D</font><font size=2>(3) sufficient? A </font><font size=2>randomised</p><p>controlled trial</font><font size=2>.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Toss<p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Magnusson</p><p>P</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of<p>Endocrinology and Gastroenterology, County Council of Östergötland,</p><p>SE-581 85, Linköping, Sweden.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>PURPOSE:</font></h4><p style=margin-bottom:0><font size=2>The effect of 40&nbsp;&mu;g<p>(1,600 IU) per day of </font><font size=2>vitamin D</font><font size=2>(3)</p><p>on serum 25-hydroxyvitamin D (25(OH)D) and markers of bone and</p><p>mineral metabolism was evaluated.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>This intervention study<p>was designed as a double-blind </font><font size=2>randomised</p><p>controlled trial</font><font size=2>. Forty-five community-dwelling</p><p>subjects (32 females), age 55-84 years, at 58° North</p><p>latitude were supplemented for 1 year with 40 μg </font><font size=2>vitamin</p><p>D</font><font size=2>(3) plus 1,000 mg calcium per day, or with</p><p>1,000 mg calcium per day for controls. Safety parameters and</p><p>25(OH)D, intact parathyroid hormone (PTH), ionized calcium,</p><p>bone-specific alkaline phosphatase (BALP), and tartrate-resistant</p><p>acid phosphatase isoform 5b (TRACP5b) were measured over the study</p><p>period.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>All subjects supplemented<p>with </font><font size=2>vitamin D</font><font size=2>(3) reached a</p><p>25(OH)D level above 50 nmol/L. Mean (SD) serum 25(OH)D increased</p><p>from 50.4 (13.5) nmol/L to 84.2 (17.5) nmol/L, range</p><p>55.0-125.0 nmol/L in the </font><font size=2>vitamin D</font><font size=2>(3)</p><p>supplemented group and the corresponding levels for the control group</p><p>were 47.3 (14.1) nmol/L and 45.7 (13.4) nmol/L, range</p><p>26.0-73.0 nmol/L. No serious adverse event was recorded and the</p><p>highest 25(OH)D level reached, 125.0 nmol/L, is well below toxic</p><p>levels. BALP and TRACP5b did not change significantly over the study</p><p>period.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>This trial suggests that a<p>daily supplementation with 40 μg </font><font size=2>vitamin</p><p>D</font><font size=2>(3) is sufficient to secure a 25(OH)D level of</p><p>50 nmol/L. No side effects were observed in the study group.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22112804><font size=2>J<p>Clin Endocrinol Metab.</font></a></u></font><font size=2> 2011 Nov</p><ol start=23><li>[Epub ahead of print]</font></p></li></ol><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Long-Term<p>Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled</p><p>Trial of Vitamin D3 and/or Calcium (RECORD Trial).</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Avenell<p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Maclennan</p><p>GS</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Jenkinson</p><p>DJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McPherson</p><p>GC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>McDonald</p><p>AM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Pant</p><p>PR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Grant</p><p>AM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Campbell</p><p>MK</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Anderson</p><p>FH</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Cooper</p><p>C</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Francis</p><p>RM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gillespie</p><p>WJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Robinson</p><p>CM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Torgerson</p><p>DJ</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wallace</p><p>WA</font></a></u></font><font size=2>; </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>the</p><p>RECORD Trial Group</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Health Services Research<p>Unit (A.A., G.S.M., D.J.J., G.C.M., A.M.M., P.R.P., A.M.G., M.K.C.),</p><p>University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United</p><p>Kingdom; Geriatric Medicine (F.H.A.), Developmental Origins of Health</p><p>and Disease, Research Division, and Medical Research Council</p><p>Lifecourse Epidemiology Unit (C.C.), University of Southampton,</p><p>Southampton SO16 6YD, and Institute of Musculoskeletal Sciences,</p><p>University of Oxford, Oxford OX3 7LD, United Kingdom; Institute for</p><p>Ageing and Health (R.M.F.), Newcastle University, Newcastle upon Tyne</p><p>NE4 5PL, United Kingdom; Hull York Medical School (W.J.G.),</p><p>University of Hull, Hull HU6 7RX, United Kingdom; Royal Infirmary of</p><p>Edinburgh (C.M.R.), Edinburgh EH3 9HB, United Kingdom; York Trials</p><p>Unit (D.J.T.), University of York, York YO10 5DD, United Kingdom; and</p><p>Medical and Surgical Sciences (W.A.W.), University of Nottingham,</p><p>Nottingham NG7 2UH, United Kingdom.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Context:</font><font size=2>Vitamin<p>D</font><font size=2> or calcium supplementation may have effects on</p><p>vascular disease and cancer.Objective:Our objective was to</p><p>investigate whether </font><font size=2>vitamin D</font><font size=2></p><p>or calcium supplementation affects mortality, vascular disease, and</p><p>cancer in older people.Design and Setting:The study included</p><p>long-term follow-up of participants in a two by two factorial,</p><p></font><font size=2>randomized controlled trial</font><font size=2></p><p>from 21 orthopedic centers in the United</p><p>Kingdom.Participants:Participants were 5292 people (85% women) aged</p><p>at least 70 yr with previous low-trauma fracture.</font></p></p><p style=margin-bottom:0><font size=2>Interventions:Participants<p>were randomly allocated to daily </font><font size=2>vitamin D</font><font size=2>(3)</p><p>(800 IU), calcium (1000 mg), both, or placebo for 24-62 months, with</p><p>a follow-up of 3 yr after intervention.Main Outcome</p><p>Measures:All-cause mortality, vascular disease mortality, cancer</p><p>mortality, and cancer incidence were evaluated.</font></p></p><p style=margin-bottom:0><font size=2>Results:In<p>intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95%</p><p>confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR</p><p>= 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI =</p><p>0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did</p><p>not differ significantly between participants allocated </font><font size=2>vitamin</p><p>D</font><font size=2> and those not. All-cause mortality (HR = 1.03;</p><p>95% CI = 0.94-1.13), vascular disease mortality (HR = 1.07; 95% CI =</p><p>0.92-1.24), cancer mortality (HR = 1.13; 95% CI = 0.91-1.40), and</p><p>cancer incidence (HR = 1.06; 95% CI = 0.91-1.23) also did not differ</p><p>significantly between participants allocated calcium and those not.</p><p>In a post hoc statistical analysis adjusting for compliance, thus</p><p>with fewer participants, trends for reduced mortality with </font><font size=2>vitamin</p><p>D</font><font size=2> and increased mortality with calcium were</p><p>accentuated, although all results remain nonsignificant.</font></p></p><p style=margin-bottom:0><font size=2>Conclusions:Daily </font><font size=2>vitamin<p>D</font><font size=2> or calcium supplementation did not affect</p><p>mortality, vascular disease, cancer mortality, or cancer incidence.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/22071212><font size=2>Am<p>J Cardiol.</font></a></u></font><font size=2> 2011 Nov 7. [Epub ahead</p><p>of print]</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> Deficiency and </font><font size=2>Supplementation</font><font size=2></p><p>and Relation to </font><font size=2>Cardiovascular</font><font size=2></p><p>Health.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Vacek<p>JL</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Vanga</p><p>SR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Good</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lai</p><p>SM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Lakkireddy</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Howard</p><p>PA</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Mid America Cardiology,<p>Division of </font><font size=2>Cardiovascular</font><font size=2></p><p>Medicine, University of Kansas Medical Center and Hospital, Kansas</p><p>City, Kansas.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Recent evidence supports<p>an association between </font><font size=2>vitamin D</font><font size=2></p><p>deficiency and hypertension, peripheral vascular disease, diabetes</p><p>mellitus, metabolic syndrome, coronary artery disease, and heart</p><p>failure. The effect of </font><font size=2>vitamin D</font><font size=2></p><p></font><font size=2>supplementation</font><font size=2>, however, has</p><p>not been well studied. We examined the associations between </font><font size=2>vitamin</p><p>D</font><font size=2> deficiency, </font><font size=2>vitamin D</font><font size=2></p><p></font><font size=2>supplementation</font><font size=2>, and patient</p><p>outcomes in a large cohort. Serum </font><font size=2>vitamin D</font><font size=2></p><p>measurements for 5 years and 8 months from a large academic</p><p>institution were matched to patient demographic, physiologic, and</p><p>disease variables. The </font><font size=2>vitamin D</font><font size=2></p><p>levels were analyzed as a continuous variable and as normal (≥30</p><p>ng/ml) or deficient (&lt;30 ng/ml). Descriptive statistics,</p><p>univariate analysis, multivariate analysis, survival analysis, and</p><p>Cox proportional hazard modeling were performed. Of 10,899 patients,</p><p>the mean age was 58 ± 15 years, 71% were women (n = 7,758),</p><p>and the average body mass index was 30 ± 8 kg/m(2). The mean</p><p>serum </font><font size=2>vitamin D</font><font size=2> level was</p><p>24.1 ± 13.6 ng/ml. Of the 10,899 patients, 3,294 (29.7%) were</p><p>in the normal </font><font size=2>vitamin D</font><font size=2> range</p><p>and 7,665 (70.3%) were deficient. </font><font size=2>Vitamin D</font><font size=2></p><p>deficiency was associated with several </font><font size=2>cardiovascular</font><font size=2>-related</p><p>diseases, including hypertension, coronary artery disease,</p><p>cardiomyopathy, and diabetes (all p &lt;0.05). </font><font size=2>Vitamin</p><p>D</font><font size=2> deficiency was a strong independent predictor</p><p>of all-cause death (odds ratios 2.64, 95% confidence interval 1.901</p><p>to 3.662, p &lt;0.0001) after adjusting for multiple clinical</p><p>variables. </font><font size=2>Vitamin D</font><font size=2></p><p></font><font size=2>supplementation</font><font size=2> conferred</p><p>substantial survival benefit (odds ratio for death 0.39, 95%</p><p>confidence interval 0.277 to 0.534, p &lt;0.0001). In conclusion,</p><p></font><font size=2>vitamin D</font><font size=2> deficiency was</p><p>associated with a significant risk of </font><font size=2>cardiovascular</font><font size=2></p><p>disease and reduced survival. </font><font size=2>Vitamin D</font><font size=2></p><p></font><font size=2>supplementation</font><font size=2> was</p><p>significantly associated with better survival, specifically in</p><p>patients with documented deficiency.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21880848><font size=2>Am<p>J Clin Nutr.</font></a></u></font><font size=2> 2011</p><p>Oct;94(4):1144-9. Epub 2011 Aug 31.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Calcium<p>and </font><font size=2>vitamin D</font><font size=2> supplements and</p><p>health outcomes: a reanalysis of the Women&rsquo;s Health Initiative (WHI)</p><p>limited-access data set.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Bolland</font></u></font><font color=#0000ff><u><font size=2><p>MJ</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Grey</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Gamble</p><p>GD</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Reid</p><p>IR</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Medicine,<p>University of Auckland, New Zealand. m.</font><font size=2>bolland</font><font size=2>@auckland.ac.nz</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Frequent use of personal,<p>nonprotocol calcium supplements obscured an adverse effect of</p><p>coadministered calcium and </font><font size=2>vitamin D</font><font size=2></p><p>(CaD) on cardiovascular risk in the Women&rsquo;s Health Initiative (WHI).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>We investigated the<p>effects of the use of personal calcium or </font><font size=2>vitamin</p><p>D</font><font size=2> supplements on other outcomes in the WHI CaD</p><p>Study (WHI CaD) by using the WHI limited-access clinical trials data</p><p>set.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>The WHI CaD was a 7-y,<p>randomized, placebo-controlled trial of CaD (1 g Ca/400 IU </font><font size=2>vitamin</p><p>D</font><font size=2> daily) in 36,282 community-dwelling,</p><p>postmenopausal women. The incidence of total cancer (excluding</p><p>nonmelanoma skin cancers), breast and colorectal cancers, hip and</p><p>total fracture, and mortality was assessed by using Cox proportional</p><p>hazards models.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>In the WHI CaD,<p>interactions between the use of either personal calcium or </font><font size=2>vitamin</p><p>D</font><font size=2> supplements and CaD were found for total,</p><p>breast, and colorectal cancers but not for fracture or mortality. In</p><p>15,646 women (43%) who were not taking personal calcium or </font><font size=2>vitamin</p><p>D</font><font size=2> supplements at randomization, CaD significantly</p><p>decreased the risk of total, breast, and invasive breast cancers by</p><p>14-20% and nonsignificantly reduced the risk of colorectal cancer by</p><p>17%. In women taking personal calcium or </font><font size=2>vitamin</p><p>D</font><font size=2> supplements, CaD did not alter cancer risk (HR:</p><p>1.06-1.26).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>For women in the WHI CaD<p>who were not taking personal calcium or </font><font size=2>vitamin D</font><font size=2></p><p>supplements at randomization, CaD decreased the risk of total,</p><p>breast, and colorectal cancers and did not change the risk of</p><p>fractures or total mortality. The nonskeletal effects of CaD may be</p><p>more important than the skeletal effects and should be considered</p><p>when evaluating these supplements. The WHI CaD trial is registered at</p><p>clinicaltrials.gov as NCT00000611.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/17556697><font size=2><span lang=de-DE>Am<p>J Clin Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>2007 Jun;85(6):1586-91.</span></font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> and calcium supplementation reduces cancer</p><p>risk: results of a randomized trial.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Lappe</font></u></font><font color=#0000ff><u><font size=2><p>JM</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Travers-Gustafson</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Davies</p><p>KM</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Recker</p><p>RR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Heaney</p><p>RP</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Osteoporosis Research<p>Center, Creighton University, Omaha, NE 68131, USA.</p><p><a href=mailto:jmlappe@creighton.edu>jmlappe@creighton.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Erratum<p>in</font></h3></p><ul><li><p lang=de-DE class=western style=margin-bottom:0><font size=2>Am<p>J Clin Nutr. 2008 Mar;87(3):794.</font></p></p></ul><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>BACKGROUND:</font></h4><p style=margin-bottom:0><font size=2>Numerous observational<p>studies have found supplemental calcium and </font><font size=2>vitamin</p><p>D</font><font size=2> to be associated with reduced risk of common</p><p>cancers. However, interventional studies to test this effect are</p><p>lacking.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>The purpose of this<p>analysis was to determine the efficacy of calcium alone and calcium</p><p>plus </font><font size=2>vitamin D</font><font size=2> in reducing</p><p>incident cancer risk of all types.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DESIGN:</font></h4><p style=margin-bottom:0><font size=2>This was a 4-y,<p>population-based, double-blind, randomized placebo-controlled trial.</p><p>The primary outcome was fracture incidence, and the principal</p><p>secondary outcome was cancer incidence. The subjects were 1179</p><p>community-dwelling women randomly selected from the population of</p><p>healthy postmenopausal women aged >55 y in a 9-county rural area</p><p>of Nebraska centered at latitude 41.4 degrees N. Subjects were</p><p>randomly assigned to receive 1400-1500 mg supplemental calcium/d</p><p>alone (Ca-only), supplemental calcium plus 1100 IU vitamin D3/d (Ca +</p><p>D), or placebo.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>When analyzed by intention<p>to treat, cancer incidence was lower in the Ca + D women than in the</p><p>placebo control subjects (P &lt; 0.03). With the use of logistic</p><p>regression, the unadjusted relative risks (RR) of incident cancer in</p><p>the Ca + D and Ca-only groups were 0.402 (P = 0.01) and 0.532 (P =</p><p>0.06), respectively. When analysis was confined to cancers diagnosed</p><p>after the first 12 mo, RR for the Ca + D group fell to 0.232 (CI:</p><p>0.09, 0.60; P &lt; 0.005) but did not change significantly for the</p><p>Ca-only group. In multiple logistic regression models, both treatment</p><p>and serum 25-hydroxyvitamin D concentrations were significant,</p><p>independent predictors of cancer risk.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Improving calcium and<p></font><font size=2>vitamin D</font><font size=2> nutritional status</p><p>substantially reduces all-cancer risk in postmenopausal women. This</p><p>trial was registered at clinicaltrials.gov as NCT00352170.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/20723187><font size=2>Trop<p>Med Int Health.</font></a></u></font><font size=2> 2010</p><p>Oct;15(10):1148-55. doi: 10.1111/j.1365-3156.2010.02578.x. Epub 2010</p><p>Aug 17.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effects<p>of </font><font size=2>vitamin D</font><font size=2> supplementation</p><p>to children diagnosed with pneumonia in </font><font size=2>Kabul</font><font size=2>:</p><p>a randomised controlled trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Manaseki-Holland<p>S</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Qader</p><p>G</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Isaq</p><p>Masher M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bruce</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Zulf</p><p>Mughal M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Chandramohan</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Walraven</p><p>G</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Aga Khan Health Services,<p></font><font size=2>Kabul</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>,</p><p>Afghanistan </font><font size=2>Kabul</font><font size=2> Medical</p><p>University, </font><font size=2>Kabul</font><font size=2>,</p><p>Afghanistan.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVES:</font></h4><p style=margin-bottom:0><font size=2>To determine whether (i)<p>supplementation of oral 100,000 iu of </font><font size=2>vitamin</p><p>D</font><font size=2>(3) (cholecalciferol) along with antibiotics</p><p>will reduce the duration of illness in children with pneumonia; (ii)</p><p>supplementation will reduce the risk of repeat episodes.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS:</font></h4><p style=margin-bottom:0><font size=2>Double-blind individually<p>randomised placebo-controlled trial in an inner-city hospital in</p><p></font><font size=2>Kabul</font><font size=2>, of 453 children aged</p><p>1-36 months, diagnosed with non-severe or severe pneumonia at the</p><p>outpatient clinic. Children with rickets, other concurrent severe</p><p>diseases, very severe pneumonia or wheeze, were excluded. Children</p><p>were given </font><font size=2>vitamin D</font><font size=2>(3) or</p><p>placebo drops additional to routine pneumonia treatment.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>RESULTS:</font></h4><p style=margin-bottom:0><font size=2>Two hundred and<p>twenty-four children received </font><font size=2>vitamin D</font><font size=2>(3;)</p><p>and 229 received placebo. There was no significant difference in the</p><p>mean number of days to recovery between the </font><font size=2>vitamin</p><p>D</font><font size=2>(3) (4.74 days; SD 2.22) and placebo arms (4.98</p><p>days; SD 2.89; P = 0.17). The risk of a repeat episode of pneumonia</p><p>within 90 days of supplementation was lower in the intervention</p><p>(92/204; 45%) than the placebo group [122/211; (58%; relative risk</p><p>0.78; 95% CI 0.64, 0.94; P = 0.01]. Children in the </font><font size=2>vitamin</p><p>D</font><font size=2>(3) group survived longer without experiencing a</p><p>repeat episode (72 days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P =</p><p>0.02).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>A single high-dose oral<p></font><font size=2>vitamin D</font><font size=2>(3) supplementation</p><p>to young children along with antibiotic treatment for pneumonia could</p><p>reduce the occurrence of repeat episodes of pneumonia.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/15886381><font size=2>JAMA.</font></a></u></font><font size=2><p>2005 May 11;293(18):2257-64.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Fracture<p>prevention with vitamin D supplementation: a meta-analysis of</p><p>randomized controlled trials.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bischoff-Ferrari<p>HA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Willett</p><p>WC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wong</p><p>JB</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Giovannucci</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dietrich</p><p>T</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Nutrition,<p>Harvard School of Public Health, Boston, Mass 02115, USA.</p><p><a href=mailto:hbischof@hsph.harvard.edu>hbischof@hsph.harvard.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONTEXT:</font></h4><p style=margin-bottom:0><font size=2>The role and dose of oral<p>vitamin D supplementation in nonvertebral fracture prevention have</p><p>not been well established.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>OBJECTIVE:</font></h4><p style=margin-bottom:0><font size=2>To estimate the<p>effectiveness of vitamin D supplementation in preventing hip and</p><p>nonvertebral fractures in older persons.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SOURCES:</font></p></h4><p style=margin-bottom:0><font size=2>A systematic review of<p>English and non-English articles using MEDLINE and the Cochrane</p><p>Controlled Trials Register (1960-2005), and EMBASE (1991-2005).</p><p>Additional studies were identified by contacting clinical experts and</p><p>searching bibliographies and abstracts presented at the American</p><p>Society for Bone and Mineral Research (1995-2004). Search terms</p><p>included randomized controlled trial (RCT), controlled clinical</p><p>trial, random allocation, double-blind method, cholecalciferol,</p><p>ergocalciferol, 25-hydroxyvitamin D, fractures, humans, elderly,</p><p>falls, and bone density.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>STUDY<p>SELECTION:</font></p></h4><p style=margin-bottom:0><font size=2>Only double-blind RCTs of<p>oral vitamin D supplementation (cholecalciferol, ergocalciferol) with</p><p>or without calcium supplementation vs calcium supplementation or</p><p>placebo in older persons (> or =60 years) that examined hip or</p><p>nonvertebral fractures were included.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>EXTRACTION:</font></p></h4><p style=margin-bottom:0><font size=2>Independent extraction of<p>articles by 2 authors using predefined data fields, including study</p><p>quality indicators.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>DATA<p>SYNTHESIS:</font></p></h4><p style=margin-bottom:0><font size=2>All pooled analyses were<p>based on random-effects models. Five RCTs for hip fracture (n = 9294)</p><p>and 7 RCTs for nonvertebral fracture risk (n = 9820) met our</p><p>inclusion criteria. All trials used cholecalciferol. Heterogeneity</p><p>among studies for both hip and nonvertebral fracture prevention was</p><p>observed, which disappeared after pooling RCTs with low-dose (400</p><p>IU/d) and higher-dose vitamin D (700-800 IU/d), separately. A vitamin</p><p>D dose of 700 to 800 IU/d reduced the relative risk (RR) of hip</p><p>fracture by 26% (3 RCTs with 5572 persons; pooled RR, 0.74; 95%</p><p>confidence interval [CI], 0.61-0.88) and any nonvertebral fracture by</p><p>23% (5 RCTs with 6098 persons; pooled RR, 0.77; 95% CI, 0.68-0.87) vs</p><p>calcium or placebo. No significant benefit was observed for RCTs with</p><p>400 IU/d vitamin D (2 RCTs with 3722 persons; pooled RR for hip</p><p>fracture, 1.15; 95% CI, 0.88-1.50; and pooled RR for any nonvertebral</p><p>fracture, 1.03; 95% CI, 0.86-1.24).</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSIONS:</font></h4><p style=margin-bottom:0><font size=2>Oral vitamin D<p>supplementation between 700 to 800 IU/d appears to reduce the risk of</p><p>hip and any nonvertebral fractures in ambulatory or institutionalized</p><p>elderly persons. An oral vitamin D dose of 400 IU/d is not sufficient</p><p>for fracture prevention.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21154195><font size=2>Horm<p>Metab Res.</font></a></u></font><font size=2> 2011 Mar;43(3):223-5.</p><p>Epub 2010 Dec 10.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Effect<p>of vitamin D supplementation on testosterone levels in men.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Pilz<p>S</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Frisch</p><p>S</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Koertke</p><p>H</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Kuhn</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Dreier</p><p>J</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Obermayer-Pietsch</p><p>B</span></font></a></u></font><font size=2><span lang=de-DE>, </span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Wehr</p><p>E</span></font></a></u></font><font size=2><span lang=de-DE>,</p><p></span></font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2><span lang=de-DE>Zittermann</p><p>A</span></font></a></u></font><font size=2><span lang=de-DE>.</span></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Department of Internal<p>Medicine, Division of Endocrinology and Metabolism, Medical</p><p>University of Graz, Austria.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>The male reproductive<p>tract has been identified as a target tissue for vitamin D, and</p><p>previous data suggest an association of 25-hydroxyvitamin D [25(OH)D]</p><p>with testosterone levels in men. We therefore aimed to evaluate</p><p>whether vitamin D supplementation influences testosterone levels in</p><p>men. Healthy overweight men undergoing a weight reduction program who</p><p>participated in a randomized controlled trial were analyzed for</p><p>testosterone levels. The entire study included 200 nondiabetic</p><p>subjects, of whom 165 participants (54 men) completed the trial.</p><p>Participants received either 83 μg (3,332 IU) vitamin D daily for</p><p>1 year (n = 31) or placebo (n =2 3). Initial 25(OH)D concentrations</p><p>were in the deficiency range (&lt; 50 nmol/l) and testosterone values</p><p>were at the lower end of the reference range (9.09-55.28 nmol/l for</p><p>males aged 20-49 years) in both groups. Mean circulating 25(OH)D</p><p>concentrations increased significantly by 53.5 nmol/l in the vitamin</p><p>D group, but remained almost constant in the placebo group. Compared</p><p>to baseline values, a significant increase in total testosterone</p><p>levels (from 10.7 ± 3.9 nmol/l to 13.4 ± 4.7 nmol/l; p</p><p>&lt; 0.001), bioactive testosterone (from 5.21 ± 1.87 nmol/l</p><p>to 6.25 ± 2.01 nmol/l; p = 0.001), and free testosterone</p><p>levels (from 0.222 ± 0.080 nmol/l to 0.267 ± 0.087</p><p>nmol/l; p = 0.001) were observed in the vitamin D supplemented group.</p><p>By contrast, there was no significant change in any testosterone</p><p>measure in the placebo group. Our results suggest that vitamin D</p><p>supplementation might increase testosterone levels. Further</p><p>randomized controlled trials are warranted to confirm this</p><p>hypothesis.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19781131><font size=2><span lang=de-DE>Br<p>J Nutr.</span></font></a></u></font><font size=2><span lang=de-DE></p><p>2010 Feb;103(4):549-55. Epub 2009 Sep 28.</span></font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D supplementation reduces insulin resistance in South Asian women</p><p>living in New Zealand who are insulin resistant and vitamin D</p><p>deficient - a randomised, placebo-controlled trial.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>von<p>Hurst PR</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Stonehouse</p><p>W</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Coad</p><p>J</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Institute of Food,<p>Nutrition and Human Health, Massey University, Private Bag 102 904,</p><p>North Shore Mail Centre, Auckland, New Zealand.</p><p><a href=mailto:p.r.vonhurst@massey.ac.nz>p.r.vonhurst@massey.ac.nz</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Low serum<p>25-hydroxyvitamin D (25(OH)D) has been shown to correlate with</p><p>increased risk of type 2 diabetes. Small, observational studies</p><p>suggest an action for vitamin D in improving insulin sensitivity</p><p>and/or insulin secretion. The objective of the present study was to</p><p>investigate the effect of improved vitamin D status on insulin</p><p>resistance (IR), utilising randomised, controlled, double-blind</p><p>intervention administering 100 microg (4000 IU) vitamin D(3) (n 42)</p><p>or placebo (n 39) daily for 6 months to South Asian women, aged 23-68</p><p>years, living in Auckland, New Zealand. Subjects were insulin</p><p>resistant - homeostasis model assessment 1 (HOMA1)>1.93 and had</p><p>serum 25(OH)D concentration &lt; 50 nmol/l. Exclusion criteria</p><p>included diabetes medication and vitamin D supplementation >25</p><p>microg (1000 IU)/d. The HOMA2 computer model was used to calculate</p><p>outcomes. Median (25th, 75th percentiles) serum 25(OH)D(3) increased</p><p>significantly from 21 (11, 40) to 75 (55, 84) nmol/l with</p><p>supplementation. Significant improvements were seen in insulin</p><p>sensitivity and IR (P = 0.003 and 0.02, respectively), and fasting</p><p>insulin decreased (P = 0.02) with supplementation compared with</p><p>placebo. There was no change in C-peptide with supplementation. IR</p><p>was most improved when endpoint serum 25(OH)D reached > or = 80</p><p>nmol/l. Secondary outcome variables (lipid profile and high</p><p>sensitivity C-reactive protein) were not affected by supplementation.</p><p>In conclusion, improving vitamin D status in insulin resistant women</p><p>resulted in improved IR and sensitivity, but no change in insulin</p><p>secretion. Optimal vitamin D concentrations for reducing IR were</p><p>shown to be 80-119 nmol/l, providing further evidence for an increase</p><p>in the recommended adequate levels. Registered Trial No.</p><p>ACTRN12607000642482.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/19957164><font size=2>Osteoporos<p>Int.</font></a></u></font><font size=2> 2010 Jul;21(7):1121-32. Epub</p><p>2009 Dec 3.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Benefit-risk<p>assessment of vitamin D supplementation.</font></h1></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Bischoff-Ferrari<p>HA</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Shao</p><p>A</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Dawson-Hughes</p><p>B</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hathcock</p><p>J</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Giovannucci</p><p>E</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Willett</p><p>WC</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Centre on Aging and<p>Mobility, Department of Rheumatology and Institute of Physical</p><p>Medicine, University Hospital Zurich, Gloriastrasse 25, 8091, Zurich,</p><p>Switzerland. <a href=mailto:Heike.Bischoff@usz.ch>Heike.Bischoff@usz.ch</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>Current intake<p>recommendations of 200 to 600 IU vitamin D per day may be</p><p>insufficient for important disease outcomes reduced by vitamin D.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>INTRODUCTION:</font></h4><p style=margin-bottom:0><font size=2>This study assessed the<p>benefit of higher-dose and higher achieved 25-hydroxyvitamin D levels</p><p>[25(OH)D] versus any associated risk.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>METHODS<p>AND RESULTS:</font></p></h4><p style=margin-bottom:0><font size=2>Based on double-blind<p>randomized control trials (RCTs), eight for falls (n = 2426) and 12</p><p>for non-vertebral fractures (n = 42,279), there was a significant</p><p>dose-response relationship between higher-dose and higher achieved</p><p>25(OH)D and greater fall and fracture prevention. Optimal benefits</p><p>were observed at the highest dose tested to date for 700 to 1000 IU</p><p>vitamin D per day or mean 25(OH)D between 75 and 110 nmol/l (30-44</p><p>ng/ml). Prospective cohort data on cardiovascular health and</p><p>colorectal cancer prevention suggested increased benefits with the</p><p>highest categories of 25(OH)D evaluated (median between 75 and 110</p><p>nmol/l). In 25 RCTs, mean serum calcium levels were not related to</p><p>oral vitamin D up to 100,000 IU per day or achieved 25(OH)D up to 643</p><p>nmol/l. Mean levels of 75 to 110 nmol/l were reached in most RCTs</p><p>with 1,800 to 4,000 IU vitamin D per day without risk.</font></p></p><h4 class=western style=margin-top:0;margin-bottom:0><font size=2>CONCLUSION:</font></h4><p style=margin-bottom:0><font size=2>Our analysis suggests that<p>mean serum 25(OH)D levels of about 75 to 110 nmol/l provide optimal</p><p>benefits for all investigated endpoints without increasing health</p><p>risks. These levels can be best obtained with oral doses in the range</p><p>of 1,800 to 4,000 IU vitamin D per day; further work is needed,</p><p>including subject and environment factors, to better define the doses</p><p>that will achieve optimal blood levels in the large majority of the</p><p>population.</font></p></p><p class=western style=margin-bottom:0><br></p><p class=western style=margin-bottom:0><font color=#0000ff><u><a href=http://www.ncbi.nlm.nih.gov/pubmed/21706518><font size=2>J<p>Bone Miner Res.</font></a></u></font><font size=2> 2011</p><p>Oct;26(10):2341-57. doi: 10.1002/jbmr.463.</font></p></p><h1 class=western style=margin-top:0;margin-bottom:0><font size=2>Vitamin<p>D</font><font size=2> supplementation during pregnancy: double-blind,</p><p>randomized clinical trial of safety and effectiveness.</font></h1></p><p class=western style=margin-bottom:0><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font color=#0000ff><u><font size=2>Hollis</font></u></font><font color=#0000ff><u><font size=2><p>BW</font></u></font></a><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Johnson</p><p>D</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Hulsey</p><p>TC</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Ebeling</p><p>M</font></a></u></font><font size=2>, </font><font color=#0000ff><u><a href="http://www.ncbi.nlm.nih.gov/pubmed?term="><font size=2>Wagner</p><p>CL</font></a></u></font><font size=2>.</font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Source</font></h3><p style=margin-bottom:0><font size=2>Division of Neonatology<p>and Department of Obstetrics and Gynecology, Medical University of</p><p>South Carolina, Charleston, SC 29425, USA. <a href=mailto:hollisb@musc.edu>hollisb@musc.edu</a></font></p></p><h3 class=western style=margin-top:0;margin-bottom:0><font size=2>Abstract</font></h3><p style=margin-bottom:0><font size=2>The need, safety, and<p>effectiveness of </font><font size=2>vitamin D</font><font size=2></p><p>supplementation during pregnancy remain controversial. In this</p><p>randomized, controlled trial, women with a singleton pregnancy at 12</p><p>to 16 weeks&rsquo; gestation received 400, 2000, or 4000</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>IU</p><p>of </font><font size=2>vitamin D</font><font size=2>(3) per day until</p><p>delivery. The primary outcome was maternal/neonatal circulating</p><p>25-hydroxyvitamin D [25(OH)D] concentration at delivery, with</p><p>secondary outcomes of a 25(OH)D concentration of 80</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>nmol/L</p><p>or greater achieved and the 25(OH)D concentration required to achieve</p><p>maximal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] production. Of</p><p>the 494 women enrolled, 350 women continued until delivery: Mean</p><p>25(OH)D concentrations by group at delivery and 1 month before</p><p>delivery were significantly different (p</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>&lt;</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>0.0001),</p><p>and the percent who achieved sufficiency was significantly different</p><p>by group, greatest in 4000-IU group (p</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>&lt;</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>0.0001).</p><p>The relative risk (RR) for achieving a concentration of 80</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>nmol/L</p><p>or greater within 1 month of delivery was significantly different</p><p>between the 2000- and the 400-IU groups (RR</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>1.52,</p><p>95% CI 1.24-1.86), the 4000- and the 400-IU groups (RR</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>1.60,</p><p>95% CI 1.32-1.95) but not between the 4000- and. 2000-IU groups</p><p>(RR</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>=</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>1.06,</p><p>95% CI 0.93-1.19). Circulating 25(OH)D had a direct influence on</p><p>circulating 1,25(OH)(2)D(3) concentrations throughout pregnancy</p><p>(p</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>&lt;</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>0.0001),</p><p>with maximal production of 1,25(OH)(2)D(3) in all strata in the</p><p>4000-IU group. There were no differences between groups on any safety</p><p>measure. Not a single adverse event was attributed to </font><font size=2>vitamin</p><p>D</font><font size=2> supplementation or circulating 25(OH)D levels.</p><p>It is concluded that </font><font size=2>vitamin D</font><font size=2></p><p>supplementation of 4000</font><font face="Arial Unicode MS, sans-serif"><font size=2> </font></font><font size=2>IU/d</p><p>for pregnant women is safe and most effective in achieving</p><p>sufficiency in all women and their neonates regardless of race,</p><p>whereas the current estimated average requirement is comparatively</p><p>ineffective at achieving adequate circulating 25(OH)D concentrations,</p><p>especially in African Americans.</font></p></p><p class=western style=margin-bottom:0><br></p></body></html></div><hr class=tag-separator><div class=tags><span>Tags: </span><span class=tag>antibiotics</span>
<span class=tag>anxiety</span>
<span class=tag>asthma</span>
<span class=tag>asthma receptor</span>
<span class=tag>atopic dermatitis</span>
<span class=tag>autoimmune</span>
<span class=tag>autoimmune and pregnancy</span>
<span class=tag>bacteria</span>
<span class=tag>bariatric surgery</span>
<span class=tag>blood clotting</span>
<span class=tag>blood levels</span>
<span class=tag>bone</span>
<span class=tag>bone cancer</span>
<span class=tag>bone loss</span>
<span class=tag>bone mineral density</span>
<span class=tag>bone stress fractures</span>
<span class=tag>brain</span>
<span class=tag>breathing</span>
<span class=tag>cancer</span>
<span class=tag>cancer in VDR</span>
<span class=tag>cardiovascular</span>
<span class=tag>child</span>
<span class=tag>childhood cancer</span>
<span class=tag>childhood pneumonia</span>
<span class=tag>childhood viruses</span>
<span class=tag>cholesterol</span>
<span class=tag>CKD</span>
<span class=tag>cognitive</span>
<span class=tag>colon cancer</span>
<span class=tag>CYPA</span>
<span class=tag>CYPR</span>
<span class=tag>cystic fibrosis</span>
<span class=tag>depression</span>
<span class=tag>depression and pregnancy</span>
<span class=tag>dermatology</span>
<span class=tag>diabetes</span>
<span class=tag>diabetes and vitamin d receptor</span>
<span class=tag>dialysis</span>
<span class=tag>dosage</span>
<span class=tag>Evidence for D</span>
<span class=tag>falls fractures</span>
<span class=tag>genetics</span>
<span class=tag>health risk</span>
<span class=tag>heart failure</span>
<span class=tag>high dose</span>
<span class=tag>hip fractures</span>
<span class=tag>hypertension</span>
<span class=tag>immunity</span>
<span class=tag>influenza</span>
<span class=tag>intervention</span>
<span class=tag>Intervention</span>
<span class=tag>kidney</span>
<span class=tag>life span</span>
<span class=tag>melanoma</span>
<span class=tag>metabolic</span>
<span class=tag>metabolic conditions</span>
<span class=tag>metabolic syndrome</span>
<span class=tag>mononucleosis</span>
<span class=tag>mood disorders</span>
<span class=tag>mortality</span>
<span class=tag>multiple sclerosis</span>
<span class=tag>multiple sclerosis and pregnancy</span>
<span class=tag>osteoporosis</span>
<span class=tag>pain</span>
<span class=tag>pediatric autoimmune</span>
<span class=tag>pneumonia</span>
<span class=tag>pregnancy</span>
<span class=tag>rheumatoid arthritis</span>
<span class=tag>rickets</span>
<span class=tag>skin cancer</span>
<span class=tag>therapeutic intervention</span>
<span class=tag>transplant</span>
<span class=tag>trauma surgery</span>
<span class=tag>tuberculosis</span>
<span class=tag>virus</span>
<span class=tag>virus and cardiovascular</span>
<span class=tag>virus and cognitive</span>
<span class=tag>viruses and pregnancy</span>
<span class=tag>viruses and vitamin d receptor</span>
<span class=tag>vitamin d</span>
<span class=tag>vitamin d and viruses</span>
<span class=tag>vitamin d blood test</span>
<span class=tag>vitamin d receptor</span>
<span class=tag>weight loss</span></div><div data-pagefind-meta=tags hidden>antibiotics, anxiety, asthma, asthma receptor, atopic dermatitis, autoimmune, autoimmune and pregnancy, bacteria, bariatric surgery, blood clotting, blood levels, bone, bone cancer, bone loss, bone mineral density, bone stress fractures, brain, breathing, cancer, cancer in VDR, cardiovascular, child, childhood cancer, childhood pneumonia, childhood viruses, cholesterol, CKD, cognitive, colon cancer, CYPA, CYPR, cystic fibrosis, depression, depression and pregnancy, dermatology, diabetes, diabetes and vitamin d receptor, dialysis, dosage, Evidence for D, falls fractures, genetics, health risk, heart failure, high dose, hip fractures, hypertension, immunity, influenza, intervention, Intervention, kidney, life span, melanoma, metabolic, metabolic conditions, metabolic syndrome, mononucleosis, mood disorders, mortality, multiple sclerosis, multiple sclerosis and pregnancy, osteoporosis, pain, pediatric autoimmune, pneumonia, pregnancy, rheumatoid arthritis, rickets, skin cancer, therapeutic intervention, transplant, trauma surgery, tuberculosis, virus, virus and cardiovascular, virus and cognitive, viruses and pregnancy, viruses and vitamin d receptor, vitamin d, vitamin d and viruses, vitamin d blood test, vitamin d receptor, weight loss</div></article></div></div><script src="/js/lightspa.js?v=1751038173"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1751038173",indexUrl:"/search/search_index.json.gz?v=1751038173"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1751038173"></script><script src="/js/tiki-redirects.js?v=1751038173"></script></body></html>